<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10302687</article-id><article-id pub-id-type="pmcid-ver">PMC10302687.1</article-id><article-id pub-id-type="pmcaid">10302687</article-id><article-id pub-id-type="pmcaiid">10302687</article-id><article-id pub-id-type="pmid">37376148</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics15061700</article-id><article-id pub-id-type="publisher-id">pharmaceutics-15-01700</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Review on Additives in Hydrogels for 3D Bioprinting of Regenerative Medicine: From Mechanism to Methodology</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Fang</surname><given-names initials="W">Wenzhuo</given-names></name><xref rid="fn1-pharmaceutics-15-01700" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="M">Ming</given-names></name><xref rid="fn1-pharmaceutics-15-01700" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="M">Meng</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jin</surname><given-names initials="Y">Yangwang</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yuhui</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="R">Ranxing</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Ying</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="K">Kaile</given-names></name><xref rid="c1-pharmaceutics-15-01700" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fu</surname><given-names initials="Q">Qiang</given-names></name><xref rid="c1-pharmaceutics-15-01700" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>G&#225;lvez-Mart&#237;nf</surname><given-names initials="P">Patricia</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Clares</surname><given-names initials="B">Beatriz</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-15-01700">Department of Urology, Affiliated Sixth People&#8217;s Hospital, Shanghai Jiaotong University, No. 600 Yi-Shan Road, Shanghai 200233, China; <email>fwz17794608029@163.com</email> (W.F.); <email>yangminguro@163.com</email> (M.Y.); </aff><author-notes><corresp id="c1-pharmaceutics-15-01700"><label>*</label>Correspondence: <email>great_z0313@sjtu.edu.cn</email> (K.Z.); <email>jamesqfu@aliyun.com</email> (Q.F.)</corresp><fn id="fn1-pharmaceutics-15-01700"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2023</year></pub-date><volume>15</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">439274</issue-id><elocation-id>1700</elocation-id><history><date date-type="received"><day>18</day><month>4</month><year>2023</year></date><date date-type="rev-recd"><day>29</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>02</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-05 14:25:11.147"><day>05</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-15-01700.pdf"/><abstract><p>The regeneration of biological tissues in medicine is challenging, and 3D bioprinting offers an innovative way to create functional multicellular tissues. One common way in bioprinting is bioink, which is one type of the cell-loaded hydrogel. For clinical application, however, the bioprinting still suffers from satisfactory performance, e.g., in vascularization, effective antibacterial, immunomodulation, and regulation of collagen deposition. Many studies incorporated different bioactive materials into the 3D-printed scaffolds to optimize the bioprinting. Here, we reviewed a variety of additives added to the 3D bioprinting hydrogel. The underlying mechanisms and methodology for biological regeneration are important and will provide a useful basis for future research.</p></abstract><kwd-group><kwd>3D bioprinting</kwd><kwd>hydrogel</kwd><kwd>bioink</kwd><kwd>tissue engineering</kwd><kwd>bionic scaffold</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Scientific Foundation of China</funding-source><award-id>82170694</award-id></award-group><award-group><funding-source>Interdisciplinary Program of Shanghai Jiao Tong University</funding-source><award-id>YG2022ZD020</award-id></award-group><award-group><funding-source>Natural Science Foundation of Shanghai</funding-source><award-id>20ZR1442100</award-id></award-group><funding-statement>This work was supported by the National Natural Scientific Foundation of China (No. 82170694), the Interdisciplinary Program of Shanghai Jiao Tong University (No. YG2022ZD020) and the Natural Science Foundation of Shanghai (No. 20ZR1442100).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-15-01700"><title>1. Introduction</title><p>Owing to the rapid development of current medical technology, a high success rate in organ transplantation and tissue repair was recently achieved. However, the limited number of organs available from donors constrain organ transplantation and tissue repair [<xref rid="B1-pharmaceutics-15-01700" ref-type="bibr">1</xref>]. In recent years, researchers focused on tissue engineering and regenerative medicine to overcome donor shortage and immune rejection. Tissue engineering focuses on creating autologous tissues or organs for transplantation by using cells, biomaterials, and some additives such as cytokines. Additionally, regenerative medicine reproduces the healthy functions of cells, tissues, or organs through substitution or regeneration [<xref rid="B2-pharmaceutics-15-01700" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-15-01700" ref-type="bibr">3</xref>].</p><p>An emerging technology is 3D printing; it made significant advances in many fields, including aerospace, consumer products, the food industry, and manufacturing, and it combines cells and biological materials [<xref rid="B4-pharmaceutics-15-01700" ref-type="bibr">4</xref>] to construct complex 3D structures, which can be used for scaffold-based or scaffold-free tissue and organ structures, micro-organisms, and single-chip organ model systems. For the medical field, 3D printing is also revolutionary in treating diseases [<xref rid="B3-pharmaceutics-15-01700" ref-type="bibr">3</xref>,<xref rid="B5-pharmaceutics-15-01700" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-15-01700" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-15-01700" ref-type="bibr">7</xref>]. The core of 3D printing lies in the printing conditions, printing technology, and suitable bioinks. Bioinks are generally a formula containing biomaterials and bioactive components that can be processed by automated manufacturing technology [<xref rid="B8-pharmaceutics-15-01700" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-15-01700" ref-type="bibr">9</xref>]. The types of bioinks include hydrogels, cell aggregates, acellular matrix, etc. [<xref rid="B10-pharmaceutics-15-01700" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01700" ref-type="bibr">11</xref>]. The ideal hydrogel materials should have good physical, chemical, and biological characteristics, such as printability, biocompatibility, degradability, mechanical properties, stability, non-toxic, and non-immunogenic, as well as promotion of cell adhesion proliferation and differentiation [<xref rid="B11-pharmaceutics-15-01700" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-15-01700" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-15-01700" ref-type="bibr">13</xref>]. However, possession of these properties does not necessarily permit the functional scaffolds to achieve optimal tissue repair, as the microenvironment and growth conditions at various implantation sites are different. Problems such as insufficient vascularization, causing ischemia and hypoxia, microbial contamination, inflammatory reactions, collagen metabolism disorders, etc., may occur after scaffold implantation into the target tissue. Scaffold implantation, tissue regeneration, wound healing, and scar formation will then fail. Therefore, it is necessary to design the specific scaffold to better enhance the regeneration-promoting ability [<xref rid="B14-pharmaceutics-15-01700" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-15-01700" ref-type="bibr">15</xref>]. In this review, we summarize different additives that were added to 3D bioprinting bioinks. As mentioned above, we divided the various additives into these four categories precisely because sufficient vascularization, lower inflammatory response and infection, and appropriate collagen deposition are key to better adaptation of the repair site to the implant and are among the indispensable factors to improve implant success. As shown in <xref rid="pharmaceutics-15-01700-t001" ref-type="table">Table 1</xref>, we first describe, in general terms, the functions of the different additives and the mechanisms by which they work, followed by examples of the specific ways in which different researchers applied them to hydrogel scaffolds and the good results that were eventually achieved. We believe that the major difference and advantage of this review is that it has the potential to be a timely report for future researchers in selecting the right additives for bioinks. By understanding the functions of different additives and the mechanisms by which they function, as well as by referring to the methodologies of others, it will help researchers to find the additives they are looking for more efficiently and conveniently.</p></sec><sec id="sec2-pharmaceutics-15-01700"><title>2. Vascularization</title><p>Good vascularization and vascular recanalization is crucial for the repair sites because blood vessels are vital to tissue repair [<xref rid="B44-pharmaceutics-15-01700" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-15-01700" ref-type="bibr">45</xref>]. Blood vessels can provide sufficient oxygen and nutrients and carry away metabolic wastes [<xref rid="B46-pharmaceutics-15-01700" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-15-01700" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-15-01700" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-15-01700" ref-type="bibr">49</xref>]. Therefore, the purpose of 3D printed scaffolds is to encourage vascular regeneration, which leads to in-tissue repair and regeneration. The details to make scaffolds are given below.</p><sec id="sec2dot1-pharmaceutics-15-01700"><title>2.1. Growth Factors</title><p>In recent years, growth factors are being widely noticed. Specific cell receptors respond differently after being stimulated by growth factors [<xref rid="B50-pharmaceutics-15-01700" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-15-01700" ref-type="bibr">51</xref>]. Adding growth factors to the 3D bioprinting process can stimulate cell proliferation and differentiation, thus increasing cell activity and increasing the success rate of 3D bioprinting [<xref rid="B52-pharmaceutics-15-01700" ref-type="bibr">52</xref>]. The activity of endothelial cells is additionally crucial for successful vascularization. The process of endothelium-mediated angiogenesis is complex and is impacted by multiple growth factors. Understanding the function of various growth factors and their methods for promoting angiogenesis is crucial for tissue repair. The growth factors that used in 3D bioprinting for vascularization such as vascular endothelial growth factor (VEGF) are listed below.</p><sec id="sec2dot1dot1-pharmaceutics-15-01700"><title>2.1.1. VEGF</title><p>VEGF is a vascular endothelial cell-specific heparin-binding growth factor that can induce vascular neogenesis in vivo and is a highly conserved homodimeric glycoprotein with a high specificity for cell mitosis. In vivo, VEGF induces endothelial cell proliferation, promotes cell migration, and inhibits apoptosis. In contrast, VEGF-induced angiogenesis with increased vascular permeability plays a critical regulatory role in the generation of blood vessels [<xref rid="B53-pharmaceutics-15-01700" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceutics-15-01700" ref-type="bibr">54</xref>]. Both the short half-life of VEGF and the lack of a suitable long-term sustained release device make it difficult to ensure effective angiogenesis as well as raise waste and safety issues [<xref rid="B3-pharmaceutics-15-01700" ref-type="bibr">3</xref>]. Therefore, it is necessary to select a suitable controlled delivery system.</p><p>Encapsulation of growth factors into microspheres before incorporating into 3D printed scaffolds was shown to be one of the most effective ways to achieve controlled release [<xref rid="B55-pharmaceutics-15-01700" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-15-01700" ref-type="bibr">56</xref>]. Wang et al. [<xref rid="B16-pharmaceutics-15-01700" ref-type="bibr">16</xref>] made bone morphogenetic protein-2 (BMP-2) and VEGF adsorbed onto silk fiber (SF) microspheres (diameter of 1.5 &#177; 0.3 &#956;m) that were prepared using a co-flow capillary device. These microspheres were, subsequently, doped into the SF/nano-hydroxyapatite (nHAp) scaffolds to provide regulated release. As shown in <xref rid="pharmaceutics-15-01700-f001" ref-type="fig">Figure 1</xref>, BMP-2 and VEGF are incorporated into SF microspheres by chemical covalent bonding via EDC/NHS (1-ethyl-3-(3-(dimethylamino) propyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS)) chemistry and physisorption, respectively, which leads to the controlled and sustained release from the SF/nHAp scaffold. The initial rapid release of VEGF mimics its expression during the early bone healing phase and promotes angiogenesis. The comparatively gradual and continuous release of BMP-2 facilitated osteogenic differentiation both in vitro and in vivo.</p><p>After 12 weeks of inserting the printed scaffold into the rat cranial defect location, a CD31 staining experiment showed that blood vessels were identified as brown, round, or oval structures. Compared with control or BMP-2 scaffolds, scaffolds that were loaded with VEGF showed a much higher blood vessel density, and the VEGF group exhibited the strongest signal among all groups. These findings suggested that the scaffolds that contained VEGF help vascularization. Furthermore, compared with BMP-2 or VEGF alone, the combination of BMP-2 and VEGF produced a synergistic effect on bone formation in rat cranial defects with good scaffold angiogenic properties and better osteogenesis, since vascularization is crucial for bone regeneration [<xref rid="B57-pharmaceutics-15-01700" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceutics-15-01700" ref-type="bibr">58</xref>].</p></sec><sec id="sec2dot1dot2-pharmaceutics-15-01700"><title>2.1.2. FGF-2</title><p>Fibroblast growth factor-2 (FGF-2) is a multifunctional peptide that promotes the growth, migration, and differentiation of many cell types [<xref rid="B59-pharmaceutics-15-01700" ref-type="bibr">59</xref>]. FGF-2 was also shown to stimulate VEGF expression, granulation tissue formation, and vascular maturation [<xref rid="B60-pharmaceutics-15-01700" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-15-01700" ref-type="bibr">61</xref>]. Xiong et al. [<xref rid="B17-pharmaceutics-15-01700" ref-type="bibr">17</xref>] used 3D printing to fabricate a gelatin-sulfonated silk composite scaffold (3DG-SF-SO<sub>3</sub>-FGF). The basic FGF-2 was incorporated in this scaffold by binding with a sulfonic acid group (SO<sub>3</sub>). SF has good biocompatibility, mechanical properties, stability, and non-inflammatory response and can be used as a repair for skin, bone, blood vessels, and other tissues [<xref rid="B62-pharmaceutics-15-01700" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceutics-15-01700" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-15-01700" ref-type="bibr">64</xref>]. Modified SF with SO<sub>3</sub> was used in this scaffold to increase its hydrophilicity and can promote the binding of FGF-2. The in vitro release profile of FGF-2 from 3DG-SF-SO<sub>3</sub>-FGF scaffold showed that a 32% burst release was detected during the first 24 h, followed by a sustained slow release profile. A total of 30% of the FGF-2 remained in the stent after 12 days. Then, 4 weeks after implantation, skin wounds of rats showed significantly enhanced regeneration of dermatomal tissue due to the addition of FGF-2. Further investigation showed that a more extensive distribution of vascular recanalization was observed in the scaffold group with FGF-2 binding. Additionally, immunohistochemistry showed a significant increase in the expression of vascular-associated proteins such as &#945;-smooth muscle actin (&#945;-SMA) and CD31. These results demonstrate the importance of FGF-2 in recruiting endogenous cells for epithelialization and angiogenesis at defective sites.</p></sec><sec id="sec2dot1dot3-pharmaceutics-15-01700"><title>2.1.3. PDGF</title><p>Some other growth factors were found to promote angiogenesis, e.g., platelet-derived growth factor (PDGF), which can recruit smooth muscle cell (SMC)/pericytes to immature vessels to stabilize and remodel them [<xref rid="B65-pharmaceutics-15-01700" ref-type="bibr">65</xref>]. The deficiency of this factor will lead to the maintenance of a proliferative endothelial cells (ECs) phenotype, which is detrimental to maturation and even causes vascular degeneration. Currently, there are few experiments in applying them alone to 3D printing technology for tissue regeneration and angiogenesis.</p></sec></sec><sec id="sec2dot2-pharmaceutics-15-01700"><title>2.2. Heparin and Its Derivatives</title><p>Heparin is a negatively charged polysaccharide macromolecule that has good affinity for angiogenic factors. Nih et al. proved that it can accelerate neovascularization by binding angiogenic factors, such as VEGF, and improving their stability [<xref rid="B66-pharmaceutics-15-01700" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-15-01700" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceutics-15-01700" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceutics-15-01700" ref-type="bibr">69</xref>]. An et al. [<xref rid="B18-pharmaceutics-15-01700" ref-type="bibr">18</xref>] coated poly-L-lysine (PLL) and heparin on the surface of 3D-printed hydrogel scaffolds, which were made from cross-linking of gelatin methacrylate (GelMA) and hyaluronic acid methacrylate (HAMA) via electrostatic interactions between PLL (positively charged) and heparin (negatively charged). Then, they were inoculated with hypoxia-inducible factor-1&#945; (HIF-1&#945;) mutated muscle-derived stem cells (MDSCs). At last, the scaffolds were implanted into the injured cavernous body of rabbits finally. After 4 months, the erectile and ejaculatory functions of rabbit&#8217;s penile corpus cavernosum were greatly improved. Additionally, compared with the non-heparin-coated group, the relative protein expression of angiogenic markers (VEGF, PDGF, and stroma cell-derived factor-1 (SDF-1)) was significantly increased in the heparin-coated group. Specifically, angiogenic factors produced by HIF-1&#945;mutant MDSCs were accumulated on the scaffold surface by adsorption of heparin, which, subsequently, stimulated angiogenesis in vivo. The increase in neovascularization further promoted the recovery of erectile and ejaculatory function in the injured penile corpus cavernosum.</p><p>Heparan sulfate (HS), one of the heparin derivatives, is a linear polysaccharide of the glycosaminoglycan family, which can be synthesized by almost all animal cells [<xref rid="B70-pharmaceutics-15-01700" ref-type="bibr">70</xref>]. It has good mechanical properties and thermal stability, and has a large number of binding sites for bioactive molecules. In addition, HS can not only protect growth factors from degradation by proteases [<xref rid="B71-pharmaceutics-15-01700" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceutics-15-01700" ref-type="bibr">72</xref>], but it also promote the binding of growth factors to their receptors, thus promoting growth factor activity [<xref rid="B73-pharmaceutics-15-01700" ref-type="bibr">73</xref>]. Jiang et al. [<xref rid="B19-pharmaceutics-15-01700" ref-type="bibr">19</xref>] fabricated a scaffold with collagen and HS and implanted it at the site of traumatic brain injury in hounds. In situ hybridization (ISH) and immunofluorescence staining showed that HS-containing scaffold promoted vascular and nerve regeneration compared with the control group, and that micro-vessel formation may underlie tissue regeneration and nerve repair.</p></sec><sec id="sec2dot3-pharmaceutics-15-01700"><title>2.3. Ionic Composition</title><p>Many studies incorporated various ionic components with osteogenic, angiogenic, and other functions directly into scaffold materials to allow the controlled delivery, or to functionalize the scaffold surface, or to make scaffolds have specific biological functions [<xref rid="B74-pharmaceutics-15-01700" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceutics-15-01700" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceutics-15-01700" ref-type="bibr">76</xref>]. In addition, most of these ions have some biological interactions with cells (e.g., promoting the expression of growth factors by endothelial cells, promoting cell migration differentiation and proliferation, etc.), and perform pro-vascularization functions via these interactions. <xref rid="pharmaceutics-15-01700-t002" ref-type="table">Table 2</xref> shows the role of the different ions in the hydrogel and briefly describes the mechanisms by which they function and how they are applied.</p><sec id="sec2dot3dot1-pharmaceutics-15-01700"><title>2.3.1. Silicon Ions</title><p>Silicon (Si) is one of the essential elements for the development of healthy bones and blood vessels [<xref rid="B86-pharmaceutics-15-01700" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceutics-15-01700" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceutics-15-01700" ref-type="bibr">88</xref>]. It was demonstrated that the addition of Si ions may promote osteogenic differentiation of human bone marrow stromal cells (hBMSCs) [<xref rid="B89-pharmaceutics-15-01700" ref-type="bibr">89</xref>], and play a significant role in enhancing angiogenesis of ECs [<xref rid="B90-pharmaceutics-15-01700" ref-type="bibr">90</xref>,<xref rid="B91-pharmaceutics-15-01700" ref-type="bibr">91</xref>]. Many researchers found that the expression of many factors related to angiogenesis (e.g., VEGF, kinase insert domain-containing receptor (KDR), and HIF-1&#945; et al.) in vascular endothelial cells was significantly boosted under the stimulation of Si ions. In addition, in vitro migration, differentiation, and tubular formation of vascular endothelial cells were stimulated in the presence of Si ions. To better utilize the pro-vascularization and osteogenic functions of Si ions, Li et al. [<xref rid="B77-pharmaceutics-15-01700" ref-type="bibr">77</xref>] used a novel calcium phosphate cement (CPC) as the basis for a scaffold that combined mesoporous silica (MS) with recombinant human bone morphogenetic protein-2 (rhBMP-2) to promote osteogenesis and angiogenesis. This bioactive mesoporous scaffold has well-interconnected macropores. Due to the inherent self-setting properties of calcium phosphate cements, the scaffolds can be printed at room temperature without sintering afterwards and have enhanced mechanical strength. This study showed that more newly formed vessels could be observed in the MS/CPC group compared to the CPC-only group. As seen in <xref rid="pharmaceutics-15-01700-f002" ref-type="fig">Figure 2</xref>, the micro-computerized tomography (&#956;CT) results of the rabbit radius&#8212;4 weeks after stent implantation&#8212;showed that abundant blood vessels formed around the CPC-only stent, and no blood vessels were observed inside the stent. The MS/CPC and MS/CPC/rhBMP-2 stents not only had abundant blood vessels around the stent, but the blood vessels also grew along the interconnected macropores inside the stent. This suggests significant promotion of vascularization by Si ions. However, this study did not delve into the mechanism of Si ions on promoting neovascularization, and so, further studies are needed in this area.</p></sec><sec id="sec2dot3dot2-pharmaceutics-15-01700"><title>2.3.2. Magnesium Ions</title><p>Magnesium (Mg) is one of the essential elements of the human body and is associated with many physiological activities [<xref rid="B92-pharmaceutics-15-01700" ref-type="bibr">92</xref>,<xref rid="B93-pharmaceutics-15-01700" ref-type="bibr">93</xref>]. Compared to other metallic or polymeric materials, Mg can promote vascular growth and improve local blood perfusion [<xref rid="B94-pharmaceutics-15-01700" ref-type="bibr">94</xref>,<xref rid="B95-pharmaceutics-15-01700" ref-type="bibr">95</xref>], they also play a direct and important role in maintaining vascular function [<xref rid="B96-pharmaceutics-15-01700" ref-type="bibr">96</xref>], especially for vascular endothelial cells. It is well known that vascular endothelial cells play an irreplaceable role in angiogenesis and that capillary branching, germination, and proliferation are dependent on them. It was shown that magnesium ions stimulate the proliferation of HUVEC and increase their response to some motogenic factors. In addition, Mg ion can also upregulate integrin function, which is one of the reasons why it can promote endothelial cell migration [<xref rid="B94-pharmaceutics-15-01700" ref-type="bibr">94</xref>,<xref rid="B95-pharmaceutics-15-01700" ref-type="bibr">95</xref>]. In addition, Mg ions were also demonstrated to have the ability to promote new bone formation and bone growth [<xref rid="B97-pharmaceutics-15-01700" ref-type="bibr">97</xref>,<xref rid="B98-pharmaceutics-15-01700" ref-type="bibr">98</xref>].</p><p>Gu et al. [<xref rid="B78-pharmaceutics-15-01700" ref-type="bibr">78</xref>] fabricated Mg-doped &#946;-TCP (Mg-TCP) scaffolds by 3D printing and sintering, in which MgO was mixed in four groups at 0, 1, 2, and 4 wt% ratios. &#946;-TCP, as one of the commonly used biomaterials for scaffold preparation, has excellent biocompatibility and biodegradability, and its composition is also similar to that of natural bone minerals [<xref rid="B99-pharmaceutics-15-01700" ref-type="bibr">99</xref>]. Endothelium-derived nitric oxide (NO) was used as an index to evaluate the angiogenic capacity. In vitro experiments showed that the 1Mg-TCP group produced the most NO compared to the other groups of human umbilical vein endothelial cells (HUVECs) cultured in extracts. This indicated that Mg<sup>2+</sup> had the strongest angiogenic capacity at this dose, but the specific correlation between the high and low angiogenic capacity and Mg<sup>2+</sup> dose was not elucidated.</p><p>Due to the inherent properties of some scaffolds, Mg<sup>2+</sup> can&#8217;t be immobilized on its inner and outer surfaces uniformly. Therefore, it should rely on other substances to assist in immobilization, such as polydopamine (PDA). Inspired by mussel adhesion, PDA is able to hold onto almost anything and was extensively studied in many surface-modification experiments [<xref rid="B100-pharmaceutics-15-01700" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceutics-15-01700" ref-type="bibr">101</xref>]. Ma et al. [<xref rid="B79-pharmaceutics-15-01700" ref-type="bibr">79</xref>] used the surface adhesion ability of PDA to make Ta-PDA-Mg scaffolds by doping Mg<sup>2+</sup> on the surface of 3D printed tantalum scaffolds. Then, Mg(NO<sub>3</sub>)<sub>2</sub> was added to the surface of the scaffolds at doses of 0, 10, 20, and 50 mg, and the four groups of scaffolds were named Ta-PDA, Ta-PDA-Mg1, Ta-PDA-Mg2, and Ta-PDA-Mg3, respectively. The results showed that the constructed Ta-PDA-Mg scaffold promoted osteogenic and angiogenic responses in vitro and in vivo compared with the control group. In particular, Ta-PDA-Mg2 is the most effective (not Ta-PDA-Mg3), and immunofluorescence showed more mature angiogenesis in this group.</p><p>There is no doubt that Mg<sup>2+</sup> promotes blood vessel regeneration, but high concentrations of Mg<sup>2+</sup> may have the opposite effect [<xref rid="B78-pharmaceutics-15-01700" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceutics-15-01700" ref-type="bibr">79</xref>]. The decreased angiogenic capacity may be related to the decrease in cell viability caused by high concentrations of Mg<sup>2+</sup>, but most experiments did not involve further studies. In addition, there are few reports on the relationship between the expression of angiogenesis-related genes in endothelial cells and Mg<sup>2+</sup> concentration.</p></sec><sec id="sec2dot3dot3-pharmaceutics-15-01700"><title>2.3.3. Copper Ions</title><p>Copper (Cu) is one of the indispensable trace elements for human beings, and the appropriate amount of Cu<sup>2+</sup> is very important for maintaining health [<xref rid="B82-pharmaceutics-15-01700" ref-type="bibr">82</xref>]. In addition, Cu<sup>2+</sup> can stimulate endothelial cell proliferation and differentiation. They promote angiogenesis by mimicking hypoxia, stabilizing the expression of HIF-1&#945;, and promoting the expression of VEGF [<xref rid="B102-pharmaceutics-15-01700" ref-type="bibr">102</xref>,<xref rid="B103-pharmaceutics-15-01700" ref-type="bibr">103</xref>,<xref rid="B104-pharmaceutics-15-01700" ref-type="bibr">104</xref>]. Tao et al. [<xref rid="B82-pharmaceutics-15-01700" ref-type="bibr">82</xref>] fabricated a novel metal-organic framework, a &#946;-tricalcium phosphate (Cu-TCPP-TCP) scaffold containing a Cu<sup>2+</sup> coordinated tetrakis (4-carboxyphenyl) porphyrin (Cu-TCPP) nanosheet interfacial structure, by using 3D printing technology. Cu-TCPP belongs to the family of metal organic frameworks (MOFs). MOF-based materials can be used for tumor therapy by converting infrared light into thermal energy in the biomedical field [<xref rid="B105-pharmaceutics-15-01700" ref-type="bibr">105</xref>,<xref rid="B106-pharmaceutics-15-01700" ref-type="bibr">106</xref>]. It turned out that Cu-TCPP-TCP scaffold supported the attachment of hBMSCs and HUVECs. It also significantly stimulated the expression of genes related to osteogenic differentiation in hBMSCs and angiogenic differentiation in HUVECs. Studies in vivo revealed that after implantation of the Cu-TCPP-TCP scaffold into femoral defects in rabbits, the scaffold effectively promoted regeneration of the femur. So, Cu<sup>2+</sup>-stimulated angiogenesis is essential for the formation of new bone tissue and plays an important role in determining the success or failure of implanted bone tissue grafts [<xref rid="B107-pharmaceutics-15-01700" ref-type="bibr">107</xref>]. In conclusion, osteogenic bioactivity of the TCP scaffold, photothermal properties of Cu-TCPP nanosheets, and angiogenic activity of Cu<sup>2+</sup> all enable the multifunctional properties of the Cu-TCPP-TCP scaffold.</p></sec></sec><sec id="sec2dot4-pharmaceutics-15-01700"><title>2.4. Vascular-Promoting Cell</title><sec id="sec2dot4dot1-pharmaceutics-15-01700"><title>2.4.1. Human Umbilical Vein Endothelial Cells</title><p>HUVECs are one of the stem cells derived from umbilical cord tissue who play an important role in angiogenesis that can prevent the need for pre-formed channels or growth factor-induced angiogenesis [<xref rid="B108-pharmaceutics-15-01700" ref-type="bibr">108</xref>]. It is one of the most popular endothelial cell lines and is widely used to study, thanks to low cost, ease of isolation, and strong angiogenic potential [<xref rid="B109-pharmaceutics-15-01700" ref-type="bibr">109</xref>]. Cidonio et al. [<xref rid="B110-pharmaceutics-15-01700" ref-type="bibr">110</xref>] fabricated a 3D scaffold printed with a bioink based on Laponite (LAP) nanoclay and, subsequently, seeded with human umbilical vein endothelial cells and loaded with VEGF. LAP nanoclay, the nanocomposites, can be used as a bioink to make hydrogels to maintain cell activity and create functional 3D implants [<xref rid="B111-pharmaceutics-15-01700" ref-type="bibr">111</xref>]. Seven days after implantation of the scaffold into the chick chorioal lantoic membrane (CAM), the 3D-printed scaffold, which was equipped with VEGF and HUVECs, was extensively bound to the CAM. In addition, neovascularization penetrated the pores of the printed structures with numerous capillaries around the scaffolds. Moreover, the combination of VEGF and HUVECs had a significantly enhanced effect compared to the individual loading VEGF or HUVECs. This suggests that the interaction of VEGF and HUVECs can be mutually optimized to reduce vascular leakage caused by excessive stimulation of vascular permeability by VEGF [<xref rid="B112-pharmaceutics-15-01700" ref-type="bibr">112</xref>].</p></sec><sec id="sec2dot4dot2-pharmaceutics-15-01700"><title>2.4.2. Mesenchymal Stem Cells</title><p>Mesenchymal stem cells (MSCs) are a group of adult stem cells of mesodermal origin that can be derived from the placenta, liver, bone marrow, umbilical cord blood, adipose tissue, and heart [<xref rid="B113-pharmaceutics-15-01700" ref-type="bibr">113</xref>]. MSCs in adult tissues often work as progenitor cells because they are highly proliferative and can differentiate into specific lineages, such as bone cells, endothelial cells, etc. They are considered to be one of the most appropriate cell sources for tissue engineering [<xref rid="B114-pharmaceutics-15-01700" ref-type="bibr">114</xref>,<xref rid="B115-pharmaceutics-15-01700" ref-type="bibr">115</xref>].</p><p>Although it was demonstrated that cartilage tissue, printed with bioink that contains MSCs, is well-vascularized in vivo because of its capability to secrete a variety of vascular growth factors such as VEGF, FGF-2, and PDGF et al., angiogenesis is often limited in peripheral areas, with no persistent vascularity in the core area of the cartilage [<xref rid="B116-pharmaceutics-15-01700" ref-type="bibr">116</xref>]. Since angiogenesis plays a crucial role in bone regeneration [<xref rid="B21-pharmaceutics-15-01700" ref-type="bibr">21</xref>,<xref rid="B107-pharmaceutics-15-01700" ref-type="bibr">107</xref>,<xref rid="B117-pharmaceutics-15-01700" ref-type="bibr">117</xref>], it is important to design a 3D-printed scaffold with a controlled internal structure that can guide the repair and vascularization of the core region within the cartilage. Daly et al. [<xref rid="B118-pharmaceutics-15-01700" ref-type="bibr">118</xref>] used Pluronic ink as a sacrificial bioink to form a network of interconnected microchannels within a GelMA hydrogel, which was filled with MSCs to ensure vascularization of the core region. Four weeks after implantation of the scaffold with microchannel into the bone defect, &#956;CT angiography showed a significant increase in the level of vascularization in the core region of the defect. This design provides the possibility to solve the difficulty of blood vessel formation within cartilage and other tissues.</p><p>In addition, a system of co-culture of osteoblasts and angiogenic cells was proposed, which can achieve complementary osteogenesis and angiogenesis [<xref rid="B119-pharmaceutics-15-01700" ref-type="bibr">119</xref>]. For example, Rong et al. [<xref rid="B120-pharmaceutics-15-01700" ref-type="bibr">120</xref>] chose induction media to co-culture bi-directionally induced human umbilical cord mesenchymal stem cells (hUCMSCs). HUCMSCs are one of the MSCs that originate from the umbilical cord of newborns. It can secrete cytokines which are related to processes such as inflammation, immune regulation, angiogenesis, and wound healing [<xref rid="B121-pharmaceutics-15-01700" ref-type="bibr">121</xref>]. The os-hUCMSCs (osteogenically induced hUCMSCs) and en-hUCMSCs (angiogenically induced hUCMSCs) were pre-induced for 3 days before co-culture was performed. In co-culture, pre-induced os-hUCMSCs and en-hUCMSCs were mixed in different ratios and, subsequently, doped into 3D-printed TCP scaffolds. Loading the scaffolds into the defective part of rat skull for 4 weeks showed that the scaffolds had the best osteogenic ability in vitro and in vivo, where the ratio of os-hUCMSCs and en-hUCMSCs was 3:1. The higher ratio the mixed en-hUCMSCs was, the more vascular tubules were formed on the matrix gel. However, this experiment was performed to guide the clinical application of hUCMSCs by directly using human-derived cells in non-immunodeficient SD rats and without postoperative immunosuppression. So, this process will inevitably cause immune rejection. In addition, the genome and proteome of bidirectionally differentiated hUCMSCs need to be further investigated.</p><p>In addition to pro-vascularization properties, MSCs in hydrogels also possess immunomodulatory as well as regulatory collagen deposition capabilities. <xref rid="pharmaceutics-15-01700-t003" ref-type="table">Table 3</xref> lists the mechanisms by which HUVECs and MSCs function in hydrogels and briefly depicts the ways in which researchers have applied them to hydrogels.</p></sec></sec><sec id="sec2dot5-pharmaceutics-15-01700"><title>2.5. Other Materials</title><p>Some other additives were demonstrated to exert a certain degree of pro-vascularization.</p><sec id="sec2dot5dot1-pharmaceutics-15-01700"><title>2.5.1. Desferrioxamine</title><p>Desferrioxamine (DFO) is an iron chelator that can bind and assist in the removal of iron ions, and is often used as a hypoxia-mimetic compound under oxygenated conditions. HIF-1&#945;, which is produced during hypoxia, acts as a cellular transcription factor, and was demonstrated to be essential for the regulation of genes related to angiogenesis and osteogenesis [<xref rid="B123-pharmaceutics-15-01700" ref-type="bibr">123</xref>,<xref rid="B124-pharmaceutics-15-01700" ref-type="bibr">124</xref>,<xref rid="B125-pharmaceutics-15-01700" ref-type="bibr">125</xref>]. When DFO was activated, it would lead to the activation of a cascade of pro-angiogenic genes, such as VEGF. Thus, DFO can promote both angiogenesis and bone regeneration when used in fracture models [<xref rid="B126-pharmaceutics-15-01700" ref-type="bibr">126</xref>,<xref rid="B127-pharmaceutics-15-01700" ref-type="bibr">127</xref>,<xref rid="B128-pharmaceutics-15-01700" ref-type="bibr">128</xref>]. Yan et al. [<xref rid="B21-pharmaceutics-15-01700" ref-type="bibr">21</xref>] designed a bionic degradable polycaprolactone (PCL) scaffold using 3D printing technology. The printed PCL scaffold has macropore and multidirectional channel structure. PCL is one of the most commonly polymers that is used in 3D-printed scaffolds with good biocompatibility and biodegradability. It can control the release of DFO by surface degradation and layer-by-layer assembly techniques [<xref rid="B129-pharmaceutics-15-01700" ref-type="bibr">129</xref>,<xref rid="B130-pharmaceutics-15-01700" ref-type="bibr">130</xref>]. Results in vitro showed that the scaffold enhanced the angiogenic activity of HUVECs and the osteogenic activity of BMSCs. Studies in vivo indicated that after implantation of the scaffold at the site of femoral defects in rats, it enhanced rapid vascular invasion and accelerated osseointegration. Overall, DFO gave the scaffold consistent ability to promote angiogenesis and osteogenesis in vitro and in vivo. However, the sample size of this study was too small and a larger sample size is needed to validate the results.</p></sec><sec id="sec2dot5dot2-pharmaceutics-15-01700"><title>2.5.2. Catalase</title><p>It was demonstrated that H<sub>2</sub>O<sub>2</sub> is produced by cells in a hypoxic state and will contribute to an environment of oxidative stress and ischemia [<xref rid="B131-pharmaceutics-15-01700" ref-type="bibr">131</xref>,<xref rid="B132-pharmaceutics-15-01700" ref-type="bibr">132</xref>]. Catalase can break down hydrogen peroxide and produce oxygen, which not only reduces the damage caused by H<sub>2</sub>O<sub>2</sub>, but the oxygen that it produces also helps to induce angiogenesis [<xref rid="B133-pharmaceutics-15-01700" ref-type="bibr">133</xref>]. Rija et al. [<xref rid="B22-pharmaceutics-15-01700" ref-type="bibr">22</xref>] intercalated catalase in hydrogels to form functional decellularized adipose tissue-alginate (DAT-A) hydrogels using 3D printing technology. <xref rid="pharmaceutics-15-01700-f003" ref-type="fig">Figure 3</xref> shows the abbreviated manufacturing process.</p><p>DAT was widely used in research and clinical applications due to its excellent biocompatibility and degradability. Its main components are collagen and sulfated glycosaminoglycans (GAG) containing hyaluronic acid (HA) [<xref rid="B134-pharmaceutics-15-01700" ref-type="bibr">134</xref>,<xref rid="B135-pharmaceutics-15-01700" ref-type="bibr">135</xref>]. In addition, DAT was shown to enhance the extracellular matrix (ECM) and cells, cell&#8211;cell interactions, and stem cell differentiation [<xref rid="B136-pharmaceutics-15-01700" ref-type="bibr">136</xref>]. After implanting the scaffold subcutaneously in rats for 4 weeks, tissue growth increased at the implantation site (&#8805;45%), inflammation reduced (&#8805;40%), and induction in angiogenesis increased (&#8805;40%), as compared to the control group. This demonstrated that the scaffold could successfully promote angiogenesis and tissue regeneration.</p></sec><sec id="sec2dot5dot3-pharmaceutics-15-01700"><title>2.5.3. Decellularized Extracellular Matrix</title><p>Decellularized extracellular matrix (dECM) bioinks with rheological and gel are promising materials for generating functional human tissues [<xref rid="B137-pharmaceutics-15-01700" ref-type="bibr">137</xref>]. During decellularization, some of the functions of the ECM are preserved, which facilitate the induced differentiation of pluripotent stem cells on dECM scaffolds into tissue-specific cell types [<xref rid="B138-pharmaceutics-15-01700" ref-type="bibr">138</xref>,<xref rid="B139-pharmaceutics-15-01700" ref-type="bibr">139</xref>].</p><p>In previous studies, various tissue-specific dECMs (fat, muscle, liver, cartilage, and blood vessels, etc.) were successfully fabricated into printable bioinks [<xref rid="B134-pharmaceutics-15-01700" ref-type="bibr">134</xref>,<xref rid="B140-pharmaceutics-15-01700" ref-type="bibr">140</xref>,<xref rid="B141-pharmaceutics-15-01700" ref-type="bibr">141</xref>]. These successful examples enabled skin-derived decellularized extracellular matrix (S-dECM) to be attempted for the formulation of bioinks based on 3D cell printing for skin tissue engineering. Kim et al. [<xref rid="B23-pharmaceutics-15-01700" ref-type="bibr">23</xref>] used S-dECM bioink to print and fabricate 3D pre-vascularized skin patches for wound healing with infusion of adipose-derived stem cells (ASCs) and endothelial progenitor cells (EPCs). The 3D-printed skin patches loaded with EPCs+ASCs showed a rapid pre-vascularization in vitro within 3 days. Immunofluorescence results after 3 weeks of implantation in mice revealed that wounds with implanted patches exhibited enhanced wound closure, neovascularization, and robust blood flow. In comparison to injection of EPCs + ASCs alone, 3D-printed skin patches using dECM bioink showed significant formation of CD31-positive blood vessels, thus promoting skin repair.</p><p>Extracellular matrix associated with cardiac tissues is also widely studied and used in 3D bioprinting today. For example, decellularized cardiac extracellular matrix hydrogel (cECM) is a promising biomaterial for myocardial repair, which can improve cardiac function and progenitor cell delivery [<xref rid="B142-pharmaceutics-15-01700" ref-type="bibr">142</xref>]. Bejleri et al. [<xref rid="B24-pharmaceutics-15-01700" ref-type="bibr">24</xref>] fabricated a 3D-bioprinted patch containing cECM for the delivery of pediatric cardiac progenitor cells hCPCs. The patch is printed with bioinks consisting of cECM, hCPCs, and GelMA. Compared to hCPCs grown in pure GelMA patches, the addition of cECM within patch results in a 30-fold increase in cardiogenic gene expression of hCPCs. As seen in the improved endothelial cell tube formation, the media from GelMA-cECM patches revealed an increased angiogenic potential (&gt;2-fold) compared to the GelMA alone group.</p><p>Overall, the successful fabrication of vascularized tissue is key to tissue engineering. Still, it is difficult to create a tissue engineering scaffold that is recognized to be very effective in promoting vascularization. Among the many additives added to 3D-printed scaffolds, most of their pro-angiogenic mechanisms are related to vascular growth factors, especially VEGF, such as stimulating VEGF expression in various ways, enhancing VEGF activity, or binding to VEGF to enhance its stability, and so on. Although VEGF plays an irreplaceable role in vasculogenesis and angiogenesis, there are also many other factors or pathways that can contribute to pro-vascularization.</p></sec><sec id="sec2dot5dot4-pharmaceutics-15-01700"><title>2.5.4. Angiogenic Peptides</title><p>Angiogenic peptides (AP) are synthetic peptides that are functionally equivalent to VEGF. AP and VEGF are known to bind to the same receptors to initiate angiogenesis. However, AP can be synthesized on a larger scale and is less expensive than VEGF, thus enabling greater use to promote angiogenesis [<xref rid="B143-pharmaceutics-15-01700" ref-type="bibr">143</xref>]. Wang et al. [<xref rid="B20-pharmaceutics-15-01700" ref-type="bibr">20</xref>] made a dual-delivery bone tissue engineering scaffold by low-temperature 3D printing of &#946;-tricalcium phosphate and osteogenic peptide (OP) containing water/PLGA/DCM emulsion&#8212;and coating AP on the scaffold surface. After implanting the scaffold into a rat cranial bone defect model for 3 months, the scaffold not only induced an improvement in new bone formation but also a regeneration of blood vessels with larger diameters compared to the control group. The scaffold achieved the dual function of enhancing bone tissue regeneration and vascularization.</p></sec></sec></sec><sec id="sec3-pharmaceutics-15-01700"><title>3. Antibacterial</title><p>Human skin and mucosal surfaces are covered by a variety of microbiota, which can be divided into two main groups&#8212;resident and transient flora. The resident flora consists of relatively fixed types of microorganisms, while the transient flora consists of non-pathogenic or potentially pathogenic microorganisms [<xref rid="B144-pharmaceutics-15-01700" ref-type="bibr">144</xref>]. It was experimentally demonstrated that the most common bacterial species is <italic toggle="yes">Staphylococcus aureus</italic> (37%), followed by <italic toggle="yes">Pseudomonas aeruginosa</italic> (17%), <italic toggle="yes">Aspergillus</italic> (10%), and <italic toggle="yes">Escherichia coli</italic> (6%) [<xref rid="B145-pharmaceutics-15-01700" ref-type="bibr">145</xref>]. The attachment of bacteria to the surface of various substances leads to the formation of biofilms, which allows bacteria to evade the action of antibiotics and causes immune responses [<xref rid="B146-pharmaceutics-15-01700" ref-type="bibr">146</xref>] and various complications such as the failure of wound healing. In addition, if bacterial membranes adhere to medical implants, they can lead to the failure of the insertion, which can also result in a significant socio-economic burden [<xref rid="B147-pharmaceutics-15-01700" ref-type="bibr">147</xref>,<xref rid="B148-pharmaceutics-15-01700" ref-type="bibr">148</xref>]. Furthermore, because any implants will lack blood and lymphatic supply, they have low blood flow and oxygen delivery, making it difficult for leukocytes to exert antimicrobial action. Although many methods were designed to promote vascularization for normal immune surveillance, implants are still at risk of developing infected lesions until an adequate vascular supply is available [<xref rid="B149-pharmaceutics-15-01700" ref-type="bibr">149</xref>,<xref rid="B150-pharmaceutics-15-01700" ref-type="bibr">150</xref>]. Therefore, it is imperative to include materials with antimicrobial activity in stents to confer antimicrobial ability to prevent and mitigate infection in implanted stents. Although different substances have different antimicrobial mechanisms, they all show goodness in vivo and in vitro antimicrobial effects. <xref rid="pharmaceutics-15-01700-f004" ref-type="fig">Figure 4</xref> enumerates the different additives incorporated in the hydrogel according to the different antimicrobial mechanisms.</p><sec id="sec3dot1-pharmaceutics-15-01700"><title>3.1. Disruption of Bacterial Cell Membranes</title><sec id="sec3dot1dot1-pharmaceutics-15-01700"><title>3.1.1. Silver Ion</title><p>Silver (Ag) is widely used as an antimicrobial agent to prevent infections during wound healing. Today, silver is mainly used in the form of metallic silver nanoparticles (AgNPs). AgNPs were experimentally demonstrated to have antibacterial activity against bacteria, yeast, and fungi [<xref rid="B151-pharmaceutics-15-01700" ref-type="bibr">151</xref>,<xref rid="B152-pharmaceutics-15-01700" ref-type="bibr">152</xref>]. In a study, Ching et al. provided several possible antimicrobial mechanisms: (1) anchoring of AgNps on bacterial membranes leading to rupture of bacterial membranes and leakage of bacterial contents, resulting in bacterial cell death; (2) nanoparticles can penetrate into bacterial membranes and interact with biomolecules, resulting in bacterial dysfunction; (3) AgNps may catalyze the reduction in O<sub>2</sub> to reactive oxygen species (ROS), leading to downregulation of antioxidant enzyme expression, DNA damage, and apoptosis [<xref rid="B153-pharmaceutics-15-01700" ref-type="bibr">153</xref>]. Incorporating AgNPs into hydrogel matrices is by physical doping, but it will lead to rapid release of Ag<sup>+</sup> into the surrounding environment [<xref rid="B154-pharmaceutics-15-01700" ref-type="bibr">154</xref>,<xref rid="B155-pharmaceutics-15-01700" ref-type="bibr">155</xref>].</p><p>To solve this problem and to exploit the antibacterial ability of Ag<sup>+</sup>, as we can see in <xref rid="pharmaceutics-15-01700-f005" ref-type="fig">Figure 5</xref>, Wu et al. [<xref rid="B85-pharmaceutics-15-01700" ref-type="bibr">85</xref>] designed a superporous polyacrylamide (PAM)/Hydroxypropyl Methyl Cellulose (HPMC) hydrogel with antibacterial ability by using Ag<sup>+</sup>-ethylene interactions and 3D printing technology.</p><p>The Ag<sup>+</sup>-ethylene interaction plays an important role in the dispersion, release, and cross-linking of AgNPs in the hydrogel matrix and their cross-linking with the PAM network. Also, this interaction facilitates the cytocompatibility and antimicrobial activity of AgNPs cross-linked hydrogels and reduces the toxicity of Ag<sup>+</sup>. In addition, HPMC was chosen to be incorporated into the formed hydrogels, mainly due to high water absorption and retention properties [<xref rid="B156-pharmaceutics-15-01700" ref-type="bibr">156</xref>]. It can confer a rapid water absorption rate to the hydrogel to facilitate the retention of more exudate, or extend its use to prevent surface drying of the wound [<xref rid="B157-pharmaceutics-15-01700" ref-type="bibr">157</xref>]. Antimicrobial experiments in vitro showed that AgNPs cross-linked dressing showed a significant zone of inhibition against both <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Escherichia coli</italic> bacterial colonies compared with the control group of hydrogel dressing containing HPMC and chitosan. Meanwhile, the wounds had smoother surface during healing and minimal scar morphology after 14 days of healing. Histological analysis indicated that the AgNPs cross-linked hydrogel dressing could inhibit the formation of scar tissue.</p></sec><sec id="sec3dot1dot2-pharmaceutics-15-01700"><title>3.1.2. Photothermal Materials</title><p>To improve the antimicrobial properties of stents, photothermal therapy (PTT) attracted extensive interest from researchers as a promising antimicrobial method [<xref rid="B158-pharmaceutics-15-01700" ref-type="bibr">158</xref>]. Due to its low side effects, deep tissue penetration, and rapid therapeutic effect, it was widely explored for use in the treatment of tumor and implant infections. However, since most photothermal agents do not have the ability to induce tissue regeneration, the development of photothermal agents should promote tissue generation and inhibit bacteria. Nie et al. [<xref rid="B25-pharmaceutics-15-01700" ref-type="bibr">25</xref>] fabricated a personalized MXene composite hydrogel scaffold GelMA/&#946;-TCP/sodium alginate (Sr2+)/MXene (Ti3C2) (GTAM) with both photothermal antibacterial and osteogenic capabilities using 3D printing technology. As a new class of transition metal carbide/nitride/carbon nitride, it has an ultrathin structure, excellent physicochemical properties, good biocompatibility, excellent near-infrared absorption and photothermal conversion efficiency, low toxicity, and good biodegradability [<xref rid="B159-pharmaceutics-15-01700" ref-type="bibr">159</xref>,<xref rid="B160-pharmaceutics-15-01700" ref-type="bibr">160</xref>]. Therefore, MXene was widely used in biomedical applications such as photodynamic therapy (PDT) [<xref rid="B161-pharmaceutics-15-01700" ref-type="bibr">161</xref>], antibacterial [<xref rid="B162-pharmaceutics-15-01700" ref-type="bibr">162</xref>], and drug delivery [<xref rid="B163-pharmaceutics-15-01700" ref-type="bibr">163</xref>], etc. It was noted that MXenes can kill microorganisms such as Gram-positive and negative bacteria by disrupting bacterial membranes directly through physical contact [<xref rid="B162-pharmaceutics-15-01700" ref-type="bibr">162</xref>,<xref rid="B164-pharmaceutics-15-01700" ref-type="bibr">164</xref>], especially when supplemented with NIR irradiation for higher antimicrobial efficiency [<xref rid="B165-pharmaceutics-15-01700" ref-type="bibr">165</xref>]. In vitro antibacterial experiments showed that the GelMA/&#946;-TCP/sodium alginate (Sr<sup>2+</sup>) (GTA) scaffold did not have antibacterial properties, regardless of NIR light irradiation. Although the physical contact of GTAM had certain antibacterial activity, the antibacterial ability was relatively weak, and only the GTAM+NIR group had significant bacterial inhibitory ability. In vivo antibacterial experiments showed that the GTAM scaffold had effective photothermal conversion abilities, and its antibacterial activity was excellent against both G (+) and G (&#8722;) bacteria under 808 nm NIR irradiation. On the other hand, GTAM composite bioink was mixed with rat bone marrow mesenchymal stem cells (rBMSCs) and then 3D-bioprinted at low temperature. The scaffolds showed good biocompatibility and promoted the proliferation and differentiation of rBMSCs. The scaffold was implanted into the mandibular defect of rats, and the treatment results under 808 nm NIR irradiation revealed significant bacterial clearance and osteogenesis-promoting effects at the implantation site. In conclusion, this bifunctional 3D-printed composite hydrogel scaffold with both antibacterial ability and the ability to promote precise bone tissue remodeling and regeneration is a novel but very promising biomaterial.</p></sec></sec><sec id="sec3dot2-pharmaceutics-15-01700"><title>3.2. Destruction of Bacterial Cell Walls</title><sec><title>Vancomycin + Ceftazidime</title><p>Vancomycin belongs to a group of glycopeptide antibiotics, which can exert a strong bactericidal ability by inhibiting cell wall biosynthesis through specific binding to the dipeptide d-Ala-d-Ala (AA) at the end of bacterial cell wall precursors [<xref rid="B166-pharmaceutics-15-01700" ref-type="bibr">166</xref>,<xref rid="B167-pharmaceutics-15-01700" ref-type="bibr">167</xref>]. Additionally, Ceftazidime can inhibit bacterial peptidoglycan synthesis by inhibiting penicillin-binding proteins, leading to cell wall instability and inhibition of synthesis and cell death [<xref rid="B168-pharmaceutics-15-01700" ref-type="bibr">168</xref>]. Yu et al. [<xref rid="B26-pharmaceutics-15-01700" ref-type="bibr">26</xref>] incorporated the combination of two types of antibiotics (vancomycin and ceftazidime) into a 3D-printed scaffold to give the scaffold a sustained release of different antibiotics. They fabricated a mesh-like PCL scaffold by using 3D printing technology and poly(lactic-co-glycolic-acid) (PLGA) nanofibers with a hybrid sheath core structure by using co-axial electrospinning technique. Subsequently, they fabricated this nanofiber membrane in two layers, namely, an electrospun PLGA/vancomycin/ceftazidime layer and a coaxially spun PLGA/BMP-2 layer. After implantation of the scaffold into the femoral defect in rabbits, the drug release profile showed that in vivo release of both antibiotics from the PLGA nanofibers showed a similar trend: the drugs were released explosively on day 1, and the release concentration decreased on day 7 until day 28 when the drug release gradually increased and the release was maintained until day 42. The concentrations of both antibiotics remained well above the 90% minimum inhibitory concentration throughout the study period. BMP-2 also showed a release profile similar to that of the antibiotics. With the stimulation of the scaffold, an abundance of growth factors was induced within the bioactive membrane of the femur. Excellent bone healing ability was found in both radiological examination and biomechanical assessment. Mechanical properties tests showed that femurs in the PCL-PLGA/antibiotic group and the PCL-PLGA/antibiotic/BMP-2 group exhibited torsional strength almost identical to that of healthy femurs. However, the experiment still has some shortcomings: the bone defect model was not an infected bone defect model and the antimicrobial effect was assumed based on the detection of local antibiotic concentrations rather than a direct test of its antimicrobial performance in vivo or in vitro. Furthermore, despite the satisfactory osseointegration, it was unknown whether the antibiotic-loaded nanofibers would behave differently when encountering the healing of large human bone defects that are much more complex.</p></sec></sec><sec id="sec3dot3-pharmaceutics-15-01700"><title>3.3. Inhibits Bacterial DNA Replication</title><sec><title>Levofloxacin</title><p>Levofloxacin, one of the quinolone antibiotics, is a broad-spectrum antibiotic used in the treatment of bone infections to combat and prevent osteomyelitis, penetrate bone trabeculae and bone cortex, and minimize the risk of bacterial resistance [<xref rid="B169-pharmaceutics-15-01700" ref-type="bibr">169</xref>]. It exerts its antimicrobial action mainly by inhibiting bacterial helicase activity, which leads to the inability of DNA to replicate and synthesize properly, ultimately causing bacterial death. Sadaba et al. [<xref rid="B27-pharmaceutics-15-01700" ref-type="bibr">27</xref>] produced poly (lactic acid) (PLA) scaffolds with 3D printing technology and, subsequently, added PDA-coated BaSO<sub>4</sub> particles within the scaffolds and adsorbed levofloxacin to impart antimicrobial properties to the scaffolds. Inorganic particle enhancers such as BaSO<sub>4</sub> particles can improve the mechanical properties of the polymer and impart additional specific properties to the scaffold [<xref rid="B170-pharmaceutics-15-01700" ref-type="bibr">170</xref>]. PDA is an adhesive that often acts as a substrate coating to be conjugated with biologically active materials, e.g., small molecule drugs and proteins, to anchor them to the scaffold surface. The PLA/PD-BaSO<sub>4</sub> scaffold containing levofloxacin effectively inhibited bacterial growth on agar disks inoculated with <italic toggle="yes">Staphylococcus aureus</italic>, and a significant zone of inhibition was observed. Mechanical property analysis of the scaffolds revealed that the composite had simultaneously high stiffness, strength, ductility, and toughness, whereas in non-traditional polymer/inorganic composites, increases in stiffness and strength usually led to significant decreases in ductility and toughness. These advantages of levofloxacin-PLA/PD-BaSO<sub>4</sub> demonstrate its potential for use in bone reconstruction applications.</p></sec></sec><sec id="sec3dot4-pharmaceutics-15-01700"><title>3.4. Inhibit Bacterial Protein Synthesis</title><sec><title>Minocycline</title><p>Minocycline, which is one of the semi-synthetic tetracycline, has broad-spectrum antimicrobial properties. It exerts its antibacterial effects by inhibiting protein synthesis in bacteria [<xref rid="B171-pharmaceutics-15-01700" ref-type="bibr">171</xref>]. In addition, minocycline has anti-inflammatory, antioxidant, and anti-apoptotic effects [<xref rid="B172-pharmaceutics-15-01700" ref-type="bibr">172</xref>]. Compared to common biomaterials, drug delivery platforms incorporating minocycline can promote cell adhesion and proliferation, cytoplasmic diffusion, etc. [<xref rid="B172-pharmaceutics-15-01700" ref-type="bibr">172</xref>,<xref rid="B173-pharmaceutics-15-01700" ref-type="bibr">173</xref>]. Martin et al. [<xref rid="B28-pharmaceutics-15-01700" ref-type="bibr">28</xref>] utilized 3D printing technology to prepare a PLA scaffold and combined the scaffold with collagen, minocycline, and bio-inspired citrate hydroxyapatite nanoparticles (cHA) to finally obtain a multifunctional 3D-printed scaffold. Hydroxyapatite nanoparticles were added to the surface of the scaffold to mimic the composition of natural bone and positively modulate osteoblasts [<xref rid="B28-pharmaceutics-15-01700" ref-type="bibr">28</xref>,<xref rid="B174-pharmaceutics-15-01700" ref-type="bibr">174</xref>], so that the multifunctional scaffold structure was closer to the human bone structure. The scaffold has properties such as uniform macropores, adequate wettability, and excellent compressive strength. To evaluate the antibacterial properties of the scaffold, two different antibacterial tests were performed against <italic toggle="yes">S. aureus</italic>. The results of the agar disc diffusion test showed that the scaffold group with the addition of minocycline effectively inhibited the growth of bacteria, and formed a significant zone of bacterial inhibition. In addition, scanning electron microscopy (SEM) evaluated the effect of scaffolds on the activity of <italic toggle="yes">S. aureus</italic> biofilm formation. The surface of PLA-Col scaffolds was completely covered by <italic toggle="yes">S. aureus</italic> biofilm, while no staphylococci were detected on the surface of the scaffold group with the addition of minocycline. In addition, the response of hBMSCs to these scaffolds showed that the addition of cHA significantly stimulated the adhesion, proliferation, and osteogenesis-related gene expression of hMSCs. Overall, the PLA scaffolds obtained by 3D printing successfully combined desirable antibacterial/antibacterial biofilm properties with osteogenic properties. They also maintained morphological and mechanical properties similar to those of human bone, offering the possibility for further clinical trials.</p></sec></sec><sec id="sec3dot5-pharmaceutics-15-01700"><title>3.5. Destruction of Biological Components within Bacteria</title><sec id="sec3dot5dot1-pharmaceutics-15-01700"><title>3.5.1. NO</title><p>NO is a natural molecule that plays an important role in inflammation, cell proliferation, angiogenesis, and wound healing [<xref rid="B175-pharmaceutics-15-01700" ref-type="bibr">175</xref>]. In addition, NO can play a bactericidal role by damaging DNA, proteins, and lipids of microorganisms. If NO is released in a controlled manner for a long time, it can inhibit bacterial growth on the surface of biological materials [<xref rid="B176-pharmaceutics-15-01700" ref-type="bibr">176</xref>]. Kabirian et al. [<xref rid="B29-pharmaceutics-15-01700" ref-type="bibr">29</xref>] designed a 3D-printed small-diameter vascular graft (SDVG) with a NO releasing coating to implant the implant into a CAM. The CAM assay is a cost-effective, simple, and rapid method to assess the biocompatibility and angiogenic capacity of biomaterials and can even be used as a bioreactor [<xref rid="B177-pharmaceutics-15-01700" ref-type="bibr">177</xref>]. The grafts were printed from polylactic acid and coated with blending of 10 wt% S-nitroso-N-acetyl-D-penicillamine mixed in a polymer matrix consisting of poly (ethylene glycol) (PEG) and PCL to achieve controlled release of NO. The NO release profile showed a burst release of NO on the first day of implantation, followed by a continuous release of NO within the normal physiological range for the next 14 days. The results of in vitro antimicrobial assays showed that the NO-releasing coating inhibited the growth of bacteria and formed a significant inhibition circle. The results of CFU counting method revealed that after 24 h of incubation, microorganisms were reduced by 99.99&#8211;100% in the presence of NO-releasing grafts, while bacteria in the control group proliferated stably. In addition, the NO-releasing grafts and control grafts were biocompatible in vitro and in vivo. Compared to controls, NO-releasing SDVGs greatly enhanced the proliferation of ECs and showed significant angiogenic potential in vivo. In conclusion, the NO-releasing 3D-printed SDVGs with accelerated healing and bactericidal properties are a very promising graft.</p></sec><sec id="sec3dot5dot2-pharmaceutics-15-01700"><title>3.5.2. Natural Plants</title><p>The occurrence of antibiotic resistance and multidrug resistance in drug-resistant strains of bacteria reduced the success of traditional synthetic antibiotic therapy. So, a new alternative treatment method derived from natural herbs is an option [<xref rid="B178-pharmaceutics-15-01700" ref-type="bibr">178</xref>]. <italic toggle="yes">Satureja cuneifolia</italic> (SC) is a natural aromatic plant with anti-Alzheimer&#8217;s, anti-diabetic, antioxidant, and anti-microbial properties [<xref rid="B179-pharmaceutics-15-01700" ref-type="bibr">179</xref>,<xref rid="B180-pharmaceutics-15-01700" ref-type="bibr">180</xref>]. In addition, it was experimentally demonstrated that SC is rich in phenolic compounds with antimicrobial activity, which are strongly oxidizing and can cause protein coagulation and destroy bacterial proteins thus exerting antimicrobial effects [<xref rid="B181-pharmaceutics-15-01700" ref-type="bibr">181</xref>]. Ilhan et al. [<xref rid="B30-pharmaceutics-15-01700" ref-type="bibr">30</xref>] used a 3D printing technique to make SA/PEG composite scaffold and loaded methanol extract of SC into it. The production of 3D-printed scaffold and tissue application of wound dressing are shown in <xref rid="pharmaceutics-15-01700-f006" ref-type="fig">Figure 6</xref>. Sodium alginate (SA) in the composite scaffold was all at 9% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) concentration, while PEG was added at different concentrations of 1, 3, and 5% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>). Phenolic acids and flavonoids in the methanolic extract of SC were analyzed in previous studies. The results show that SC was able to express strong biological activity [<xref rid="B182-pharmaceutics-15-01700" ref-type="bibr">182</xref>].</p><p>The 3D-printed scaffolds showed excellent antimicrobial ability, especially forming a significant inhibition circle around <italic toggle="yes">Staphylococcus aureus</italic> (Gram-positive bacteria), as they contained antimicrobial SC extracts. In addition, the scaffolds exhibited good biocompatibility and low cytotoxicity, and the incorporation of SC generated ideal porosity and mechanical properties of the scaffolds. In conclusion, the SA/PEG/SC 3D scaffold showed great potential for diabetic wound healing and bacterial infection and is expected to be an ideal tissue-engineered wound dressing.</p></sec><sec id="sec3dot5dot3-pharmaceutics-15-01700"><title>3.5.3. Nanodiamonds</title><p>Nanodiamonds (NDS) are increasingly being applied in biomedicine, considering their ability to create a tunable surface [<xref rid="B183-pharmaceutics-15-01700" ref-type="bibr">183</xref>], and good biocompatibility [<xref rid="B184-pharmaceutics-15-01700" ref-type="bibr">184</xref>]. Nanodiamond, as an antimicrobial agent, attracted extensive research interest. Regarding its antimicrobial mechanism, the active oxygen-containing groups on the surface of NDS promote their interaction with cellular components to quickly kill Gram-positive and negative bacteria and prevent bacterial adhesion [<xref rid="B185-pharmaceutics-15-01700" ref-type="bibr">185</xref>]. Nowadays, NDS are mostly incorporated into implants in the form of material coatings or films to function [<xref rid="B186-pharmaceutics-15-01700" ref-type="bibr">186</xref>,<xref rid="B187-pharmaceutics-15-01700" ref-type="bibr">187</xref>]. Rifai et al. [<xref rid="B31-pharmaceutics-15-01700" ref-type="bibr">31</xref>] fabricated selective laser melting titanium (SLM-Ti) scaffolds by using 3D printing and selective laser melting (SLM), and applied nanodiamond (ND) coating on the scaffolds for functionalization modification. As one of the mostly used techniques for manufacturing metal implants, SLM technology often uses powdered metals bonded in a layer-by-layer process to create complex structures, using mainly stainless steel, cobalt-chromium, and titanium. The metals used are mainly stainless steel, cobalt-chromium, and titanium, among others, as they have good biocompatibility and mechanical stability. The concentrations of ND coated on the stent surface varied from 0.075, 0.75, to 7.5% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>. The results of in vitro antimicrobial assays showed that after 18 h of growth of <italic toggle="yes">S. aureus</italic> attached to the uncoated and ND-coated stents, the stent group with the lowest ND concentration of 0.075% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic> had the most <italic toggle="yes">S. aureus</italic> attached, compared to the uncoated control group. After the ND concentration was increased to 0.75% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>, the density of <italic toggle="yes">S. aureus</italic> was reduced by 50%, compared to the stent group with ND of 0.075% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>. The highest ND concentration (7.5% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) group showed even an 88% reduction in <italic toggle="yes">S. aureus</italic> adhesion. SEM micrographs also confirmed that there was less <italic toggle="yes">S. aureus</italic> adhesion as the ND concentration increased. After inoculating human skin fibroblasts (HDF) and osteoblasts (OB) on four groups of scaffolds and culturing them for 3 days, the maximum HDF and OB cell densities were found on samples at the highest concentration of ND (7.5% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>), with a 32% and 29% increase in density, respectively, compared to the control group. Overall, with the use of 3D-printed SLM-Ti in orthopedic implants, modifying its surface with ND provides a simple, rapid, and beneficial cell-implant interface.</p></sec></sec><sec id="sec3dot6-pharmaceutics-15-01700"><title>3.6. Multi-Mechanism Antibacterial</title><sec id="sec3dot6dot1-pharmaceutics-15-01700"><title>3.6.1. Chitosan</title><p>Chitosan (CS) is a natural polysaccharide derived from deacetylation of chitin, and consists mainly of d-glucosamine and N-acetyl-d-glucosamine [<xref rid="B188-pharmaceutics-15-01700" ref-type="bibr">188</xref>]. Chitosan is now widely used in biomedical applications, including tissue engineering, infection control, and wound healing [<xref rid="B188-pharmaceutics-15-01700" ref-type="bibr">188</xref>,<xref rid="B189-pharmaceutics-15-01700" ref-type="bibr">189</xref>]. Its hemostatic and antimicrobial functions can accelerate the transition from the hemostatic to the inflammatory phase after wound trauma and modulate the inflammatory response [<xref rid="B190-pharmaceutics-15-01700" ref-type="bibr">190</xref>]. Its antimicrobial activity results from the interaction of the positive charge it carries with ions on the surface of negatively charged cells. Such activity disrupts bacterial cell membranes, prevents the transport of cellular material, increases the internal osmotic pressure, and causes the rupture of microbial cells, among other things. In addition, it interacts with bacterial DNA and prevents DNA transcription, thus inhibiting microbial ribonucleic acid (RNA) synthesis [<xref rid="B191-pharmaceutics-15-01700" ref-type="bibr">191</xref>]. Intini et al. [<xref rid="B32-pharmaceutics-15-01700" ref-type="bibr">32</xref>] fabricated a 3D chitosan scaffold and implanted it into the skin defects of diabetic rats. Twenty days after implantation, it was shown that the scaffold exhibited good biocompatibility and cytocompatibility. Both MTT assay and neutral red analysis showed that the chitosan matrix was non-cytotoxic. Seeded normal human skin fibroblast (Nhdf) and keratinocyte (HaCaT) cells were viable to grow and colonize the 3D chitosan matrix. An analysis of epidermal wounds in rats revealed that after 7 days, the wounds looked approximately 50% less than the initial area in both animals treated or untreated with chitosan scaffolds, with no significant difference between the two. After 10 days, the wounds treated with chitosan scaffolds had healed, while in the control animals, there was still crusting. After 14 days, the wounds were completely healed in all groups, with only scars visible. Overall, treatment with chitosan scaffolds improved and accelerated wound healing compared to untreated animals, and no signs of infection were observed, probably due to its inherent antimicrobial activity. Histological analysis of the wounds also showed that the chitosan group exhibited more intense tissue reorganization and more mature tissue formation on the wounds.</p></sec><sec id="sec3dot6dot2-pharmaceutics-15-01700"><title>3.6.2. Zinc Ions</title><p>Zinc (Zn) ions, one of the chemical bactericides, have good antimicrobial activity and play an important role in tissue differentiation [<xref rid="B192-pharmaceutics-15-01700" ref-type="bibr">192</xref>]. The antimicrobial activity of Zn particles was investigated and reported in numerous articles, but mostly in the form of Zn oxide nanoparticles [<xref rid="B193-pharmaceutics-15-01700" ref-type="bibr">193</xref>,<xref rid="B194-pharmaceutics-15-01700" ref-type="bibr">194</xref>,<xref rid="B195-pharmaceutics-15-01700" ref-type="bibr">195</xref>]. Zn oxide nanoparticles are a potential broad-spectrum nano antibiotic to demonstrate their strong antibacterial properties against <italic toggle="yes">Escherichia coli</italic> [<xref rid="B196-pharmaceutics-15-01700" ref-type="bibr">196</xref>], <italic toggle="yes">Staphylococcus aureus</italic> [<xref rid="B197-pharmaceutics-15-01700" ref-type="bibr">197</xref>,<xref rid="B198-pharmaceutics-15-01700" ref-type="bibr">198</xref>], and <italic toggle="yes">Klebsiella pneumoniae</italic> [<xref rid="B199-pharmaceutics-15-01700" ref-type="bibr">199</xref>], etc. However, its antimicrobial mechanism is complex, and the antimicrobial effect exhibited may be the result of several different mechanisms acting together. For example, Li et al. [<xref rid="B200-pharmaceutics-15-01700" ref-type="bibr">200</xref>] suggested that due to the negative charge of the bacterial film, an electrostatic reaction between the film and the oppositely charged ZnO nanoparticles leads to the rupture of the film eventually triggering bacterial death. It was also suggested that ZnO nanoparticles can release free Zn<sup>2+</sup> to disrupt the internal ionic homeostasis of the bacterium and, subsequently, lead to the death of the bacterium. However, there is no unified conclusion on which mechanism is the main one.</p><p>Li et al. [<xref rid="B81-pharmaceutics-15-01700" ref-type="bibr">81</xref>] used 3D printing and bilayer modification techniques to fabricate a 3D ceramic implant with excellent mechanical properties, broad-spectrum antibacterial, and anti-infective properties. They made yttrium oxide-stabilized zirconium oxide (3Y-ZrO<sub>2</sub>) nanopowder into 3Y-ZrO<sub>2</sub> ceramic by 3D printing, mold plasticity, and sintering. The mechanical properties were enhanced by uniformly coating ISO resin onto the ceramic by a thermal spraying process at high temperature and pressure. Subsequently, ZnO nanosolution was dropped on this ceramic to finally produce ZnO-ISO bilayer modified ceramics [<xref rid="B201-pharmaceutics-15-01700" ref-type="bibr">201</xref>]. Impact test, bending test, tensile test, and compression test of ISO resin modified ceramics showed that mechanical properties of ISO resin modified ceramics were significantly improved. In addition, the ISO resin did not inhibit the growth of <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Escherichia coli</italic>. There was no significant difference in the number of bacterial colonies between the ISO resin-modified ceramic group and the unmodified ceramic group. However, the ZnO-ISO bilayer modified ceramics showed excellent antibacterial performance against both <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">E. coli</italic>. There was almost no colony formation after treatment of bacteria with ZnO-ISO bilayer modified ceramics. Finally, 14 days after implantation of the bilayer-modified ceramics made by 3D bioprinting, the mice in both the experimental and control groups were normal, with no significant differences in all examinations. This indicates that the ISO resin material has excellent biocompatibility. This study successfully designed a 3D ceramic implant combining excellent mechanical properties and good antimicrobial properties through the bilayer modification technique. But its long-term effects in vivo and in vivo antimicrobial properties are still unknown.</p></sec><sec id="sec3dot6dot3-pharmaceutics-15-01700"><title>3.6.3. Copper Ions</title><p>Copper (Cu) is one of the important elements involved in physiological processes in living organisms and can act as a cofactor for key metabolic enzymes [<xref rid="B202-pharmaceutics-15-01700" ref-type="bibr">202</xref>,<xref rid="B203-pharmaceutics-15-01700" ref-type="bibr">203</xref>]. In addition, Cu<sup>2+</sup> was shown to have efficient antibacterial activity against various bacteria, including <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Escherichia coli</italic> [<xref rid="B204-pharmaceutics-15-01700" ref-type="bibr">204</xref>]. The mechanism may be that when Cu<sup>2+</sup> is present as a free ion, it will generate highly toxic hydroxyl radicals from hydrogen peroxide and superoxide [<xref rid="B205-pharmaceutics-15-01700" ref-type="bibr">205</xref>,<xref rid="B206-pharmaceutics-15-01700" ref-type="bibr">206</xref>]. The generated hydroxyl radicals can oxidize with most bacterial macromolecules to exert antibacterial effects [<xref rid="B207-pharmaceutics-15-01700" ref-type="bibr">207</xref>,<xref rid="B208-pharmaceutics-15-01700" ref-type="bibr">208</xref>]. In addition, Cu<sup>2+</sup> can be associated with affecting the bacterial outer membrane potential, leading to the rupture of the bacterial membrane, and eventually to bacterial death. Vidakis et al. [<xref rid="B83-pharmaceutics-15-01700" ref-type="bibr">83</xref>] used 3D printing technology to prepare nanocomposites of medical grade polyamide 12 (PA12) with Cu<sup>2+</sup> oxide (cuprous oxide) in different ratios (choosing 0.5 wt.%, 1.0 wt.%, 2.0 wt.%, 4.0 wt.%, and 6.0 wt.% weight ratio loading of cuprous oxide). Additionally, 3D printing technology, also known as additive manufacturing (AM) technology, was used in a wide range of these applications [<xref rid="B209-pharmaceutics-15-01700" ref-type="bibr">209</xref>,<xref rid="B210-pharmaceutics-15-01700" ref-type="bibr">210</xref>]. Fused filament fabrication (FFF), as one of the AM technologies, is based on thermoplastic polymers and/or composite materials [<xref rid="B211-pharmaceutics-15-01700" ref-type="bibr">211</xref>,<xref rid="B212-pharmaceutics-15-01700" ref-type="bibr">212</xref>]. The medical-grade PA12 material used in this experiment is often used as a matrix material, together with metal and oxide fillers in AM applications that require antimicrobial properties in 3D scaffolds [<xref rid="B213-pharmaceutics-15-01700" ref-type="bibr">213</xref>,<xref rid="B214-pharmaceutics-15-01700" ref-type="bibr">214</xref>]. In addition, PA12 is commonly used in 3D-printed tissue engineering experiments, as it has excellent toughness properties, the capability to extend extensively before fracture, and the excellent thermodynamic properties [<xref rid="B215-pharmaceutics-15-01700" ref-type="bibr">215</xref>,<xref rid="B216-pharmaceutics-15-01700" ref-type="bibr">216</xref>]. As shown in <xref rid="pharmaceutics-15-01700-f007" ref-type="fig">Figure 7</xref> and <xref rid="pharmaceutics-15-01700-f008" ref-type="fig">Figure 8</xref>, after culturing the scaffolds in Petri dishes containing Gram-negative <italic toggle="yes">Escherichia coli</italic> and Gram-positive <italic toggle="yes">Staphylococcus aureus</italic> for 24 h, all groups showed good antibacterial activity. The group with a cuprous oxide ratio of 4.0 wt.% showed the highest antibacterial effect against both bacteria.</p><p>Other than the above antimicrobial materials and their antimicrobial mechanisms, many other materials can be used as scaffold additives to impart antimicrobial properties to 3D-printed tissue engineering. In conclusion, excellent antimicrobial properties of scaffolds are the prerequisite and foundation for scaffolds to implant and function in vivo, and more antimicrobial materials and different antimicrobial mechanisms can be applied in 3D printed tissue engineering scaffolds.</p></sec></sec></sec><sec id="sec4-pharmaceutics-15-01700"><title>4. Immunomodulation</title><p>Immunomodulation refers to the physiological function of the body to recognize and exclude antigenic foreign substances, and maintain its own physiological dynamic balance and relative stability. It is often divided into humoral and cellular immunity, involving various immune cells, such as lymphocytes, macrophages, and NK cells. The immune regulation involved in tissue engineering repair is mostly anti-inflammatory, that is, the regulation of macrophage polarization. Macrophages are one of the main cells that regulate non-specific immune responses, and polarized macrophages play a very important role in inflammatory responses, injury repair, and angiogenesis [<xref rid="B217-pharmaceutics-15-01700" ref-type="bibr">217</xref>]. Macrophages can be regulated to differentiate into two types&#8212;classically activated (M1 type) and alternatively activated (M2 type) [<xref rid="B218-pharmaceutics-15-01700" ref-type="bibr">218</xref>,<xref rid="B219-pharmaceutics-15-01700" ref-type="bibr">219</xref>]. M1 type macrophages can be activated by lipopolysaccharide (LPS), T lymphocyte-derived lymphokines, and cytokines involved in T cell-mediated immune responses [<xref rid="B220-pharmaceutics-15-01700" ref-type="bibr">220</xref>]. After activation, they can secrete pro-inflammatory factors, recruit inflammatory cells against pathogens, and assume many important roles in the early stages of inflammation [<xref rid="B221-pharmaceutics-15-01700" ref-type="bibr">221</xref>]. However, sustained M1-type activation can cause tissue damage and lead to inflammatory diseases. In contrast, M2-type macrophages are mainly activated by Th2 cytokines such as IL-4, IL-13, and prostaglandin E2, which are responsible for suppressing the inflammatory response and tissue repair effects to restore the tissue to its original state [<xref rid="B222-pharmaceutics-15-01700" ref-type="bibr">222</xref>,<xref rid="B223-pharmaceutics-15-01700" ref-type="bibr">223</xref>]. However, excessive activation of the M2 type, in turn, can cause excessive tissue repair and cause fibrosis, among other things. Therefore, finding substances that can balance the polarization of M1-M2 type macrophages is the key to the successful application of tissue engineering [<xref rid="B224-pharmaceutics-15-01700" ref-type="bibr">224</xref>,<xref rid="B225-pharmaceutics-15-01700" ref-type="bibr">225</xref>].</p><sec id="sec4dot1-pharmaceutics-15-01700"><title>4.1. Adrenocorticosteroids</title><sec id="sec4dot1dot1-pharmaceutics-15-01700"><title>4.1.1. Dexamethasone</title><p>Dexamethasone (DEX) is a synthetic corticosteroid chemical that is commonly used clinically as an anti-inflammatory agent. It was shown to exert anti-inflammatory effects through various pathways, such as reducing the expression of cyclooxygenase 2 (COX-2). It inhibits prostaglandin production, inflammatory signaling, and neutrophil and macrophage exudation and aggregation to the site of inflammation to exert anti-inflammatory effects [<xref rid="B226-pharmaceutics-15-01700" ref-type="bibr">226</xref>,<xref rid="B227-pharmaceutics-15-01700" ref-type="bibr">227</xref>]. Although it was demonstrated that long-term administration of DEX can attenuate the tissue inflammatory response, there are significant side effects such as osteoporosis, gastrointestinal bleeding, and immunosuppression due to long-term systemic exposure to high concentrations of glucocorticoid drugs [<xref rid="B228-pharmaceutics-15-01700" ref-type="bibr">228</xref>,<xref rid="B229-pharmaceutics-15-01700" ref-type="bibr">229</xref>]. Therefore, constructing a hybrid scaffold by using 3D printing processing and adding DEX to the scaffold can be a good way to achieve a high dose in the target tissue and a low dose systemically, which can exert anti-inflammatory effects and reduce its side effects at the same time. However, since DEX is a lipophilic substance, its water solubility is low and it is not efficient when loaded into scaffolds [<xref rid="B230-pharmaceutics-15-01700" ref-type="bibr">230</xref>,<xref rid="B231-pharmaceutics-15-01700" ref-type="bibr">231</xref>]. Therefore, it is important to utilize a safe medium to load DEX more efficiently into scaffolds. Lee et al. [<xref rid="B33-pharmaceutics-15-01700" ref-type="bibr">33</xref>] designed a robust and biodegradable 3D tubular scaffold by the combination of electrostatic spinning technique (ELSP) and 3D printing technique, and, subsequently, loaded DEX onto this scaffold using a mild surface modification reaction of PDA, polyethyleneimine (PEI), and carboxymethyl &#946;-cyclodextrin (&#946;CD). Carboxymethyl-&#946;CD is a cyclic oligosaccharide with a hydrophilic outer surface and a central lipophilic lumen [<xref rid="B232-pharmaceutics-15-01700" ref-type="bibr">232</xref>]. Therefore, carboxymethyl-&#946;CD can form inclusion complexes with DEX, which not only allows massive loading of DEX, but also regenerates tracheal tissue after transplantation and has anti-inflammatory activity [<xref rid="B233-pharmaceutics-15-01700" ref-type="bibr">233</xref>,<xref rid="B234-pharmaceutics-15-01700" ref-type="bibr">234</xref>]. To introduce carboxymethyl-&#946;CD, they used PDA and PEI chemical modifications to introduce an amine-rich surface on the PCL scaffold, thus allowing carboxymethyl-&#946;CD to graft through amide bonds [<xref rid="B235-pharmaceutics-15-01700" ref-type="bibr">235</xref>,<xref rid="B236-pharmaceutics-15-01700" ref-type="bibr">236</xref>]. Compression tests of this composite scaffold demonstrated that the fabricated 3D tubular scaffold has stronger mechanical properties than natural rabbit tracheal tissue. In addition, atomic force microscopy (AFM) and X-ray photoelectron spectroscopy (XPS) analysis showed that the surface treatment of the scaffold was successful because a large amount of DEX was loaded onto the scaffold [<xref rid="B232-pharmaceutics-15-01700" ref-type="bibr">232</xref>]. In addition, they quantified the amount of tumor necrosis factor-&#945; (TNF-&#945;) and IL-6 secreted by cells on RAW 264.7 cells before and after LPS treatment by ELISA. As shown in <xref rid="pharmaceutics-15-01700-f009" ref-type="fig">Figure 9</xref>, cells on the membrane expressed high amounts of TNF-&#945; and IL-6 under LPS treatment. However, cells on PCLDP&#946;+DEX expressed significantly lower amounts of TNF-&#945; and IL-6 than cells on PCL, suggesting that the DEX-containing scaffold exhibited significantly enhanced anti-inflammatory activity.</p><p>Four weeks after implantation of the stent at the tracheal defect in rabbits, the PCLDP&#946; stent loaded with DEX exhibited higher cell adhesion and stronger tracheal mucosa regeneration, and formed a more patent airway. In conclusion, this 3D tubular scaffold loaded with DEX has good potential for regeneration of tracheal tissue and anti-inflammatory effects, offering the possibility of future tracheal transplantation therapy.</p></sec><sec id="sec4dot1dot2-pharmaceutics-15-01700"><title>4.1.2. Prednisolone</title><p>As one of the adrenocorticosteroids, prednisolone and DEX have similar anti-inflammatory effects. prednisolone can inhibit the accumulation of inflammatory cells (including macrophages and leukocytes) at sites of inflammation, and their phagocytosis. Furthermore, it can prevent the release of lysosomal enzymes, and the synthesis and release of chemical mediators of inflammation. Farto-Vaamonde et al. [<xref rid="B34-pharmaceutics-15-01700" ref-type="bibr">34</xref>] utilized two different ways to load prednisolone or DEX into a 3D-printed PLA scaffold. The first one immerses the pre-printed 3D PLA scaffold in a prednisolone solution, which covers its surface with prednisolone and allows for rapid release to exert its antimicrobial properties. The second one immerses the polylactic acid filament in DEX solution to make the polylactic acid swells reversibly. The melting of the polylactic acid during the subsequent 3D printing process helps the effective integration of DEX in the printed filament. It can also achieve continuous slow release for osteoinduction. These two loading methods offer the possibility to generate different drug concentration gradients in the same scaffold and allow different drugs to exhibit different release patterns. The ability of the scaffold to attenuate the inflammatory response was tested by macrophages stimulated with LPS. The blank scaffolds did not attenuate the levels of PEG2 and TNF&#945;, which were similar to those of the positive controls (positive control refers to stimulated macrophage cells). Differently, all scaffolds surface loaded with prednisolone caused a significant decrease in PEG2 and TNF&#945; levels, as effective as free drug dispersed in cell culture medium (ANOVA <italic toggle="yes">p</italic> &lt; 0.001; multiple range test <italic toggle="yes">p</italic> &lt; 0.05). By contrast, scaffolds loaded with DEX did not significantly change the inflammatory response. In addition, all scaffolds showed good biocompatibility with fibroblasts, macrophages, and hMSCs, and loading of various drugs did not impair the printability or mechanical properties of the scaffolds.</p></sec></sec><sec id="sec4dot2-pharmaceutics-15-01700"><title>4.2. Metal Ions</title><sec id="sec4dot2dot1-pharmaceutics-15-01700"><title>4.2.1. Copper Ions</title><p>Copper is one of the essential trace elements and plays an essential regulatory role in the maintenance of physiological homeostasis [<xref rid="B237-pharmaceutics-15-01700" ref-type="bibr">237</xref>]. In addition to the previously mentioned pro-vascularizing and antibacterial effects, Cu is also important in immune regulation. Many studies demonstrated the positive role of Cu<sup>2+</sup> in the fight against arthritis, and Cu<sup>2+</sup> deficiency decreases bone strength and increases the incidence of osteoarthritis [<xref rid="B238-pharmaceutics-15-01700" ref-type="bibr">238</xref>,<xref rid="B239-pharmaceutics-15-01700" ref-type="bibr">239</xref>]. The mechanism is that Cu<sup>2+</sup> plays an important part in regulating the polarization of macrophages. It can inhibit the activation of macrophages and suppress the synthesis and release of inflammatory factors [<xref rid="B240-pharmaceutics-15-01700" ref-type="bibr">240</xref>]. Lin et al. [<xref rid="B84-pharmaceutics-15-01700" ref-type="bibr">84</xref>] made Cu-BGC scaffolds by incorporating different concentrations of Cu<sup>2+</sup> (0.781&#8211;25 mg/mL) into bioactive microcrystalline glass using 3D printing technology. After attaching chondrocytes to the scaffold for 12 h, a significant increase occurred on the proliferation of chondrocytes in the Cu-BGC group, as compared to the BGC group and the blank control group. After detecting the HIF pathway using RT-qPCR analysis, the expression level of HIF-1&#945; was significantly enhanced in the Cu-BGC group after 3 days of incubation in ionic extracts, as compared to the other two groups. The relevant genes and HIF-1&#945; genes were subsequently examined in chondrocytes cultured under different concentrations of Cu<sup>2+</sup>. The final results showed that Cu<sup>2+</sup> ions released from the Cu-BGC scaffold played an important role in promoting chondrocyte proliferation and differentiation and activating the HIF pathway for cartilage repair. Subsequently, the immunomodulatory effect of the scaffold was evaluated by studying the expression of inflammatory cytokines and macrophage surface markers. The results showed that on days 1 and 3, the expression of pro-inflammatory cytokine genes was suppressed and that of anti-inflammatory cytokine genes was increased in macrophages cultured with Cu-BGC ionic extract at a range of concentrations (0.781&#8211;25 mg/mL), as compared to the BGC and CTR groups. In addition, the expression of M1 surface marker (iNOS) was significantly suppressed and the expression of M2 surface marker (CD206) was significantly enhanced in macrophages of this group. All these results suggest that the ionic extract of Cu-BGC can promote the shift of macrophages from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype. Finally, the scaffold was implanted into the cartilage defect on the femoral condyle of rabbits, and in vivo histological studies also showed that the Cu-BGC scaffold group significantly improved cartilage regeneration and enhanced the recovery of the osteochondral interface. Overall, the Cu<sup>2+</sup>, released from this Cu-BGC scaffold, triggered the immune response and suppressed the inflammatory response in osteochondral tissue&#8212;by activating the HIF signaling pathway, reducing damage to cartilage tissue, and promoting chondrocyte proliferation and maturation. This may provide a way to prevent and treat osteoarthritis associated with osteochondral defects in the future.</p></sec><sec id="sec4dot2dot2-pharmaceutics-15-01700"><title>4.2.2. Magnesium Ions</title><p>Mg ions are one of the main ions important for maintaining normal physiological functions in humans, and they serves as a cofactor for more than 300 enzymes to play a vital role in regulating the physiological functions of the heart and nerves, and regulate blood pressure and immune regulation [<xref rid="B93-pharmaceutics-15-01700" ref-type="bibr">93</xref>,<xref rid="B241-pharmaceutics-15-01700" ref-type="bibr">241</xref>,<xref rid="B242-pharmaceutics-15-01700" ref-type="bibr">242</xref>]. It was demonstrated in many studies that nuclear factor-&#954;B (NF-&#954;B) is a central regulator of inflammation-induced cytokine production. Also, I&#954;B&#945; shares an activation pathway with NF-&#954;B. Mg<sup>2+</sup> increase I&#954;B&#945; levels, but lead to reduced NF-&#954;B activation and secretion of cytokines such as interleukin-6 (IL-6) and tumor necrosis factor &#945; [<xref rid="B243-pharmaceutics-15-01700" ref-type="bibr">243</xref>,<xref rid="B244-pharmaceutics-15-01700" ref-type="bibr">244</xref>,<xref rid="B245-pharmaceutics-15-01700" ref-type="bibr">245</xref>]. In addition, it was also found that the Notch1 pathway promotes inflammatory macrophage polarization [<xref rid="B246-pharmaceutics-15-01700" ref-type="bibr">246</xref>,<xref rid="B247-pharmaceutics-15-01700" ref-type="bibr">247</xref>], and the interaction of Mg<sup>2+</sup> and Icariin can synergistically inhibit Notch1 protein expression to exert anti-inflammatory effects. Wang et al. [<xref rid="B80-pharmaceutics-15-01700" ref-type="bibr">80</xref>] fabricated porous, 3D, Ti<sub>6</sub>Al<sub>4</sub>V scaffolds (PT) and placed them in a 72-well plate. The solutions were prepared: (a) 5 wt.% SF aqueous solution, (b) 1 mg/mL icariin in 5 wt.% SF aqueous solution, (c) 4 mg/mL Mg-MOF-74 in 5 wt.% SF aqueous solution, and (d) 4 mg/mL ICA@MOF in 5 wt.% SF aqueous solution. The four solutions were slowly injected into the PT in the 72-well plate until the PT was completely submerged by the solution. Finally, four groups of samples were achieved: (a) PT/SF (Ti/SF); (b) PT/SF/MOF (Ti/SF/MOF); (c) PT/SF/icariin (Ti/SF/I); (d) PT/SF/ICA@MOF (Ti/SF/MOF/I). Icariin was demonstrated to induce the differentiation of monocytes into macrophages and can function as an inhibitor of the NF-&#954;B signaling pathway through upregulation of the PI3K/Akt pathway, thereby significantly inhibiting the release of pro-inflammatory cytokines such as IL-6 and TNF-&#945; [<xref rid="B248-pharmaceutics-15-01700" ref-type="bibr">248</xref>,<xref rid="B249-pharmaceutics-15-01700" ref-type="bibr">249</xref>]. Furthermore, MOFs that are incorporated in scaffolds have excellent drug delivery capabilities due to their excellent chemical properties, biodegradability, and high porosity [<xref rid="B250-pharmaceutics-15-01700" ref-type="bibr">250</xref>]. MOF-74, one of the MOFs, has low cytotoxicity and controlled drug release properties and can be used as a drug release platform [<xref rid="B251-pharmaceutics-15-01700" ref-type="bibr">251</xref>]. To further verify the polarization of macrophages, immunofluorescence staining was used to monitor iNOS (green, M1 marker) and Arg-1 (red, M2 marker) in Raw264.7 cultured for 4 days. The results showed that the majority of macrophages in the Ti/SF group were of M1 phenotype (green). M2-type macrophages dominated (red), especially in the Ti/SF/MOF/I group. This was mainly due to the release of a certain concentration of Mg<sup>2+</sup> in the MOF of this group. Although the concentration of icariin was higher in the Ti/SF/I group, its anti-inflammatory effect was weaker than that of the Ti/SF/MOF/I group, probably because icariin has an optimal concentration and too high concentration may cause cytotoxic side effects and waste of resources, etc. Subsequently, they examined the expression content of Notch1 protein in each group using cellular immunofluorescence and Western blotting. <xref rid="pharmaceutics-15-01700-f010" ref-type="fig">Figure 10</xref> shows that the level of Notch1 protein in the Ti/SF/MOF/I group containing ICA@MOF was significantly lower than the other three groups.</p><p>Overall, the Ti/SF/MOF/I group had the highest M2 macrophage intensity and the lowest Notch1 protein expression level, which was mainly due to the synergistic immunomodulatory effects of Mg<sup>2+</sup> and icariin released continuously from SF/ICA@MOF. In addition, they implanted the composite PT scaffold into the distal femoral medulla of osteoporotic rats and showed abundant new bone formation at both the peripheral and internal sites of the implantation site. The scaffold had good mechanical properties and biocompatibility, which significantly improved bone metabolism and promoted osseointegration. The scaffold greatly exerted anti-inflammatory effects and significantly improved osteoporotic integration using the sustained controlled release of icariin and Mg<sup>2+</sup> from MOFs, offering the possibility of clinical practice for titanium prostheses in patients with osteoporosis.</p></sec></sec><sec id="sec4dot3-pharmaceutics-15-01700"><title>4.3. Animal Sources</title><sec id="sec4dot3dot1-pharmaceutics-15-01700"><title>4.3.1. Interleukin-4</title><p>Interleukin-4 (IL-4) is one of the cytokines of the T helper (Th2) family of cells [<xref rid="B252-pharmaceutics-15-01700" ref-type="bibr">252</xref>]. The activation of the typical pathway of IL-4 production causes phosphorylation of STAT6 and upregulation of GATA-binding protein 3 (GATA3) expression [<xref rid="B253-pharmaceutics-15-01700" ref-type="bibr">253</xref>], which, in turn, constitutes a major factor in the transcriptional regulation of Th2 cells. Therefore, IL-4 can activate the production of Th2 cytokine and, thus, promotes the polarization of M2-type macrophages. In addition, IL-4 has the ability to antagonize the Th1-driven pro-inflammatory immune response, as evidenced by the downregulation of the synthesis of pro-inflammatory cytokines such as IL-10 and TNF-&#945; [<xref rid="B254-pharmaceutics-15-01700" ref-type="bibr">254</xref>] and the inhibition of pro-inflammatory chemokines [<xref rid="B255-pharmaceutics-15-01700" ref-type="bibr">255</xref>]. Therefore, IL-4 was used in 3D-printed tissue engineering due to its excellent immunomodulatory ability. Wang et al. [<xref rid="B35-pharmaceutics-15-01700" ref-type="bibr">35</xref>] used GelMA-Dextran (PGelDex) as bioink and incorporated both IL-4-loaded Ag-coated gold nanorods (AgGNRs) and hMSCs to confer anti-infective and immunomodulatory functions to the scaffold. Subsequently, to verify the immunomodulatory efficacy of IL-4, they performed an inflammation-inducing treatment of the bioink with IFN-&#947; and LPS. After 24 h of incubation, qRT-PCR analysis showed a significant decrease in M1 macrophage markers and a significant increase in M2 macrophage markers in the IL-4 and IL-4+MSC groups, as compared to the control group. The results suggested that bioink loaded with IL-4 and MSCs successfully polarized M1 macrophages to M2 type and exerted anti-inflammatory effects. There were many studies demonstrating the possible therapeutic inflammatory and immunomodulatory functions of MSCs [<xref rid="B256-pharmaceutics-15-01700" ref-type="bibr">256</xref>], but their specific intrinsic molecular pathways and mechanisms of action are still under further investigation. Overall, they loaded two functional agents, namely IL-4@AgGNRs and MSCs, in the hydrogel. AgGNRs have the ability to eliminate the infection. Additionally, the synergistic effect of IL-4 and MSCs could induce the polarization of macrophage phenotype from M1 to M2 phenotype. Ultimately, a composite scaffold was made with simultaneous antibacterial, anti-inflammatory, and cytoarchitectural properties.</p></sec><sec id="sec4dot3dot2-pharmaceutics-15-01700"><title>4.3.2. Mesenchymal Stem Cells</title><p>The function of MSCs in the immune regulation in tissue repair was demonstrated in various disease models [<xref rid="B257-pharmaceutics-15-01700" ref-type="bibr">257</xref>,<xref rid="B258-pharmaceutics-15-01700" ref-type="bibr">258</xref>]. However, their specific intrinsic anti-inflammatory molecular mechanisms are still under investigation due to their complex and diverse cell composition. It was suggested that it can act as a modulator of the inflammatory response, with paracrine activity being markedly promoted during inflammation [<xref rid="B257-pharmaceutics-15-01700" ref-type="bibr">257</xref>]. It can result in the secretion of large amounts of cytokines and factors that induce a shift from an M1-type pro-inflammatory phenotype to an M2-type anti-inflammatory phenotype in macrophages [<xref rid="B259-pharmaceutics-15-01700" ref-type="bibr">259</xref>], and a reduction in the production of pro-inflammatory cytokines by macrophages [<xref rid="B260-pharmaceutics-15-01700" ref-type="bibr">260</xref>]. Paul et al. [<xref rid="B122-pharmaceutics-15-01700" ref-type="bibr">122</xref>] used hydrogel-coated endometrial mesenchymal stem cells (eMSCs) and 3D melt electrospun wire nets to generate tissue-engineered scaffolds as a potential therapy for pelvic organ prolapse (POP). They firstly fabricated 3D-printed PCL mesh by using melt electrospinning (MES) at different temperatures, followed by optimizing the aloe vera-SA (AV-ALG) composite hydrogel ratio to 1:1 (1% AV-1% ALG), and finally bioprinted purified eMSCs in this composite hydrogel onto the MES-printed mesh. Implantation of the scaffold into the subcutaneous tissue of NSG mice for 1 week revealed that eMSCs printed onto MES promoted tissue integration and eMSCs retention. Detection of macrophage phenotype at the implantation site revealed a significant reduction in CCR7M1-type macrophages within the MES-Hyd group and MES-Hyd-eMSCs group, as compared to the control MES group. This suggests that AV-ALG hydrogel inhibits macrophage responses and functions to reduce inflammation compared to the MES control group. Furthermore, the addition of eMSCs further reduced the M1 inflammatory macrophage response and increased the M2 macrophages, as compared to the MES-Hyd group. Macrophage quantification showed significantly higher total F4/80+ macrophages in the control MES group and the MES-Hyd-eMSCs group compared with MES-Hyd, where the majority of the MES-only group were M1-type macrophages, whereas the majority of the F4/80 macrophages in the MES-Hyd-eMSCs group were anti-inflammatory M2-type macrophages of the CD206 phenotype. Overall, the addition of eMSCs to the scaffold exerted a regulatory role on the inflammatory response and provided a suitable candidate for tissue engineering repair of POP.</p></sec><sec id="sec4dot3dot3-pharmaceutics-15-01700"><title>4.3.3. Ac2-26 Peptide</title><p>Ac2-26 peptide, the peptide located at the N-terminal end of ANXA1 of 26 amino acids, was found to inhibit TNF-&#945; production in monocytes, inhibit NF-&#954;B signaling of the proinflammatory pathway [<xref rid="B261-pharmaceutics-15-01700" ref-type="bibr">261</xref>], and promote phagocytosis of neutrophils [<xref rid="B262-pharmaceutics-15-01700" ref-type="bibr">262</xref>,<xref rid="B263-pharmaceutics-15-01700" ref-type="bibr">263</xref>]. Xu et al. [<xref rid="B36-pharmaceutics-15-01700" ref-type="bibr">36</xref>] fabricated a polylactic acid/4-arm polyethylene glycol hydrogel (PCL@tetra-PEG) composite scaffold as a tissue engineered meniscus (TEM). The PCL scaffold was fabricated with tapering porous and heterogeneous structures, and BMSCs were then seeded on them. The PCL@tetra-PEG scaffold was subsequently generated in a metal mold using a rotation-immersion method, in which tetra-PEG hydrogel not only improves the biomechanical properties of the PCL@tetra-PEG scaffold to fit the native meniscus, but also helps achieve different regional encapsulation and spatiotemporal zonal release of two human growth factors (CTGF and TGF-&#946;3). Significantly, the simultaneous encapsulation of Ac2-26 peptide within the composite scaffold can perform anti-inflammatory and antioxidant effects, regulate the complex microenvironment, and promote tissue regeneration.</p><p>In vitro inflammatory cell model experiments showed that high concentrations of Ac2-26 peptide could effectively inhibit the production of ROS, and reactive nitrogen species (RNS) in macrophages which were induced by LPS. The Western Blot results showed that the expression of M1-type macrophage markers iNOS and COX-2 were significantly increased after LPS treatment. In contrast, after 12 h of Ac2-26 peptide treatment, the expression of iNOS and COX-2 decreased significantly as compared with the control group, and the higher the concentration of Ac2-26 peptide was, the more obvious the down-regulation of iNOS expression was. Moreover, in contrast to M1 markers, M2-type markers including Arg-1 and IL-10 were significantly upregulated after Ac2-26 peptide treatment. All these results indicated that Ac2-26 peptide promoted the phenotypic transformation of macrophage phenotype from M1 to M2 type, and exerted anti-inflammatory and antioxidant effects, to favor the promotion of tissue regeneration. Moreover, they used immunofluorescence and qPCR to assess the role of different types of pores on inducing tissue differentiation at the defect. It showed that the progressive pore meniscal scaffold was more favorable for inducing fibrocartilage differentiation of MSCs, and could induce in vitro expression of COL-1 and COL-2 with more heterogeneity than that of the homogeneous pore meniscal scaffold.</p></sec></sec><sec id="sec4dot4-pharmaceutics-15-01700"><title>4.4. Plant Sources</title><sec id="sec4dot4dot1-pharmaceutics-15-01700"><title>4.4.1. Curcumin</title><p>Curcumin, a hydrophobic polyphenol, is the main component of turmeric. Demethoxycurcumin and bis-demethoxycurcumin can also be extracted from turmeric, but they both have lower activity levels than curcumin [<xref rid="B264-pharmaceutics-15-01700" ref-type="bibr">264</xref>,<xref rid="B265-pharmaceutics-15-01700" ref-type="bibr">265</xref>]. Curcumin was demonstrated to have the ability to target and regulate several molecules, including inflammatory cytokines, growth factors, and apoptosis-related proteins. It has multiple functions such as anti-inflammatory, antioxidant, and antitumor effects. The mechanism of its anti-inflammatory effects was investigated by its inhibitory effect on cytokine production and expression [<xref rid="B266-pharmaceutics-15-01700" ref-type="bibr">266</xref>,<xref rid="B267-pharmaceutics-15-01700" ref-type="bibr">267</xref>]. It was found that curcumin can exert anti-inflammatory activity in LPS/interferon-&#947; (IFN-&#947;)-treated macrophages through several mechanisms, for example, by blocking (NF-&#954;B and signal transducer and activator of transcription 1 (STAT1) signaling pathways, thereby inhibiting LPS-induced IL-6 expression in RAW264.7 cells [<xref rid="B268-pharmaceutics-15-01700" ref-type="bibr">268</xref>]. In addition, flavin derivatives can also inhibit NO, TNF-&#945;, and IL-1&#946; expression by suppressing the mitogen-activated protein kinase (MAPK)/NF-&#954;B pathway in IFN-&#947;/LPS-stimulated macrophages [<xref rid="B269-pharmaceutics-15-01700" ref-type="bibr">269</xref>]. Chen et al. [<xref rid="B37-pharmaceutics-15-01700" ref-type="bibr">37</xref>] made mesoporous CS (MesoCS/curcumin) scaffolds with curcumin. MesoCS nanoparticles were first prepared using a template [<xref rid="B270-pharmaceutics-15-01700" ref-type="bibr">270</xref>], followed by dissolving turmeric as a stock solution in 0.5 M NaOH to a concentration of 0 mg/mL, 2 mg/mL, 5 mg/mL, and 10 mM (i.e., C0, C2, C5, and C10, respectively), and finally, mixing the scaffolds at the same 0.4 mL/g liquid/powder ratio to make the scaffolds. The hMSCs were cultured in this composite scaffold and the expression levels of TNF-&#945; and IL-1 were detected after LPS treatment for 1, 3, and 7 days. The results showed that the expression levels of TNF-&#945; and IL-1 were significantly inhibited in the C2 and C5 groups, as compared with the C0 group (<italic toggle="yes">p</italic> &lt; 0.05). The expression levels of TNF-&#945; were not significantly decreased in the C10 group. This suggests that scaffolds containing certain concentrations of curcumin have significant anti-inflammatory potential to inhibit LPS-induced TNF-&#945; and IL-1 expression. In contrast, high doses of curcumin (C10) may cause apoptosis mediated by metal ions (e.g., Ca ions) [<xref rid="B271-pharmaceutics-15-01700" ref-type="bibr">271</xref>,<xref rid="B272-pharmaceutics-15-01700" ref-type="bibr">272</xref>]. Furthermore, the MesoCS/curcumin scaffold showed good biocompatibility and physical properties, and the addition of curcumin did not alter the crystalline properties of MesoCS. Overall, the MesoCS/curcumin scaffold prepared in this study is expected to be a new material for bone tissue engineering and bone regenerative medicine. Although the side effects of curcumin such as hemodilution [<xref rid="B273-pharmaceutics-15-01700" ref-type="bibr">273</xref>] and decreased blood glucose [<xref rid="B274-pharmaceutics-15-01700" ref-type="bibr">274</xref>] remain to be addressed, the scaffold will have great potential for further clinical practice.</p></sec><sec id="sec4dot4dot2-pharmaceutics-15-01700"><title>4.4.2. Isoflavones</title><p>Isoflavones are among the most common phytohormones and soybean and its products are the largest dietary source of them [<xref rid="B275-pharmaceutics-15-01700" ref-type="bibr">275</xref>]. Genistein, one of the classes of isoflavones, has a wide range of biological activities, such as inhibition of cancer growth [<xref rid="B276-pharmaceutics-15-01700" ref-type="bibr">276</xref>], promotion of osteoblast and alkaline phosphatase activity [<xref rid="B277-pharmaceutics-15-01700" ref-type="bibr">277</xref>], and immunomodulation [<xref rid="B278-pharmaceutics-15-01700" ref-type="bibr">278</xref>,<xref rid="B279-pharmaceutics-15-01700" ref-type="bibr">279</xref>]. The excellent immunomodulatory effects of genistein are attributed to its multiple anti-inflammatory mechanisms, such as its ability to eliminate free radicals produced by macrophages during inflammation, thereby reducing the release of various inflammatory mediators induced by ROS [<xref rid="B280-pharmaceutics-15-01700" ref-type="bibr">280</xref>,<xref rid="B281-pharmaceutics-15-01700" ref-type="bibr">281</xref>]. It has the ability to inhibit the phosphorylation of I&#954;B, an inhibitor of NF-&#954;B, thereby reducing the degradation of I&#954;B, inhibiting NF-&#954;B activation, and, subsequently, reducing the pro-inflammatory cytokine production [<xref rid="B282-pharmaceutics-15-01700" ref-type="bibr">282</xref>,<xref rid="B283-pharmaceutics-15-01700" ref-type="bibr">283</xref>] among others. Sarkar et al. [<xref rid="B38-pharmaceutics-15-01700" ref-type="bibr">38</xref>] loaded three soy isoflavones (Genistein, Daidzein, and Glycitein) in a 5:4:1 ratio, mimicking their original ratios in soy, on 3D-printed TCP scaffolds with pores. In vitro release profile showed controlled release in acidic and physiological buffered media over 16 days. Results of osteosarcoma cell culture experiments showed a 90% reduction in osteosarcoma (MG-63) cell viability and proliferation capacity after 11 days of cultivation, which implies the potential preventive ability of the scaffold against osteosarcoma cell lines. In addition, the scaffold showed good biocompatibility: the scaffold exhibited the ability to promote osteoblast proliferation and differentiation under both static and dynamic conditions. Finally, the scaffold was examined for in vivo immunomodulatory capacity. Twenty-four hours after implantation of the scaffold into the defective distal femur of rats, H&amp;E staining examination revealed reduced neutrophil recruitment at the implantation site. Overall, they conferred in vitro chemopreventive, osteoclast-promoting, and immunomodulatory abilities to the scaffold by incorporating isoflavones and designing a versatile bone graft substitute. The downside is that the anti-inflammatory properties of this experiment were not analyzed for macrophages, polarization, and inflammatory factor concentrations. Long-term in vivo studies are needed.</p></sec><sec id="sec4dot4dot3-pharmaceutics-15-01700"><title>4.4.3. Quercetin</title><p>Quercetin is a flavonoid monomeric compound found in natural plants with various physiological effects such as anti-inflammatory, antioxidant, antitumor, and osteogenic [<xref rid="B284-pharmaceutics-15-01700" ref-type="bibr">284</xref>,<xref rid="B285-pharmaceutics-15-01700" ref-type="bibr">285</xref>]. Quercetin was found to impact the M1/M2 phenotype transition in macrophages, inhibiting M1 phenotype polarization and promoting its polarization to the M2 phenotype [<xref rid="B286-pharmaceutics-15-01700" ref-type="bibr">286</xref>]. Because it can induce phosphorylation of protein kinase B and promote signal transduction and nuclear translocation of transcriptional activator protein 6 (STAT6), it can increase the expression of the M2 phenotype upon binding to anti-inflammatory cytokine-related genes [<xref rid="B287-pharmaceutics-15-01700" ref-type="bibr">287</xref>]. In addition, there were experiments that demonstrated that quercetin can block the NF-&#954;B signaling pathway, thus promoting M2 polarization for anti-inflammatory repair effects [<xref rid="B288-pharmaceutics-15-01700" ref-type="bibr">288</xref>]. Wang et al. [<xref rid="B39-pharmaceutics-15-01700" ref-type="bibr">39</xref>] fabricated layered micro/nano surfaces on the surface of Ti<sub>6</sub>Al<sub>4</sub>V implants using 3D printing technique, alkali heat treatment, and hydrothermal treatment after deposition of titanium dioxide (TiO<sub>2</sub>) on this surface. This increased the adsorption of specific substances on Ti<sub>6</sub>Al<sub>4</sub>V implants and made them more biocompatible. Since quercetin has an excellent ability to chelate metal cations [<xref rid="B289-pharmaceutics-15-01700" ref-type="bibr">289</xref>], it can be adsorbed as a monomer on TiO<sub>2</sub>, effectively creating a quercetin coating on the surface of the 3D-printed Ti<sub>6</sub>Al<sub>4</sub>V implant. SEM results of 24-h adhesion of RAW 264.7 cells in vitro showed that macrophages on the quercetin-containing coating group were mostly polarized to the M2 phenotype and had more pseudopods. This indicated there were more adequate attachments and diffusions. RBMSCs proliferation also showed similar results. Representative cytokine concentrations secreted by macrophages with M1/M2 phenotypes were further examined by ELISA. The M1 phenotype secreted reduced concentrations of IL-1&#946; cytokines, whereas the M2 phenotype secreted increased concentrations of VEGF-&#945; cytokines. Furthermore, after 7 days of cell adhesion, the addition of quercetin coating elevated the ALP expression on the surface of the motifs, as compared with the control group, thus revealing that quercetin does have the function of promoting osteogenic differentiation of rbMSCs. Finally, the scaffold was implanted into the femoral condylar defect in rats. Two weeks later, the control group showed a severe inflammatory response compared with the group loaded with quercetin. A large quantity of inflammatory cells such as monocytes, neutrophils, and macrophages, and a significant expression of the M1 macrophage biomarker IL-1&#946;, was found in the implantation site. In contrast, inflammatory cells were significantly reduced, and IL-1&#946; expression was significantly decreased in the loaded quercetin scaffold. These indicated the superior anti-inflammatory effect of quercetin at the site of inflammation in vivo. Overall, the loading of quercetin conferred osteointegration-promoting and immunomodulatory properties to the 3D-printed titanium implants, offering the possibility of future applications in clinical osteointegration.</p></sec></sec></sec><sec id="sec5-pharmaceutics-15-01700"><title>5. Regulation of Collagen Deposition</title><p>Collagen, the most abundant protein in mammals (25&#8211;30% of total protein mass), is one of the main components of connective tissue. It is closely related to disease and aging, cell proliferation, migration and differentiation, and fibrosis formation [<xref rid="B290-pharmaceutics-15-01700" ref-type="bibr">290</xref>]. More than 20 types of collagen were identified, of which the most abundant and well-studied are type I, type II, and type III collagens [<xref rid="B291-pharmaceutics-15-01700" ref-type="bibr">291</xref>]. In addition, collagen is mostly found in the interstitial matrix of thin-walled organs and serves as a scaffolding structure to stabilize and maintain tissue integrity. Therefore, imbalance of collagen metabolism plays a crucial role in the development of certain diseases. In the middle and late stages of injury repair, however, an imbalance in the ratio of type I to type III collagen (type I collagen replaces type III collagen), and often leads to fibrotic lesions and scar formation [<xref rid="B292-pharmaceutics-15-01700" ref-type="bibr">292</xref>,<xref rid="B293-pharmaceutics-15-01700" ref-type="bibr">293</xref>]. Collagen metabolism is regulated by signaling pathways such as TGF-&#946;/Smad, PI3K/Akt, MAPK, and NF-&#954;B, and each pathway interacts with each other to mediate collagen metabolism [<xref rid="B294-pharmaceutics-15-01700" ref-type="bibr">294</xref>,<xref rid="B295-pharmaceutics-15-01700" ref-type="bibr">295</xref>,<xref rid="B296-pharmaceutics-15-01700" ref-type="bibr">296</xref>]. Therefore, there are many studies that regulate collagen deposition by adding some kind of signaling pathway modulating substance to 3D-printed tissue engineering scaffolds or adding some kind of collagen-containing substance directly to the scaffold to make the collagen deposition at the scaffold implantation injury repair with specific tissue specificity. Thus, they can better promote efficient and scar-free repair at the implantation site and promote tissue regeneration.</p><sec id="sec5dot1-pharmaceutics-15-01700"><title>5.1. Direct Regulation</title><sec id="sec5dot1dot1-pharmaceutics-15-01700"><title>5.1.1. Collagen</title><p>As mentioned above, different types and ratios of collagen deposition play different roles in different periods of wound repair. So, it is crucial to form tissue-specific collagen deposition at the implantation injury site, to promote regeneration of wound repair tissue, and to avoid scar tissue formation due to excessive collagen deposition. Martin et al. [<xref rid="B28-pharmaceutics-15-01700" ref-type="bibr">28</xref>] used 3D printing technology to prepare a PLA-collagen -minocycline-nanohydroxyapatite scaffold; the specific preparation process was mentioned in the <xref rid="sec3-pharmaceutics-15-01700" ref-type="sec">Section 3</xref>. They added collagen directly to the 3D-printed scaffold. The scaffold had good osteogenic properties, morphological and mechanical properties matching those of bone trabeculae. The addition of collagen enhanced the structural strength of the scaffold and formed a scaffold support closer to the scaffold itself. It also had a positive effect on bone differentiation and metabolism.</p></sec><sec id="sec5dot1dot2-pharmaceutics-15-01700"><title>5.1.2. Extracellular Matrix</title><p>In spite of the good effects from direct addition of collagen to scaffolds, rapid degradation and shrinkage are inevitable after long-term implantation, and so, their lifespan is very limited [<xref rid="B297-pharmaceutics-15-01700" ref-type="bibr">297</xref>,<xref rid="B298-pharmaceutics-15-01700" ref-type="bibr">298</xref>]. The application of dECM as an ink for 3D bioprinting can be a good solution. Extracellular matrix is mainly composed of various components such as collagen, non-collagen, and elastin [<xref rid="B299-pharmaceutics-15-01700" ref-type="bibr">299</xref>], and collagen as the main component can not only give the extracellular matrix the function of directly regulating collagen deposition, but also avoid the degradation and shrinkage process caused by a single collagen. Kim et al. [<xref rid="B23-pharmaceutics-15-01700" ref-type="bibr">23</xref>] used S-dECM bioink to print and fabricate 3D pre-vascularized skin patches for wound healing with infusion of ASCs and EPCs. After implanting the patches into mice for 2 weeks, the 3D cell-printed skin tissues using dECM as bioink were very stable, had less shrinkage, and contained abundant type I and III collagen, as well as fibronectin with better cellular integrity as compared to the single collagen group. In addition, the cytoskeleton of tissue repair and epithelialization (KGF-1)-related gene expression levels were also higher in the dECM-as-bioink group. Therefore, using extracellular matrix as a 3D bioprinting ink could better regulate collagen deposition and promote tissue repair and regeneration. However, the issue of cell-related immunogenicity of its heterologous tissues should not be ignored, and the cells of donor tissues need to be completely removed, and so, the use of dECM as bioink for preclinical or even clinical applications still needs to be carefully experimented and considered before use.</p></sec></sec><sec id="sec5dot2-pharmaceutics-15-01700"><title>5.2. Indirect Regulation</title><sec id="sec5dot2dot1-pharmaceutics-15-01700"><title>5.2.1. Copper Ion</title><p>Cu<sup>2+</sup> is one of the essential ions for the human body. As mentioned above, Cu ions have antibacterial, immunomodulatory, and pro-vascularizing effects, and play a huge role in human metabolic processes. It was demonstrated that Cu<sup>2+</sup> ions can upregulate HIF-1 expression by activating and binding to the &#945;-subunit of HIF-1 factor, and inhibiting the activity of HIF-1 and the inhibitory factor of HIF-1 [<xref rid="B104-pharmaceutics-15-01700" ref-type="bibr">104</xref>,<xref rid="B300-pharmaceutics-15-01700" ref-type="bibr">300</xref>]. The activation of the HIF pathway further stimulates the expression of SOX-9, which leads to increased levels of COL II and ACAN expression in chondrocytes increased [<xref rid="B301-pharmaceutics-15-01700" ref-type="bibr">301</xref>,<xref rid="B302-pharmaceutics-15-01700" ref-type="bibr">302</xref>]. This regulates collagen deposition and promotes chondrocyte synthesis and development. Lin et al. [<xref rid="B84-pharmaceutics-15-01700" ref-type="bibr">84</xref>] fabricated Cu-BGC scaffolds by doping different concentrations of Cu<sup>2+</sup> (0.781&#8211;25 mg/mL) into bioactive microcrystalline glass with 3D printing technology. The results showed that the expression of SOX9 in cartilage was significantly increased after treatment with Cu<sup>2+</sup>. In addition, the expression of COL II and ACAN genes in chondrocytes was also significantly elevated after day 3 of Cu<sup>2+</sup> treatment. In vitro results also showed that Cu<sup>2+</sup> concentration in the range of 0.5&#8211;16 ppm significantly increased the expression of COL II and NCAD proteins. Chondrocyte proliferation and maturation were stimulated and elevated compared to the control group.</p></sec><sec id="sec5dot2dot2-pharmaceutics-15-01700"><title>5.2.2. Silk Fiber</title><p>In addition to the above-mentioned pro-vascularization functions, SF was also shown to be able to regulate collagen deposition to some extent. As one of the filamentous proteins, <italic toggle="yes">Antheraea assama</italic> SF can improve cell fate and promote ECM secretion owing to its Arg-Gly-Asp (RGD) content. Bandyopadhyay et al. [<xref rid="B40-pharmaceutics-15-01700" ref-type="bibr">40</xref>] mixed a blend of SF from mulberry (<italic toggle="yes">Bombyx mori</italic>) and non-mulberry (<italic toggle="yes">Antheraea assama</italic>) silk with gelatin as inks for 3D bioprinting to simulate the extracellular microenvironment of the meniscus. Subsequently, EDC and NHS were chemically cross-linked to enhance their stability and mechanical strength. Finally, porcine meniscal fibrocartilage cells were seeded in the scaffold. After 7 days, the expression of sox-9, aggrecan, and collagen II genes were significantly increased. After 21 days, a significant increase in the secretion of sGAG and the deposition of ECM components (i.e., collagen) was detected. This suggests that <italic toggle="yes">Antheraea assama</italic> SF can indirectly regulate collagen deposition by promoting the secretion of ECM for implant site-specific collagen deposition.</p></sec><sec id="sec5dot2dot3-pharmaceutics-15-01700"><title>5.2.3. Curcumin</title><p>Curcumin is one of the main active components of the rhizome of the turmeric plant. In addition to the above-mentioned functions of promoting angiogenesis, immunomodulation, and antioxidation, Bose et al. [<xref rid="B41-pharmaceutics-15-01700" ref-type="bibr">41</xref>] also demonstrated that curcumin has the function of inhibiting the NF-&#954;&#946; signaling pathway, thus promoting osteoblast differentiation and the secretion of ECM. They fabricated a PCL-PEG+curcumin-coated TCP scaffold using 3D printing technology. After implanting the scaffold into rats for 6 weeks, this scaffold group showed significant new bone formation and mineralization, as compared with the control group. Tissue staining showed various types of type II collagen, and the scaffold implantation greatly promoted ECM formation and angiogenesis. The results suggest that curcumin promotes the formation and deposition of ECM by promoting osteogenesis, thereby indirectly and specifically regulating collagen deposition.</p></sec><sec id="sec5dot2dot4-pharmaceutics-15-01700"><title>5.2.4. Mesenchymal Stem Cells</title><p>MSCs are multipotent differentiated cells that can be induced to differentiate into stromal cells, osteoblasts, hepatocytes, and other cells and were widely used in disease models to regulate wound healing and tissue regeneration [<xref rid="B303-pharmaceutics-15-01700" ref-type="bibr">303</xref>,<xref rid="B304-pharmaceutics-15-01700" ref-type="bibr">304</xref>]. It was demonstrated that MSCs play a major role in regulating collagen production and inhibiting scar formation during the proliferative and mature phases of injury repair.</p><p>The main mechanisms of MSCs for scar inhibition are as follows. 1. Inhibition of inflammation in scar tissue. In detail, excessive inflammatory response is one of the main causes of scar formation. MSCs can shorten the inflammatory period and reduce the inflammatory response by acting as a chemotactic agent for various cytokines that contribute to wound healing, such as TNF, IL-8, PDGF [<xref rid="B305-pharmaceutics-15-01700" ref-type="bibr">305</xref>]. In the meanwhile, they can immunomodulate inflammatory cells in scar formation by secreting various factors and extracellular vesicles [<xref rid="B306-pharmaceutics-15-01700" ref-type="bibr">306</xref>]. 2. MSCs can affect fibroblast activity in scar formation and can reduce scar formation by inhibiting the gene expression of TGF-&#946;1 and decreasing type I collagen production [<xref rid="B307-pharmaceutics-15-01700" ref-type="bibr">307</xref>]. In addition, MSCs can inhibit fibroblast proliferation and migration, as well as inhibit angiogenesis in scar tissue. 3. MSCs can play a positive role in collagen remodeling in scar tissue, and can regulate the expression of matrix metalloproteinase (MMP) by secreting tissue inhibitor metalloproteinase (TIMP), thereby delaying or reducing scar formation [<xref rid="B308-pharmaceutics-15-01700" ref-type="bibr">308</xref>]. In details, in a rat skin burn model, MSCs not only promoted the proliferation of epithelial cells at the skin wound, but also increased the expression of CK19, PCNA, Col I, and Col III [<xref rid="B309-pharmaceutics-15-01700" ref-type="bibr">309</xref>]. Paul et al. [<xref rid="B122-pharmaceutics-15-01700" ref-type="bibr">122</xref>] used hydrogel-coated eMSCs and 3D melt electrospun wire nets to generate tissue-engineered scaffolds for POP. The specific production process was mentioned in the previous section. Picro Sirius red staining in <xref rid="pharmaceutics-15-01700-f011" ref-type="fig">Figure 11</xref> shows collagen deposition in and around the reticular area of the MES-Hyd-eMSCs group as compared to MES and MES-Hyd alone. MES-Hyd shows no collagen within the first week of implantation.</p><p>The fate of the mesh after 1 week of implantation in vivo was assessed by SEM in <xref rid="pharmaceutics-15-01700-f012" ref-type="fig">Figure 12</xref>, showing little degradation of the scaffold after 1 week, as expected for a PCL-based mesh. The deposition of new collagen fibers appeared lower in MES alone (<xref rid="pharmaceutics-15-01700-f012" ref-type="fig">Figure 12</xref>A&#8211;C) and MES_Hyd (<xref rid="pharmaceutics-15-01700-f012" ref-type="fig">Figure 12</xref>D&#8211;F). On the other hand, MES_Hyd_eMSCs showed better evidence of tissue integration and new collagen deposition (<xref rid="pharmaceutics-15-01700-f012" ref-type="fig">Figure 12</xref>G&#8211;I).</p><p>All these results suggest that the addition of MSCs to scaffolds can better regulate collagen deposition and promote tissue integration and regeneration. Additionally, among the many different sources of MSCs, human gingival mesenchymal stem cells (hGMSCs) are abundant and readily available [<xref rid="B310-pharmaceutics-15-01700" ref-type="bibr">310</xref>,<xref rid="B311-pharmaceutics-15-01700" ref-type="bibr">311</xref>]. In addition, gingival cells have a mechanism similar to fetal tissue healing, and exhibit greater ability to heal scar-free wounds than dermal fibroblasts [<xref rid="B312-pharmaceutics-15-01700" ref-type="bibr">312</xref>]. Shafiee et al. [<xref rid="B313-pharmaceutics-15-01700" ref-type="bibr">313</xref>] fabricated a bionic medical polycaprolactone (mPCL) dressing with hGMSCs using 3D printing technology. The medical polycaprolactone dressing has a pore structure and excellent mechanical properties that mimic the layered structure of skin collagen fibers. This facilitates skin wound healing and reduces scar formation. After implantation of the dressing containing hGMSCs into rats for 6 weeks, wound contraction was significantly reduced in the mPCL dressing group, as compared with the control group. Tissue regeneration was significantly improved by granulation and re-epithelialization. In addition, Masson staining showed significant collagen I deposition in the wound area, and the collagen I deposition exhibited an ordered, directionally dispersed narrower form. Overall, mPCL dressings containing hGMSCs resulted in more rapid wound healing, regulated collagen deposition, and reduced scar formation in the rat model.</p></sec><sec id="sec5dot2dot5-pharmaceutics-15-01700"><title>5.2.5. Granulocyte Colony-Stimulating Factor</title><p>Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic factor produced by lymphocytes, macrophages, and endothelial cells, and it promotes the proliferation and differentiation of bone marrow hematopoietic cells [<xref rid="B314-pharmaceutics-15-01700" ref-type="bibr">314</xref>]. In addition, as an anti-inflammatory protein, endometrial stem cell-derived G-CSF can reduce scar formation by reducing Gli2 protein expression levels to regulate collagen deposition and reduce endometrial fibrosis [<xref rid="B315-pharmaceutics-15-01700" ref-type="bibr">315</xref>,<xref rid="B316-pharmaceutics-15-01700" ref-type="bibr">316</xref>]. However, G-CSF has a short half-life in vivo due to receptor-mediated clearance, renal metabolic elimination, and enzymatic degradation [<xref rid="B317-pharmaceutics-15-01700" ref-type="bibr">317</xref>,<xref rid="B318-pharmaceutics-15-01700" ref-type="bibr">318</xref>]. Furthermore, due to the continuous migration of G-CSF in the uterine cavity, it cannot maintain a consistently high concentration at the endometrial injury to achieve good therapeutic efficacy. Therefore, to maintain the long-term drug concentration of G-CSF at the site of endometrial injury and to reduce the adverse consequences of a single high-dose administration, it is of great significance to construct a sustained release system of G-CSF. Wen et al. [<xref rid="B42-pharmaceutics-15-01700" ref-type="bibr">42</xref>] made G-CSF-loaded slow-release microsphere (G-CSF-SRM) hydrogel scaffolds with 3D printing technology. They mixed recombinant human G-CSF, dextrose, and polyethylene glycol in a mass ratio of 1:5:50, and stirred and freeze-dried them. Then, the obtained G-CSF-dextran-PLGA microspheres were processed by curing, hardening, and freeze-drying to complete the G-CSF microsphere preparation. Finally, the prepared G-CSF microspheres were mixed and printed with 20% gelatin and 4% SA to make a 3D-printed G-CSF-SRM hydrogel scaffold. The in vitro cumulative release of G-CSF over time was measured by ELISA. It showed that G-CSF was continuously released from the microspheres for more than 1 month, and the drug release became slow and regular after the explosive release just after implantation. Five weeks after implantation of the scaffold at the endometrial injury in rats, HE staining results showed that the number of endometrial cells and good endometrial regeneration were significantly increased in the group implanted with 3D-printed G-CSF-SRM hydrogel scaffold, whose endometrial thickness and number of glands were significantly higher than the remaining four groups. However, their inflammatory cells and inflammatory factors IL-1&#946;, IL-6, TNF-&#945; expression levels were lower. In addition, Masson staining results showed that this group had relatively less collagen deposition and less fibrosis. Thus, endometrial inflammatory cell infiltration and endometrial fibrosis were significantly reduced due to G-CSF, which effectively prevented fibrous exudation-mediated adhesion and scar formation.</p></sec><sec id="sec5dot2dot6-pharmaceutics-15-01700"><title>5.2.6. Piezoelectric Effect</title><p>It was demonstrated that bioelectricity plays a crucial role in promoting wound healing [<xref rid="B319-pharmaceutics-15-01700" ref-type="bibr">319</xref>]. However, the gradual weakening of bioelectric stimulation with wound healing may cause disruption of gene regulation, leading to downregulation of the wound healing cascade and eventually disorganized deposition of collagen fibers and abnormal remodeling of the ECM, which delayed wound healing and resulted in the formation of scar tissue [<xref rid="B320-pharmaceutics-15-01700" ref-type="bibr">320</xref>,<xref rid="B321-pharmaceutics-15-01700" ref-type="bibr">321</xref>]. Therefore, to solve these problems, Liang et al. [<xref rid="B43-pharmaceutics-15-01700" ref-type="bibr">43</xref>] fabricated a novel ZnO nanoparticle-modified PVDF/SA piezoelectric hydrogel 3D scaffold (ZPFSA). As one of the commonly used piezoelectric materials, polyvinylidene fluoride (PVDF) has excellent piezoelectric properties, biocompatibility, thermal stability, and resistance to chemical irritation [<xref rid="B322-pharmaceutics-15-01700" ref-type="bibr">322</xref>]. However, since PVDF is a superhydrophobic polymer, it is contrary to the wetting behaviors of hydrogels and preparing them as hydrogels is a great challenge [<xref rid="B323-pharmaceutics-15-01700" ref-type="bibr">323</xref>]. Therefore, the incorporation of SA precisely reduces the hydrophobicity of PVDF and creates the possibility of preparing hydrogels from its 3D printing. Moreover, the addition of nanoparticles can enhance the piezoelectric properties of PVDF by promoting the polarization of PVDF [<xref rid="B324-pharmaceutics-15-01700" ref-type="bibr">324</xref>]. The 3D-printed ZPFSA scaffold was implanted into the defective skin on the back of rats, and the immunohistochemical results showed that the CD31 expression in the ZPFSA 0.5 group was higher than the other groups on day 7 after implantation. This indicated that the wound tissue in the ZPFSA 0.5 group had active angiogenesis to ensure adequate blood supply to the wound. &#945;-SMA is an &#945;-smooth muscle actin secreted by myofibroblasts, which has high expression in the middle and late stages of tissue healing and proliferation to promote wound contraction. However, at the end of wound healing, myofibroblast apoptosis causes a gradual decrease in &#945;-SMA expression to prevent excessive contraction of collagen fibers and formation of scar tissue [<xref rid="B325-pharmaceutics-15-01700" ref-type="bibr">325</xref>]. At day 14 after implantation, the wound in the ZPFSA0.5 group was close to healing and its &#945;-SMA content was maintained at a low level. The other groups were still in the late stage of healing and had higher &#945;-SMA content. Thus, the ZPFSA0.5 group reduced the possibility of scar formation by accelerating wound healing. In addition, immunohistochemical results showed that the expression of three growth factors, EGF, VEGF, and TGF-&#946;, was higher in the ZPFSA 0.5 group than in the other groups, implying that the electrical stimulation was generated by the ZPFSA piezoelectric scaffold when receiving stress. This could promote the production of cellular growth factors, which greatly accelerated the wound healing process and effectively prevented the formation of scar tissue.</p></sec></sec></sec><sec id="sec6-pharmaceutics-15-01700"><title>6. Future Perspective and Concluding Remarks</title><p>This review outlined current important advances in 3D bioprinting of tissue and/or organ engineering. The different additives were classified into four categories according to the different functions they conferred on the scaffold: vascularization, antibacterial, immunomodulation, and regulation of collagen deposition. The mechanisms and the methods of incorporating bioinks were detailed. Many additives can fulfill two or more functions from their excellent properties. For example, many metal ions can not only be antibacterial, but also perform immunomodulatory functions. Extracellular matrix can not only promote vascularization, but also regulate collagen deposition and reduce scar tissue formation, etc. All these summaries offer the possibility of adding small amounts of additives to achieve multiple effects in the future, which will facilitate 3D-bioprinted scaffolds to perform their functions and promote tissue regeneration more efficiently and effortlessly. However, although many experiments in animals or in vitro achieved good outcomes, only a few printed scaffolds were applied to human experiments for research. We think there are many reasons for this; for example: these constructs need to be specific to the relevant characteristics of the graft site (appropriate cell type, ideal mechanical properties, and other required associated cues, such as neovascularization, low inflammatory properties, sterility, and appropriate collagen deposition), which is often a challenge for transplantation [<xref rid="B326-pharmaceutics-15-01700" ref-type="bibr">326</xref>]. So, future work can be dedicated to the suitable scaffolds to general clinics. Suitable additives can be used according to the different specific environments of the implantation site, thus achieving specific functional modulation, or even meeting one additive to achieve multiple functions, greatly improving transplantation success, reducing the complexity and economic cost of bioprinting, and, finally, facilitating the translation of the constructs from animal experiments to the clinic. Looking forward to the future, it is bright to design the tissue-specific 3D-bioprinted scaffolds and add efficient additives to achieve multi-functions, and then use them in tissue regeneration in human treatment.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>W.F., M.L. and R.Y., writing&#8212;original draft, M.Y. and Y.W. (Yuhui Wang), writing&#8212;review and editing; W.F., Y.J. and Y.W. (Ying Wang), figure drawing; K.Z. and Q.F., conceptualization, writing&#8212;review and editing, funding acquisition. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">3D</td><td align="left" valign="middle" rowspan="1" colspan="1">Three dimensional</td><td align="left" valign="middle" rowspan="1" colspan="1">VEGF</td><td align="left" valign="middle" rowspan="1" colspan="1">vascular endothelial growth factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMP-2</td><td align="left" valign="middle" rowspan="1" colspan="1">bone morphogenetic protein-2</td><td align="left" valign="middle" rowspan="1" colspan="1">SF</td><td align="left" valign="middle" rowspan="1" colspan="1">silk fiber</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">nHAp</td><td align="left" valign="middle" rowspan="1" colspan="1">nano-hydroxyapatite</td><td align="left" valign="middle" rowspan="1" colspan="1">EDC</td><td align="left" valign="middle" rowspan="1" colspan="1">1-ethyl-3-(3-(dimethylamino) propyl) carbodiimide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NHS</td><td align="left" valign="middle" rowspan="1" colspan="1">N-hydroxysuccinimide</td><td align="left" valign="middle" rowspan="1" colspan="1">FGF-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Fibroblast growth factor-2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SO<sub>3</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">sulfonic acid group</td><td align="left" valign="middle" rowspan="1" colspan="1">&#945;-SMA</td><td align="left" valign="middle" rowspan="1" colspan="1">&#945;-smooth muscle actin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDGF</td><td align="left" valign="middle" rowspan="1" colspan="1">platelet-derived growth factor</td><td align="left" valign="middle" rowspan="1" colspan="1">SMC</td><td align="left" valign="middle" rowspan="1" colspan="1">Smooth muscle cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECs</td><td align="left" valign="middle" rowspan="1" colspan="1">endothelial cells</td><td align="left" valign="middle" rowspan="1" colspan="1">PLL</td><td align="left" valign="middle" rowspan="1" colspan="1">poly-L-lysine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GelMA</td><td align="left" valign="middle" rowspan="1" colspan="1">Gelatin methacrylate</td><td align="left" valign="middle" rowspan="1" colspan="1">HAMA</td><td align="left" valign="middle" rowspan="1" colspan="1">Hyaluronic acid methacrylate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HIF-1&#945;</td><td align="left" valign="middle" rowspan="1" colspan="1">hypoxia-inducible factor-1&#945;</td><td align="left" valign="middle" rowspan="1" colspan="1">MDSCs</td><td align="left" valign="middle" rowspan="1" colspan="1">muscle-derived stem cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SDF-1</td><td align="left" valign="middle" rowspan="1" colspan="1">stroma cell-derived factor-1</td><td align="left" valign="middle" rowspan="1" colspan="1">HS</td><td align="left" valign="middle" rowspan="1" colspan="1">Heparan sulfate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ISH</td><td align="left" valign="middle" rowspan="1" colspan="1">In situ hybridization</td><td align="left" valign="middle" rowspan="1" colspan="1">hBMSCs</td><td align="left" valign="middle" rowspan="1" colspan="1">human bone marrow stromal cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KDR</td><td align="left" valign="middle" rowspan="1" colspan="1">kinase insert domain-containing receptor</td><td align="left" valign="middle" rowspan="1" colspan="1">CPC</td><td align="left" valign="middle" rowspan="1" colspan="1">calcium phosphate cement</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MS</td><td align="left" valign="middle" rowspan="1" colspan="1">Mesoporous Silica</td><td align="left" valign="middle" rowspan="1" colspan="1">rhBMP-2</td><td align="left" valign="middle" rowspan="1" colspan="1">recombinant human bone morphogenetic protein-2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#956;CT</td><td align="left" valign="middle" rowspan="1" colspan="1">Micro-computerised Tomography</td><td align="left" valign="middle" rowspan="1" colspan="1">NO</td><td align="left" valign="middle" rowspan="1" colspan="1">nitric oxide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDA</td><td align="left" valign="middle" rowspan="1" colspan="1">polydopamine</td><td align="left" valign="middle" rowspan="1" colspan="1">HUVECs</td><td align="left" valign="middle" rowspan="1" colspan="1">human umbilical vein endothelial cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TCP</td><td align="left" valign="middle" rowspan="1" colspan="1">Tricalcium phosphate</td><td align="left" valign="middle" rowspan="1" colspan="1">MOFs</td><td align="left" valign="middle" rowspan="1" colspan="1">metal organic frameworks</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAM</td><td align="left" valign="middle" rowspan="1" colspan="1">chorioal lantoic membrane</td><td align="left" valign="middle" rowspan="1" colspan="1">MSCs</td><td align="left" valign="middle" rowspan="1" colspan="1">Mesenchymal stem cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hUCMSCs</td><td align="left" valign="middle" rowspan="1" colspan="1">human umbilical cord mesenchymal stem cells</td><td align="left" valign="middle" rowspan="1" colspan="1">DFO</td><td align="left" valign="middle" rowspan="1" colspan="1">Desferrioxamine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Polycaprolactone</td><td align="left" valign="middle" rowspan="1" colspan="1">DAT-A</td><td align="left" valign="middle" rowspan="1" colspan="1">decellularized adipose tissue-alginate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GAG</td><td align="left" valign="middle" rowspan="1" colspan="1">glycosaminoglycans</td><td align="left" valign="middle" rowspan="1" colspan="1">HA</td><td align="left" valign="middle" rowspan="1" colspan="1">hyaluronic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">dECM</td><td align="left" valign="middle" rowspan="1" colspan="1">decellularized extracellular matrix</td><td align="left" valign="middle" rowspan="1" colspan="1">ASCs</td><td align="left" valign="middle" rowspan="1" colspan="1">adipose-derived stem cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EPCs</td><td align="left" valign="middle" rowspan="1" colspan="1">endothelial progenitor cells</td><td align="left" valign="middle" rowspan="1" colspan="1">AP</td><td align="left" valign="middle" rowspan="1" colspan="1">Angiogenic peptides</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OP</td><td align="left" valign="middle" rowspan="1" colspan="1">osteogenic peptide</td><td align="left" valign="middle" rowspan="1" colspan="1">ROS</td><td align="left" valign="middle" rowspan="1" colspan="1">reactive oxygen species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PAM</td><td align="left" valign="middle" rowspan="1" colspan="1">polyacrylamide</td><td align="left" valign="middle" rowspan="1" colspan="1">HPMC</td><td align="left" valign="middle" rowspan="1" colspan="1">Hydroxypropyl Methyl Cellulose</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PTT</td><td align="left" valign="middle" rowspan="1" colspan="1">photothermal therapy</td><td align="left" valign="middle" rowspan="1" colspan="1">PDT</td><td align="left" valign="middle" rowspan="1" colspan="1">photodynamic therapy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" rowspan="1" colspan="1">poly(lactic-co-glycolic-acid)</td><td align="left" valign="middle" rowspan="1" colspan="1">PLA</td><td align="left" valign="middle" rowspan="1" colspan="1">poly (lactic acid)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">cHA</td><td align="left" valign="middle" rowspan="1" colspan="1">citrate hydroxyapatite nanoparticles</td><td align="left" valign="middle" rowspan="1" colspan="1">SEM</td><td align="left" valign="middle" rowspan="1" colspan="1">scanning electron microscopy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SDVG</td><td align="left" valign="middle" rowspan="1" colspan="1">small-diameter vascular graft</td><td align="left" valign="middle" rowspan="1" colspan="1">PEG</td><td align="left" valign="middle" rowspan="1" colspan="1">poly (ethylene glycol)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SC</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Satureja cuneifolia</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">NDS</td><td align="left" valign="middle" rowspan="1" colspan="1">Nanodiamonds</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SLM</td><td align="left" valign="middle" rowspan="1" colspan="1">selective laser melting</td><td align="left" valign="middle" rowspan="1" colspan="1">RNA</td><td align="left" valign="middle" rowspan="1" colspan="1">ribonucleic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AM</td><td align="left" valign="middle" rowspan="1" colspan="1">additive manufacturing</td><td align="left" valign="middle" rowspan="1" colspan="1">FFF</td><td align="left" valign="middle" rowspan="1" colspan="1">Fused filament fabrication</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PA12</td><td align="left" valign="middle" rowspan="1" colspan="1">polyamide 12</td><td align="left" valign="middle" rowspan="1" colspan="1">LPS</td><td align="left" valign="middle" rowspan="1" colspan="1">lipopolysaccharide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DEX</td><td align="left" valign="middle" rowspan="1" colspan="1">Dexamethasone</td><td align="left" valign="middle" rowspan="1" colspan="1">COX-2</td><td align="left" valign="middle" rowspan="1" colspan="1">cyclooxygenase 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ELSP</td><td align="left" valign="middle" rowspan="1" colspan="1">electrostatic spinning technique</td><td align="left" valign="middle" rowspan="1" colspan="1">&#946;CD</td><td align="left" valign="middle" rowspan="1" colspan="1">&#946;-cyclodextrin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PEI</td><td align="left" valign="middle" rowspan="1" colspan="1">polyethyleneimine</td><td align="left" valign="middle" rowspan="1" colspan="1">AFM</td><td align="left" valign="middle" rowspan="1" colspan="1">atomic force microscopy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">XPS</td><td align="left" valign="middle" rowspan="1" colspan="1">X-ray photoelectron spectroscopy</td><td align="left" valign="middle" rowspan="1" colspan="1">eMSCs</td><td align="left" valign="middle" rowspan="1" colspan="1">endometrial mesenchymal stem cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">POP</td><td align="left" valign="middle" rowspan="1" colspan="1">pelvic organ prolapse</td><td align="left" valign="middle" rowspan="1" colspan="1">MES</td><td align="left" valign="middle" rowspan="1" colspan="1">melt electrospinning</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF-&#945;</td><td align="left" valign="middle" rowspan="1" colspan="1">tumor necrosis factor-&#945;</td><td align="left" valign="middle" rowspan="1" colspan="1">RNS</td><td align="left" valign="middle" rowspan="1" colspan="1">reactive nitrogen species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NF-&#954;B</td><td align="left" valign="middle" rowspan="1" colspan="1">nuclear factor-&#954;B</td><td align="left" valign="middle" rowspan="1" colspan="1">STAT1</td><td align="left" valign="middle" rowspan="1" colspan="1">signal transducer and activator of transcription 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAPK</td><td align="left" valign="middle" rowspan="1" colspan="1">mitogen-activated protein kinase</td><td align="left" valign="middle" rowspan="1" colspan="1">MMP</td><td align="left" valign="middle" rowspan="1" colspan="1">matrix metalloproteinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TIMP</td><td align="left" valign="middle" rowspan="1" colspan="1">tissue inhibitor metalloproteinase</td><td align="left" valign="middle" rowspan="1" colspan="1">hGMSCs</td><td align="left" valign="middle" rowspan="1" colspan="1">human gingival mesenchymal stem cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mPCL</td><td align="left" valign="middle" rowspan="1" colspan="1">medical polycaprolactone</td><td align="left" valign="middle" rowspan="1" colspan="1">G-CSF</td><td align="left" valign="middle" rowspan="1" colspan="1">Granulocyte colony-stimulating factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PVDF</td><td align="left" valign="middle" rowspan="1" colspan="1">polyvinylidene fluoride</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-pharmaceutics-15-01700"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosseini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Maroufi</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Saghati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Asadi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Darabi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S.N.S.</given-names></name><name name-style="western"><surname>Hosseinkhani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rahbarghazi</surname><given-names>R.</given-names></name></person-group><article-title>Current progress in hepatic tissue regeneration by tissue engineering</article-title><source>J. Transl. Med.</source><year>2019</year><volume>17</volume><fpage>383</fpage><pub-id pub-id-type="doi">10.1186/s12967-019-02137-6</pub-id><pub-id pub-id-type="pmid">31752920</pub-id><pub-id pub-id-type="pmcid">PMC6873477</pub-id></element-citation></ref><ref id="B2-pharmaceutics-15-01700"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozbolat</surname><given-names>I.T.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ozbolat</surname><given-names>V.</given-names></name></person-group><article-title>Application areas of 3D bioprinting</article-title><source>Drug Discov. Today</source><year>2016</year><volume>21</volume><fpage>1257</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2016.04.006</pub-id><pub-id pub-id-type="pmid">27086009</pub-id></element-citation></ref><ref id="B3-pharmaceutics-15-01700"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beheshtizadeh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lotfibakhshaiesh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pazhouhnia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hoseinpour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nafari</surname><given-names>M.</given-names></name></person-group><article-title>A review of 3D bio-printing for bone and skin tissue engineering: A commercial approach</article-title><source>J. Mater. Sci.</source><year>2020</year><volume>55</volume><fpage>3729</fpage><lpage>3749</lpage><pub-id pub-id-type="doi">10.1007/s10853-019-04259-0</pub-id></element-citation></ref><ref id="B4-pharmaceutics-15-01700"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dave</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chandrawati</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dehghani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>V.G.</given-names></name></person-group><article-title>3D printing of biopolymer nanocomposites for tissue engineering: Nanomaterials, processing and structure-function relation</article-title><source>Eur. Polym. J.</source><year>2019</year><volume>121</volume><fpage>109340</fpage><pub-id pub-id-type="doi">10.1016/j.eurpolymj.2019.109340</pub-id></element-citation></ref><ref id="B5-pharmaceutics-15-01700"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aljohani</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name></person-group><article-title>Bioprinting and its applications in tissue engineering and regenerative medicine</article-title><source>Int. J. Biol. Macromol.</source><year>2018</year><volume>107</volume><fpage>261</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2017.08.171</pub-id><pub-id pub-id-type="pmid">28870749</pub-id></element-citation></ref><ref id="B6-pharmaceutics-15-01700"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>3D printing of hydrogel composite systems: Recent advances in technology for tissue engineering</article-title><source>Int. J. Bioprint.</source><year>2018</year><volume>4</volume><fpage>126</fpage><pub-id pub-id-type="doi">10.18063/ijb.v4i1.126</pub-id><pub-id pub-id-type="pmid">33102909</pub-id><pub-id pub-id-type="pmcid">PMC7582009</pub-id></element-citation></ref><ref id="B7-pharmaceutics-15-01700"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganguly</surname><given-names>S.</given-names></name><name name-style="western"><surname>Margel</surname><given-names>S.</given-names></name></person-group><article-title>3D printed magnetic polymer composite hydrogels for hyperthermia and magnetic field driven structural manipulation</article-title><source>Prog. Polym. Sci.</source><year>2022</year><volume>131</volume><fpage>101574</fpage><pub-id pub-id-type="doi">10.1016/j.progpolymsci.2022.101574</pub-id></element-citation></ref><ref id="B8-pharmaceutics-15-01700"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groll</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burdick</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Derby</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gelinsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heilshorn</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>J&#252;ngst</surname><given-names>T.</given-names></name><name name-style="western"><surname>Malda</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mironov</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A definition of bioinks and their distinction from biomaterial inks</article-title><source>Biofabrication</source><year>2018</year><volume>11</volume><fpage>013001</fpage><pub-id pub-id-type="doi">10.1088/1758-5090/aaec52</pub-id><pub-id pub-id-type="pmid">30468151</pub-id></element-citation></ref><ref id="B9-pharmaceutics-15-01700"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yilmaz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Al Rashid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Evis</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ko&#231;</surname><given-names>M.</given-names></name></person-group><article-title>Bioprinting: A review of processes, materials and applications</article-title><source>Bioprinting</source><year>2021</year><volume>23</volume><fpage>e00148</fpage><pub-id pub-id-type="doi">10.1016/j.bprint.2021.e00148</pub-id></element-citation></ref><ref id="B10-pharmaceutics-15-01700"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabirian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mozafari</surname><given-names>M.</given-names></name></person-group><article-title>Decellularized ECM-derived bioinks: Prospects for the future</article-title><source>Methods</source><year>2020</year><volume>171</volume><fpage>108</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2019.04.019</pub-id><pub-id pub-id-type="pmid">31051254</pub-id></element-citation></ref><ref id="B11-pharmaceutics-15-01700"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hospodiuk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sosnoski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ozbolat</surname><given-names>I.T.</given-names></name></person-group><article-title>The bioink: A comprehensive review on bioprintable materials</article-title><source>Biotechnol Adv.</source><year>2017</year><volume>35</volume><fpage>217</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2016.12.006</pub-id><pub-id pub-id-type="pmid">28057483</pub-id></element-citation></ref><ref id="B12-pharmaceutics-15-01700"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gungor-Ozkerim</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Inci</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Khademhosseini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dokmeci</surname><given-names>M.R.</given-names></name></person-group><article-title>Bioinks for 3D bioprinting: An overview</article-title><source>Biomater. Sci.</source><year>2018</year><volume>6</volume><fpage>915</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1039/C7BM00765E</pub-id><pub-id pub-id-type="pmid">29492503</pub-id><pub-id pub-id-type="pmcid">PMC6439477</pub-id></element-citation></ref><ref id="B13-pharmaceutics-15-01700"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhowmik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bain</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Bhowmick</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mollick</surname><given-names>M.M.R.</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maity</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Effect of xanthan gum and guar gum on in situ gelling ophthalmic drug delivery system based on poloxamer-407</article-title><source>Int. J. Biol. Macromol.</source><year>2013</year><volume>62</volume><fpage>117</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2013.08.024</pub-id><pub-id pub-id-type="pmid">23988556</pub-id></element-citation></ref><ref id="B14-pharmaceutics-15-01700"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganguly</surname><given-names>S.</given-names></name><name name-style="western"><surname>Das</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Das</surname><given-names>N.C.</given-names></name></person-group><article-title>Synthesis of polydopamine-coated halloysite nanotube-based hydrogel for controlled release of a calcium channel blocker</article-title><source>RSC Adv.</source><year>2016</year><volume>6</volume><fpage>105350</fpage><lpage>105362</lpage><pub-id pub-id-type="doi">10.1039/C6RA24153K</pub-id></element-citation></ref><ref id="B15-pharmaceutics-15-01700"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Orasugh</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bhattacharyya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>D.</given-names></name></person-group><article-title>Cellulose nanofibrils/chitosan based transdermal drug delivery vehicle for controlled release of ketorolac tromethamine</article-title><source>New J. Chem.</source><year>2017</year><volume>41</volume><fpage>15312</fpage><lpage>15319</lpage><pub-id pub-id-type="doi">10.1039/C7NJ02539D</pub-id></element-citation></ref><ref id="B16-pharmaceutics-15-01700"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C.J.J.o.M.C.B.</given-names></name></person-group><article-title>Controlled dual delivery of low doses of BMP-2 and VEGF in a silk fibroin&#8211;nanohydroxyapatite scaffold for vascularized bone regeneration</article-title><source>J. Mater. Chem. B</source><year>2017</year><volume>5</volume><fpage>6963</fpage><lpage>6972</lpage><pub-id pub-id-type="pmid">32264345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c7tb00949f</pub-id></element-citation></ref><ref id="B17-pharmaceutics-15-01700"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Heng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bunpetch</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>H.J.S.R.</given-names></name></person-group><article-title>A Gelatin-sulfonated Silk Composite Scaffold based on 3D Printing Technology Enhances Skin Regeneration by Stimulating Epidermal Growth and Dermal Neovascularization</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>4288</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-04149-y</pub-id><pub-id pub-id-type="pmid">28655891</pub-id><pub-id pub-id-type="pmcid">PMC5487355</pub-id></element-citation></ref><ref id="B18-pharmaceutics-15-01700"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Functional reconstruction of injured corpus cavernosa using 3D-printed hydrogel scaffolds seeded with HIF-1&#945;-expressing stem cells</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>2687</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16192-x</pub-id><pub-id pub-id-type="pmid">32483116</pub-id><pub-id pub-id-type="pmcid">PMC7264263</pub-id></element-citation></ref><ref id="B19-pharmaceutics-15-01700"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>3D printing collagen/heparin sulfate scaffolds boost neural network reconstruction and motor function recovery after traumatic brain injury in canine</article-title><source>Biomater. Sci.</source><year>2020</year><volume>8</volume><fpage>6362</fpage><lpage>6374</lpage><pub-id pub-id-type="doi">10.1039/D0BM01116A</pub-id><pub-id pub-id-type="pmid">33026366</pub-id></element-citation></ref><ref id="B20-pharmaceutics-15-01700"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name></person-group><article-title>Cryogenic 3D printing of dual-delivery scaffolds for improved bone regeneration with enhanced vascularization</article-title><source>Bioact. Mater.</source><year>2021</year><volume>6</volume><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2020.07.007</pub-id><pub-id pub-id-type="pmid">32817920</pub-id><pub-id pub-id-type="pmcid">PMC7426490</pub-id></element-citation></ref><ref id="B21-pharmaceutics-15-01700"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sandler</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.S.</given-names></name><etal/></person-group><article-title>Vascularized 3D printed scaffolds for promoting bone regeneration</article-title><source>Biomaterials</source><year>2019</year><volume>190</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.10.033</pub-id><pub-id pub-id-type="pmid">30415019</pub-id></element-citation></ref><ref id="B22-pharmaceutics-15-01700"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rijal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Pati</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>D.W.</given-names></name></person-group><article-title>Robust tissue growth and angiogenesis in large-sized scaffold by reducing H(<sub>2</sub>)O(<sub>2</sub>)-mediated oxidative stress</article-title><source>Biofabrication</source><year>2017</year><volume>9</volume><fpage>015013</fpage><pub-id pub-id-type="doi">10.1088/1758-5090/9/1/015013</pub-id><pub-id pub-id-type="pmid">28155851</pub-id></element-citation></ref><ref id="B23-pharmaceutics-15-01700"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>D.W.</given-names></name></person-group><article-title>3D cell printing of in vitro stabilized skin model and in vivo pre-vascularized skin patch using tissue-specific extracellular matrix bioink: A step towards advanced skin tissue engineering</article-title><source>Biomaterials</source><year>2018</year><volume>168</volume><fpage>38</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.03.040</pub-id><pub-id pub-id-type="pmid">29614431</pub-id></element-citation></ref><ref id="B24-pharmaceutics-15-01700"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bejleri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Streeter</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Nachlas</surname><given-names>A.L.Y.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gaetani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Christman</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M.E.</given-names></name></person-group><article-title>A Bioprinted Cardiac Patch Composed of Cardiac-Specific Extracellular Matrix and Progenitor Cells for Heart Repair</article-title><source>Adv. Healthc. Mater.</source><year>2018</year><volume>7</volume><fpage>e1800672</fpage><pub-id pub-id-type="doi">10.1002/adhm.201800672</pub-id><pub-id pub-id-type="pmid">30379414</pub-id><pub-id pub-id-type="pmcid">PMC6521871</pub-id></element-citation></ref><ref id="B25-pharmaceutics-15-01700"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huangfu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>3D printing of MXene composite hydrogel scaffolds for photothermal antibacterial activity and bone regeneration in infected bone defect models</article-title><source>Nanoscale</source><year>2022</year><volume>14</volume><fpage>8112</fpage><lpage>8129</lpage><pub-id pub-id-type="doi">10.1039/D2NR02176E</pub-id><pub-id pub-id-type="pmid">35612416</pub-id></element-citation></ref><ref id="B26-pharmaceutics-15-01700"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Ueng</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.J.</given-names></name></person-group><article-title>A Three-Dimensional Printed Polycaprolactone Scaffold Combined with Co-Axially Electrospun Vancomycin/Ceftazidime/Bone Morphological Protein-2 Sheath-Core Nanofibers for the Repair of Segmental Bone Defects During the Masquelet Procedure</article-title><source>Int. J. Nanomed.</source><year>2020</year><volume>15</volume><fpage>913</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.2147/IJN.S238478</pub-id><pub-id pub-id-type="pmcid">PMC7027567</pub-id><pub-id pub-id-type="pmid">32103946</pub-id></element-citation></ref><ref id="B27-pharmaceutics-15-01700"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadaba</surname><given-names>N.</given-names></name><name name-style="western"><surname>Larra&#241;aga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Orpella-Aceret</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bettencourt</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Biggs</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>I.A.C.</given-names></name><name name-style="western"><surname>Ugartemendia</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sarasua</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Zuza</surname><given-names>E.</given-names></name></person-group><article-title>Benefits of Polydopamine as Particle/Matrix Interface in Polylactide/PD-BaSO(<sub>4</sub>) Scaffolds</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>5480</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21155480</pub-id><pub-id pub-id-type="pmid">32751908</pub-id><pub-id pub-id-type="pmcid">PMC7432262</pub-id></element-citation></ref><ref id="B28-pharmaceutics-15-01700"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Gon&#231;alves</surname><given-names>L.</given-names></name><name name-style="western"><surname>Claudio</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Grenho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Bettencourt</surname><given-names>A.F.</given-names></name></person-group><article-title>Engineering a multifunctional 3D-printed PLA-collagen-minocycline-nanoHydroxyapatite scaffold with combined antimicrobial and osteogenic effects for bone regeneration</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2019</year><volume>101</volume><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2019.03.056</pub-id><pub-id pub-id-type="pmid">31029308</pub-id></element-citation></ref><ref id="B29-pharmaceutics-15-01700"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabirian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Brouki Milan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zamanian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heying</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mozafari</surname><given-names>M.</given-names></name></person-group><article-title>Nitric oxide-releasing vascular grafts: A therapeutic strategy to promote angiogenic activity and endothelium regeneration</article-title><source>Acta Biomater.</source><year>2019</year><volume>92</volume><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2019.05.002</pub-id><pub-id pub-id-type="pmid">31059835</pub-id></element-citation></ref><ref id="B30-pharmaceutics-15-01700"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilhan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cesur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Topal</surname><given-names>F.</given-names></name><name name-style="western"><surname>Albayrak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guncu</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Cam</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Taskin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sasmazel</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Aksu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Development of <italic toggle="yes">Satureja cuneifolia</italic>-loaded sodium alginate/polyethylene glycol scaffolds produced by 3D-printing technology as a diabetic wound dressing material</article-title><source>Int. J. Biol. Macromol.</source><year>2020</year><volume>161</volume><fpage>1040</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.06.086</pub-id><pub-id pub-id-type="pmid">32544577</pub-id></element-citation></ref><ref id="B31-pharmaceutics-15-01700"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rifai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Reineck</surname><given-names>P.</given-names></name><name name-style="western"><surname>Elbourne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mayes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sarker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dekiwadia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Ohshima</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Engineering the Interface: Nanodiamond Coating on 3D-Printed Titanium Promotes Mammalian Cell Growth and Inhibits <italic toggle="yes">Staphylococcus aureus</italic> Colonization</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><fpage>24588</fpage><lpage>24597</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b07064</pub-id><pub-id pub-id-type="pmid">31199619</pub-id></element-citation></ref><ref id="B32-pharmaceutics-15-01700"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Intini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Elviri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mros</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bergonzi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bianchera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Flammini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Govoni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barocelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bettini</surname><given-names>R.</given-names></name><etal/></person-group><article-title>3D-printed chitosan-based scaffolds: An in vitro study of human skin cell growth and an in-vivo wound healing evaluation in experimental diabetes in rats</article-title><source>Carbohydr. Polym.</source><year>2018</year><volume>199</volume><fpage>593</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2018.07.057</pub-id><pub-id pub-id-type="pmid">30143167</pub-id></element-citation></ref><ref id="B33-pharmaceutics-15-01700"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Eom</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.A.</given-names></name></person-group><article-title>Dexamethasone loaded bilayered 3D tubular scaffold reduces restenosis at the anastomotic site of tracheal replacement: In vitro and in vivo assessments</article-title><source>Nanoscale</source><year>2020</year><volume>12</volume><fpage>4846</fpage><lpage>4858</lpage><pub-id pub-id-type="doi">10.1039/C9NR10341D</pub-id><pub-id pub-id-type="pmid">32016227</pub-id></element-citation></ref><ref id="B34-pharmaceutics-15-01700"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farto-Vaamonde</surname><given-names>X.</given-names></name><name name-style="western"><surname>Auriemma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aquino</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Concheiro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alvarez-Lorenzo</surname><given-names>C.</given-names></name></person-group><article-title>Post-manufacture loading of filaments and 3D printed PLA scaffolds with prednisolone and dexamethasone for tissue regeneration applications</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2019</year><volume>141</volume><fpage>100</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2019.05.018</pub-id><pub-id pub-id-type="pmid">31112767</pub-id></element-citation></ref><ref id="B35-pharmaceutics-15-01700"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Flores</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>A multifunctional micropore-forming bioink with enhanced anti-bacterial and anti-inflammatory properties</article-title><source>Biofabrication</source><year>2022</year><volume>14</volume><fpage>024105</fpage><pub-id pub-id-type="doi">10.1088/1758-5090/ac5936</pub-id><pub-id pub-id-type="pmcid">PMC8962756</pub-id><pub-id pub-id-type="pmid">35226880</pub-id></element-citation></ref><ref id="B36-pharmaceutics-15-01700"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.K.</given-names></name></person-group><article-title>Protein-spatiotemporal partition releasing gradient porous scaffolds and anti-inflammatory and antioxidant regulation remodel tissue engineered anisotropic meniscus</article-title><source>Bioact. Mater.</source><year>2023</year><volume>20</volume><fpage>194</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2022.05.019</pub-id><pub-id pub-id-type="pmid">35702607</pub-id><pub-id pub-id-type="pmcid">PMC9160676</pub-id></element-citation></ref><ref id="B37-pharmaceutics-15-01700"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Shie</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.F.</given-names></name></person-group><article-title>Anti-inflammation performance of curcumin-loaded mesoporous calcium silicate cement</article-title><source>J. Formos. Med. Assoc. = Taiwan Yi Zhi</source><year>2017</year><volume>116</volume><fpage>679</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2017.06.005</pub-id><pub-id pub-id-type="pmid">28684019</pub-id></element-citation></ref><ref id="B38-pharmaceutics-15-01700"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bose</surname><given-names>S.</given-names></name></person-group><article-title>Controlled release of soy isoflavones from multifunctional 3D printed bone tissue engineering scaffolds</article-title><source>Acta Biomater.</source><year>2020</year><volume>114</volume><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2020.07.006</pub-id><pub-id pub-id-type="pmid">32652224</pub-id><pub-id pub-id-type="pmcid">PMC8009492</pub-id></element-citation></ref><ref id="B39-pharmaceutics-15-01700"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>Quercetin-Coating Promotes Osteogenic Differentiation, Osseointegration and Anti-Inflammatory Properties of Nano-Topographic Modificated 3D-Printed Ti<sub>6</sub>Al<sub>4</sub>V Implant</article-title><source>Front. Bioeng. Biotechnol.</source><year>2022</year><volume>10</volume><fpage>933135</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2022.933135</pub-id><pub-id pub-id-type="pmid">35757806</pub-id><pub-id pub-id-type="pmcid">PMC9213674</pub-id></element-citation></ref><ref id="B40-pharmaceutics-15-01700"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bandyopadhyay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>B.B.</given-names></name></person-group><article-title>A three-dimensional printed silk-based biomimetic tri-layered meniscus for potential patient-specific implantation</article-title><source>Biofabrication</source><year>2019</year><volume>12</volume><fpage>015003</fpage><pub-id pub-id-type="doi">10.1088/1758-5090/ab40fa</pub-id><pub-id pub-id-type="pmid">31480031</pub-id></element-citation></ref><ref id="B41-pharmaceutics-15-01700"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bose</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>D.</given-names></name></person-group><article-title>Effects of PCL, PEG and PLGA polymers on curcumin release from calcium phosphate matrix for in vitro and in vivo bone regeneration</article-title><source>Mater. Today. Chem.</source><year>2018</year><volume>8</volume><fpage>110</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.mtchem.2018.03.005</pub-id><pub-id pub-id-type="pmid">30480167</pub-id><pub-id pub-id-type="pmcid">PMC6251318</pub-id></element-citation></ref><ref id="B42-pharmaceutics-15-01700"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>W.</given-names></name></person-group><article-title>3D-printed hydrogel scaffold-loaded granulocyte colony-stimulating factor sustained-release microspheres and their effect on endometrial regeneration</article-title><source>Biomater. Sci.</source><year>2022</year><volume>10</volume><fpage>3346</fpage><lpage>3358</lpage><pub-id pub-id-type="doi">10.1039/D2BM00109H</pub-id><pub-id pub-id-type="pmid">35588302</pub-id></element-citation></ref><ref id="B43-pharmaceutics-15-01700"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z.</given-names></name></person-group><article-title>3D Printed Piezoelectric Wound Dressing with Dual Piezoelectric Response Models for Scar-Prevention Wound Healing</article-title><source>ACS Appl. Mater. Interfaces</source><year>2022</year><volume>14</volume><fpage>30507</fpage><lpage>30522</lpage><pub-id pub-id-type="doi">10.1021/acsami.2c04168</pub-id><pub-id pub-id-type="pmid">35768948</pub-id></element-citation></ref><ref id="B44-pharmaceutics-15-01700"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Balla</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bodhak</surname><given-names>S.</given-names></name></person-group><article-title>Current Developments in 3D Bioprinting for Tissue and Organ Regeneration&#8211;A Review</article-title><source>Front. Mech. Eng.</source><year>2020</year><volume>6</volume><fpage>589171</fpage><pub-id pub-id-type="doi">10.3389/fmech.2020.589171</pub-id></element-citation></ref><ref id="B45-pharmaceutics-15-01700"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos-Beato</surname><given-names>P.</given-names></name><name name-style="western"><surname>Midha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pitsillides</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Torii</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kalaskar</surname><given-names>D.M.</given-names></name></person-group><article-title>Biofabrication of the osteochondral unit and its applications: Current and future directions for 3D bioprinting</article-title><source>J. Tissue Eng.</source><year>2022</year><volume>13</volume><fpage>20417314221133480</fpage><pub-id pub-id-type="doi">10.1177/20417314221133480</pub-id><pub-id pub-id-type="pmid">36386465</pub-id><pub-id pub-id-type="pmcid">PMC9643769</pub-id></element-citation></ref><ref id="B46-pharmaceutics-15-01700"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eming</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Brachvogel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Odorisio</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>M.</given-names></name></person-group><article-title>Regulation of angiogenesis: Wound healing as a model</article-title><source>Prog. Histochem.</source><year>2008</year><volume>42</volume><fpage>115</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.proghi.2007.06.001</pub-id><pub-id pub-id-type="pmid">17980716</pub-id></element-citation></ref><ref id="B47-pharmaceutics-15-01700"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Crane</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>M.</given-names></name></person-group><article-title>PDGF-BB secreted by preosteoclasts induces CD31hiEmcnhi vessel subtype in coupling osteogenesis</article-title><source>Nat. Med.</source><year>2014</year><volume>20</volume><fpage>1270</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1038/nm.3668</pub-id><pub-id pub-id-type="pmid">25282358</pub-id><pub-id pub-id-type="pmcid">PMC4224644</pub-id></element-citation></ref><ref id="B48-pharmaceutics-15-01700"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fahimipour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rasoulianboroujeni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dashtimoghadam</surname><given-names>E.</given-names></name><name name-style="western"><surname>Khoshroo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tahriri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bastami</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lobner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tayebi</surname><given-names>L.J.D.M.</given-names></name></person-group><article-title>3D printed TCP-based scaffold incorporating VEGF-loaded PLGA microspheres for craniofacial tissue engineering</article-title><source>Dent. Mater.</source><year>2017</year><volume>33</volume><fpage>1205</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1016/j.dental.2017.06.016</pub-id><pub-id pub-id-type="pmid">28882369</pub-id><pub-id pub-id-type="pmcid">PMC6013845</pub-id></element-citation></ref><ref id="B49-pharmaceutics-15-01700"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>T.-S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H.-D.</given-names></name></person-group><article-title>Freeform 3D printing of vascularized tissues: Challenges and strategies</article-title><source>J. Tissue Eng.</source><year>2021</year><volume>12</volume><fpage>20417314211057236</fpage><pub-id pub-id-type="doi">10.1177/20417314211057236</pub-id><pub-id pub-id-type="pmid">34868539</pub-id><pub-id pub-id-type="pmcid">PMC8638074</pub-id></element-citation></ref><ref id="B50-pharmaceutics-15-01700"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianco</surname><given-names>P.</given-names></name></person-group><article-title>Stem cells and bone: A historical perspective</article-title><source>Bone</source><year>2015</year><volume>70</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2014.08.011</pub-id><pub-id pub-id-type="pmid">25171959</pub-id></element-citation></ref><ref id="B51-pharmaceutics-15-01700"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martino</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Briquez</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>J.A.</given-names></name></person-group><article-title>Extracellular matrix-inspired growth factor delivery systems for bone regeneration</article-title><source>Adv. Drug Deliv. Rev.</source><year>2015</year><volume>94</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.04.007</pub-id><pub-id pub-id-type="pmid">25895621</pub-id></element-citation></ref><ref id="B52-pharmaceutics-15-01700"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>You</surname><given-names>C.</given-names></name><name name-style="western"><surname>Han</surname><given-names>C.</given-names></name><etal/></person-group><article-title>3D bioprinting for skin tissue engineering: Current status and perspectives</article-title><source>J. Tissue Eng.</source><year>2021</year><volume>12</volume><fpage>20417314211028574</fpage><pub-id pub-id-type="doi">10.1177/20417314211028574</pub-id><pub-id pub-id-type="pmid">34345398</pub-id><pub-id pub-id-type="pmcid">PMC8283073</pub-id></element-citation></ref><ref id="B53-pharmaceutics-15-01700"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henning</surname><given-names>R.J.</given-names></name></person-group><article-title>Therapeutic angiogenesis: Angiogenic growth factors for ischemic heart disease</article-title><source>Future Cardiol.</source><year>2016</year><volume>12</volume><fpage>585</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.2217/fca-2016-0006</pub-id><pub-id pub-id-type="pmid">27420190</pub-id></element-citation></ref><ref id="B54-pharmaceutics-15-01700"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribatti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vacca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nico</surname><given-names>B.</given-names></name><name name-style="western"><surname>Roncali</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dammacco</surname><given-names>F.</given-names></name></person-group><article-title>Postnatal vasculogenesis</article-title><source>Mech. Dev.</source><year>2001</year><volume>100</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/S0925-4773(00)00522-0</pub-id><pub-id pub-id-type="pmid">11165474</pub-id></element-citation></ref><ref id="B55-pharmaceutics-15-01700"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Sequential and sustained release of SDF-1 and BMP-2 from silk fibroin-nanohydroxyapatite scaffold for the enhancement of bone regeneration</article-title><source>Biomater</source><year>2016</year><volume>106</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.08.023</pub-id><pub-id pub-id-type="pmid">27566869</pub-id></element-citation></ref><ref id="B56-pharmaceutics-15-01700"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wenk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wandrey</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Merkle</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Meinel</surname><given-names>L.</given-names></name></person-group><article-title>Silk fibroin spheres as a platform for controlled drug delivery</article-title><source>J. Control. Release</source><year>2008</year><volume>132</volume><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2008.08.005</pub-id><pub-id pub-id-type="pmid">18761384</pub-id></element-citation></ref><ref id="B57-pharmaceutics-15-01700"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zelzer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mclean</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Fukai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Reginato</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lovejoy</surname><given-names>S.</given-names></name><name name-style="western"><surname>D&#8217;Amore</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>B.R.</given-names></name></person-group><article-title>Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis</article-title><source>Development</source><year>2002</year><volume>129</volume><fpage>1893</fpage><pub-id pub-id-type="doi">10.1242/dev.129.8.1893</pub-id><pub-id pub-id-type="pmid">11934855</pub-id></element-citation></ref><ref id="B58-pharmaceutics-15-01700"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerber</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Vu</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Werb</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>N.J.N.M.</given-names></name></person-group><article-title>VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation</article-title><source>Nat. Med.</source><year>1999</year><volume>5</volume><fpage>623</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/9467</pub-id><pub-id pub-id-type="pmid">10371499</pub-id></element-citation></ref><ref id="B59-pharmaceutics-15-01700"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiede</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bayat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zechel</surname><given-names>C.J.A.o.A.-a.A.</given-names></name></person-group><article-title>Basic fibroblast growth factor: A potential new therapeutic tool for the treatment of hypertrophic and keloid scars</article-title><source>Ann. Anat. Anat. Anz.</source><year>2009</year><volume>191</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.aanat.2008.10.001</pub-id><pub-id pub-id-type="pmid">19071002</pub-id></element-citation></ref><ref id="B60-pharmaceutics-15-01700"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.J.B.</given-names></name></person-group><article-title>Heparin-Based Coacervate of FGF2 Improves Dermal Regeneration by Asserting a Synergistic Role with Cell Proliferation and Endogenous Facilitated VEGF for Cutaneous Wound Healing</article-title><source>Biomacromolecules</source><year>2016</year><volume>17</volume><fpage>2168</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.6b00398</pub-id><pub-id pub-id-type="pmid">27196997</pub-id></element-citation></ref><ref id="B61-pharmaceutics-15-01700"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claffey</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Mullen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keough</surname><given-names>M.J.L.I.</given-names></name></person-group><article-title>Fibroblast Growth Factor 2 Activation of Stromal Cell Vascular Endothelial Growth Factor Expression and Angiogenesis</article-title><source>Lab. Investig.</source><year>2001</year><volume>81</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1038/labinvest.3780212</pub-id><pub-id pub-id-type="pmid">11204275</pub-id></element-citation></ref><ref id="B62-pharmaceutics-15-01700"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Vunjak-Novakovic</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>D.L.</given-names></name></person-group><article-title>Stem cell-based tissue engineering with silk biomaterials</article-title><source>Biomaterials</source><year>2006</year><volume>27</volume><fpage>6064</fpage><lpage>6082</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2006.07.008</pub-id><pub-id pub-id-type="pmid">16890988</pub-id></element-citation></ref><ref id="B63-pharmaceutics-15-01700"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name></person-group><article-title>Silk-molded flexible, ultrasensitive, and highly stable electronic skin for monitoring human physiological signals</article-title><source>Adv. Mater.</source><year>2014</year><volume>26</volume><fpage>1336</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1002/adma.201304248</pub-id><pub-id pub-id-type="pmid">24347340</pub-id></element-citation></ref><ref id="B64-pharmaceutics-15-01700"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Heng</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>H.W.</given-names></name></person-group><article-title>The effect of incorporation of exogenous stromal cell-derived factor-1 alpha within a knitted silk-collagen sponge scaffold on tendon regeneration</article-title><source>Biomaterials</source><year>2010</year><volume>31</volume><fpage>7239</fpage><lpage>7249</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.05.040</pub-id><pub-id pub-id-type="pmid">20615544</pub-id></element-citation></ref><ref id="B65-pharmaceutics-15-01700"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benjamin</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Hemo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Keshet</surname><given-names>E.</given-names></name></person-group><article-title>A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF</article-title><source>Development</source><year>1998</year><volume>125</volume><fpage>1591</fpage><lpage>1598</lpage><pub-id pub-id-type="doi">10.1242/dev.125.9.1591</pub-id><pub-id pub-id-type="pmid">9521897</pub-id></element-citation></ref><ref id="B66-pharmaceutics-15-01700"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nih</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Gojgini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carmichael</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Segura</surname><given-names>T.</given-names></name></person-group><article-title>Dual-function injectable angiogenic biomaterial for the repair of brain tissue following stroke</article-title><source>Nat. Mater.</source><year>2018</year><volume>17</volume><fpage>642</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1038/s41563-018-0083-8</pub-id><pub-id pub-id-type="pmid">29784996</pub-id><pub-id pub-id-type="pmcid">PMC6019573</pub-id></element-citation></ref><ref id="B67-pharmaceutics-15-01700"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.J.</given-names></name></person-group><article-title>Unlockable Nanocomplexes with Self-Accelerating Nucleic Acid Release for Effective Staged Gene Therapy of Cardiovascular Diseases</article-title><source>Adv. Mater.</source><year>2018</year><volume>30</volume><fpage>1801570</fpage><pub-id pub-id-type="doi">10.1002/adma.201801570</pub-id><pub-id pub-id-type="pmid">29920798</pub-id></element-citation></ref><ref id="B68-pharmaceutics-15-01700"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Villasante</surname><given-names>A.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Metz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kanai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells</article-title><source>Nat. Biomed. Eng.</source><year>2018</year><volume>2</volume><fpage>293</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/s41551-018-0229-7</pub-id><pub-id pub-id-type="pmid">30271672</pub-id><pub-id pub-id-type="pmcid">PMC6159913</pub-id></element-citation></ref><ref id="B69-pharmaceutics-15-01700"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hudalla</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Koepsel</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>W.L.</given-names></name></person-group><article-title>Surfaces that sequester serum-borne heparin amplify growth factor activity</article-title><source>Adv. Mater.</source><year>2011</year><volume>23</volume><fpage>5415</fpage><lpage>5418</lpage><pub-id pub-id-type="doi">10.1002/adma.201103046</pub-id><pub-id pub-id-type="pmid">22028244</pub-id><pub-id pub-id-type="pmcid">PMC4410730</pub-id></element-citation></ref><ref id="B70-pharmaceutics-15-01700"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Revzin</surname><given-names>A.</given-names></name></person-group><article-title>Multilayered heparin hydrogel microwells for cultivation of primary hepatocytes</article-title><source>Adv. Healthc. Mater.</source><year>2014</year><volume>3</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1002/adhm.201300054</pub-id><pub-id pub-id-type="pmid">23828859</pub-id><pub-id pub-id-type="pmcid">PMC4354952</pub-id></element-citation></ref><ref id="B71-pharmaceutics-15-01700"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Katagiri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Toyoda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yanai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>U.I.</given-names></name><name name-style="western"><surname>Koike</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takaoka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kamijo</surname><given-names>R.</given-names></name></person-group><article-title>Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>23246</fpage><lpage>23253</lpage><pub-id pub-id-type="doi">10.1074/jbc.M511039200</pub-id><pub-id pub-id-type="pmid">16754660</pub-id></element-citation></ref><ref id="B72-pharmaceutics-15-01700"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Billings</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Shore</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Glaser</surname><given-names>D.L.</given-names></name></person-group><article-title>Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>1080</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1074/jbc.M513414200</pub-id><pub-id pub-id-type="pmid">17020882</pub-id></element-citation></ref><ref id="B73-pharmaceutics-15-01700"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carretero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soares da Costa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Novoa-Carballal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pashkuleva</surname><given-names>I.</given-names></name></person-group><article-title>Design of protein delivery systems by mimicking extracellular mechanisms for protection of growth factors</article-title><source>Acta Biomater.</source><year>2017</year><volume>63</volume><fpage>283</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2017.08.042</pub-id><pub-id pub-id-type="pmid">28864252</pub-id></element-citation></ref><ref id="B74-pharmaceutics-15-01700"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>3D-printed scaffolds with synergistic effect of hollow-pipe structure and bioactive ions for vascularized bone regeneration</article-title><source>Biomaterials</source><year>2017</year><volume>135</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.05.005</pub-id><pub-id pub-id-type="pmid">28499127</pub-id></element-citation></ref><ref id="B75-pharmaceutics-15-01700"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name></person-group><article-title>Recent Advances in Scaffold Design and Material for Vascularized Tissue-Engineered Bone Regeneration</article-title><source>Adv. Healthc. Mater.</source><year>2019</year><volume>8</volume><fpage>e1801433</fpage><pub-id pub-id-type="doi">10.1002/adhm.201801433</pub-id><pub-id pub-id-type="pmid">30938094</pub-id></element-citation></ref><ref id="B76-pharmaceutics-15-01700"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name></person-group><article-title>Silicate bioceramics enhanced vascularization and osteogenesis through stimulating interactions between endothelia cells and bone marrow stromal cells</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>3803</fpage><lpage>3818</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.01.039</pub-id><pub-id pub-id-type="pmid">24486216</pub-id></element-citation></ref><ref id="B77-pharmaceutics-15-01700"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>RhBMP-2 loaded 3D-printed mesoporous silica/calcium phosphate cement porous scaffolds with enhanced vascularization and osteogenesis properties</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>41331</fpage><pub-id pub-id-type="doi">10.1038/srep41331</pub-id><pub-id pub-id-type="pmid">28128363</pub-id><pub-id pub-id-type="pmcid">PMC5269721</pub-id></element-citation></ref><ref id="B78-pharmaceutics-15-01700"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>W.</given-names></name></person-group><article-title>Three-dimensional Printed Mg-Doped &#946;-TCP Bone Tissue Engineering Scaffolds: Effects of Magnesium Ion Concentration on Osteogenesis and Angiogenesis In Vitro</article-title><source>Tissue Eng. Regen. Med.</source><year>2019</year><volume>16</volume><fpage>415</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1007/s13770-019-00192-0</pub-id><pub-id pub-id-type="pmid">31413945</pub-id><pub-id pub-id-type="pmcid">PMC6675836</pub-id></element-citation></ref><ref id="B79-pharmaceutics-15-01700"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name></person-group><article-title>Immobilizing magnesium ions on 3D printed porous tantalum scaffolds with polydopamine for improved vascularization and osteogenesis</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2020</year><volume>117</volume><fpage>111303</fpage><pub-id pub-id-type="doi">10.1016/j.msec.2020.111303</pub-id><pub-id pub-id-type="pmid">32919664</pub-id></element-citation></ref><ref id="B80-pharmaceutics-15-01700"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>W.</given-names></name></person-group><article-title>A novel hierarchical biofunctionalized 3D-printed porous Ti<sub>6</sub>Al<sub>4</sub>V scaffold with enhanced osteoporotic osseointegration through osteoimmunomodulation</article-title><source>J. Nanobiotechnol.</source><year>2022</year><volume>20</volume><fpage>68</fpage><pub-id pub-id-type="doi">10.1186/s12951-022-01277-0</pub-id><pub-id pub-id-type="pmcid">PMC8817481</pub-id><pub-id pub-id-type="pmid">35123501</pub-id></element-citation></ref><ref id="B81-pharmaceutics-15-01700"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ai</surname><given-names>F.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>&#8220;The return of ceramic implants&#8221;: Rose stem inspired dual layered modification of ceramic scaffolds with improved mechanical and anti-infective properties</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2018</year><volume>93</volume><fpage>873</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2018.08.044</pub-id><pub-id pub-id-type="pmid">30274123</pub-id></element-citation></ref><ref id="B82-pharmaceutics-15-01700"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>3D printing of metal-organic framework nanosheets-structured scaffolds with tumor therapy and bone construction</article-title><source>Biofabrication</source><year>2020</year><volume>12</volume><fpage>025005</fpage><pub-id pub-id-type="doi">10.1088/1758-5090/ab5ae3</pub-id><pub-id pub-id-type="pmid">31756727</pub-id></element-citation></ref><ref id="B83-pharmaceutics-15-01700"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidakis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Petousis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Michailidis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Grammatikos</surname><given-names>S.</given-names></name><name name-style="western"><surname>David</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Mountakis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Argyros</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boura</surname><given-names>O.</given-names></name></person-group><article-title>Development and Optimization of Medical-Grade Multi-Functional Polyamide 12-Cuprous Oxide Nanocomposites with Superior Mechanical and Antibacterial Properties for Cost-Effective 3D Printing</article-title><source>Nanomaterials</source><year>2022</year><volume>12</volume><elocation-id>534</elocation-id><pub-id pub-id-type="doi">10.3390/nano12030534</pub-id><pub-id pub-id-type="pmid">35159879</pub-id><pub-id pub-id-type="pmcid">PMC8838813</pub-id></element-citation></ref><ref id="B84-pharmaceutics-15-01700"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>Copper-incorporated bioactive glass-ceramics inducing anti-inflammatory phenotype and regeneration of cartilage/bone interface</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>6300</fpage><lpage>6313</lpage><pub-id pub-id-type="doi">10.7150/thno.36120</pub-id><pub-id pub-id-type="pmid">31534552</pub-id><pub-id pub-id-type="pmcid">PMC6735521</pub-id></element-citation></ref><ref id="B85-pharmaceutics-15-01700"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y.</given-names></name></person-group><article-title>Combination of the Silver-Ethylene Interaction and 3D Printing To Develop Antibacterial Superporous Hydrogels for Wound Management</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><fpage>33734</fpage><lpage>33747</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b14090</pub-id><pub-id pub-id-type="pmid">31436081</pub-id></element-citation></ref><ref id="B86-pharmaceutics-15-01700"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Punsar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karvonen</surname><given-names>M.J.</given-names></name></person-group><article-title>Inverse relation of silicon in drinking water and atherosclerosis in Finland</article-title><source>Lancet</source><year>1977</year><volume>1</volume><fpage>538</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(77)91393-9</pub-id><pub-id pub-id-type="pmid">65628</pub-id></element-citation></ref><ref id="B87-pharmaceutics-15-01700"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pietak</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Stott</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Sayer</surname><given-names>M.</given-names></name></person-group><article-title>Silicon substitution in the calcium phosphate bioceramics</article-title><source>Biomaterials</source><year>2007</year><volume>28</volume><fpage>4023</fpage><lpage>4032</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2007.05.003</pub-id><pub-id pub-id-type="pmid">17544500</pub-id></element-citation></ref><ref id="B88-pharmaceutics-15-01700"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.-J.</given-names></name><name name-style="western"><surname>Na</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S.</given-names></name><etal/></person-group><article-title>3D-Printed Functional Hydrogel by DNA-Induced Biomineralization for Accelerated Diabetic Wound Healing</article-title><source>Adv. Sci.</source><year>2023</year><volume>2</volume><fpage>2300816</fpage><pub-id pub-id-type="doi">10.1002/advs.202300816</pub-id><pub-id pub-id-type="pmcid">PMC10265106</pub-id><pub-id pub-id-type="pmid">37076933</pub-id></element-citation></ref><ref id="B89-pharmaceutics-15-01700"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Song</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name></person-group><article-title>Stimulation of osteogenesis and angiogenesis of hBMSCs by delivering Si ions and functional drug from mesoporous silica nanospheres</article-title><source>Acta Biomater.</source><year>2015</year><volume>21</volume><fpage>178</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2015.04.019</pub-id><pub-id pub-id-type="pmid">25910640</pub-id></element-citation></ref><ref id="B90-pharmaceutics-15-01700"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorustovich</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Roether</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Boccaccini</surname><given-names>A.R.</given-names></name></person-group><article-title>Effect of bioactive glasses on angiogenesis: A review of in vitro and in vivo evidences</article-title><source>Tissue Eng. Part B Rev.</source><year>2010</year><volume>16</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1089/ten.teb.2009.0416</pub-id><pub-id pub-id-type="pmid">19831556</pub-id></element-citation></ref><ref id="B91-pharmaceutics-15-01700"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerhardt</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Widdows</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Erol</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Burch</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Sanz-Herrera</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ochoa</surname><given-names>I.</given-names></name><name name-style="western"><surname>St&#228;mpfli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roqan</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Gabe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The pro-angiogenic properties of multi-functional bioactive glass composite scaffolds</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>4096</fpage><lpage>4108</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.02.032</pub-id><pub-id pub-id-type="pmid">21411138</pub-id></element-citation></ref><ref id="B92-pharmaceutics-15-01700"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieves</surname><given-names>J.W.</given-names></name></person-group><article-title>Bone. Maximizing bone health-magnesium, BMD and fractures</article-title><source>Nat. Rev. Endocrinol.</source><year>2014</year><volume>10</volume><fpage>255</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2014.39</pub-id><pub-id pub-id-type="pmid">24686202</pub-id></element-citation></ref><ref id="B93-pharmaceutics-15-01700"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Baaij</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Hoenderop</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Bindels</surname><given-names>R.J.</given-names></name></person-group><article-title>Magnesium in man: Implications for health and disease</article-title><source>Physiol. Rev.</source><year>2015</year><volume>95</volume><fpage>1</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1152/physrev.00012.2014</pub-id><pub-id pub-id-type="pmid">25540137</pub-id></element-citation></ref><ref id="B94-pharmaceutics-15-01700"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bernardini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rayssiguier</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mazur</surname><given-names>A.</given-names></name></person-group><article-title>High concentrations of magnesium modulate vascular endothelial cell behaviour in vitro</article-title><source>Biochim. Biophys. Acta</source><year>2004</year><volume>1689</volume><fpage>6</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2004.02.004</pub-id><pub-id pub-id-type="pmid">15158908</pub-id></element-citation></ref><ref id="B95-pharmaceutics-15-01700"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernardini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nasulewic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mazur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>J.A.</given-names></name></person-group><article-title>Magnesium and microvascular endothelial cells: A role in inflammation and angiogenesis</article-title><source>Front. Biosci. A J. Virtual Libr.</source><year>2005</year><volume>10</volume><fpage>1177</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.2741/1610</pub-id><pub-id pub-id-type="pmid">15769616</pub-id></element-citation></ref><ref id="B96-pharmaceutics-15-01700"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romani</surname><given-names>A.M.P.</given-names></name></person-group><article-title>Beneficial Role of Mg(2+) in Prevention and Treatment of Hypertension</article-title><source>Int. J. Hypertens.</source><year>2018</year><volume>2018</volume><fpage>9013721</fpage><pub-id pub-id-type="doi">10.1155/2018/9013721</pub-id><pub-id pub-id-type="pmid">29992053</pub-id><pub-id pub-id-type="pmcid">PMC6016150</pub-id></element-citation></ref><ref id="B97-pharmaceutics-15-01700"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>K.W.K.</given-names></name></person-group><article-title>Bone grafts and biomaterials substitutes for bone defect repair: A review</article-title><source>Bioact. Mater.</source><year>2017</year><volume>2</volume><fpage>224</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2017.05.007</pub-id><pub-id pub-id-type="pmid">29744432</pub-id><pub-id pub-id-type="pmcid">PMC5935655</pub-id></element-citation></ref><ref id="B98-pharmaceutics-15-01700"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarafder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dernell</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Bandyopadhyay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bose</surname><given-names>S.</given-names></name></person-group><article-title>SrO- and MgO-doped microwave sintered 3D printed tricalcium phosphate scaffolds: Mechanical properties and in vivo osteogenesis in a rabbit model</article-title><source>J. Biomed. Mater. Res. Part B Appl. Biomater.</source><year>2015</year><volume>103</volume><fpage>679</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1002/jbm.b.33239</pub-id><pub-id pub-id-type="pmid">25045131</pub-id></element-citation></ref><ref id="B99-pharmaceutics-15-01700"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Enhanced osteogenic differentiation and biomineralization in mouse mesenchymal stromal cells on a &#946;-TCP robocast scaffold modified with collagen nanofibers</article-title><source>RSC Adv.</source><year>2016</year><volume>6</volume><fpage>23588</fpage><lpage>23598</lpage><pub-id pub-id-type="doi">10.1039/C5RA26670J</pub-id></element-citation></ref><ref id="B100-pharmaceutics-15-01700"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L.</given-names></name></person-group><article-title>Polydopamine-Based Surface Modification of Novel Nanoparticle-Aptamer Bioconjugates for In Vivo Breast Cancer Targeting and Enhanced Therapeutic Effects</article-title><source>Theranostics</source><year>2016</year><volume>6</volume><fpage>470</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.7150/thno.14184</pub-id><pub-id pub-id-type="pmid">26941841</pub-id><pub-id pub-id-type="pmcid">PMC4775858</pub-id></element-citation></ref><ref id="B101-pharmaceutics-15-01700"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Layered double hydroxide/poly-dopamine composite coating with surface heparinization on Mg alloys: Improved anticorrosion, endothelialization and hemocompatibility</article-title><source>Biomater. Sci.</source><year>2018</year><volume>6</volume><fpage>1846</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1039/C8BM00298C</pub-id><pub-id pub-id-type="pmid">29789824</pub-id></element-citation></ref><ref id="B102-pharmaceutics-15-01700"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Farnaghi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Friis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>Copper-doped mesoporous silica nanospheres, a promising immunomodulatory agent for inducing osteogenesis</article-title><source>Acta Biomater.</source><year>2016</year><volume>30</volume><fpage>334</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2015.11.033</pub-id><pub-id pub-id-type="pmid">26596565</pub-id></element-citation></ref><ref id="B103-pharmaceutics-15-01700"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Venojarvi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trikha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ellison</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name></person-group><article-title>Copper-induced vascular endo-thelial growth factor expression and wound healing</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2002</year><volume>282</volume><fpage>H1821</fpage><lpage>H1827</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01015.2001</pub-id><pub-id pub-id-type="pmid">11959648</pub-id></element-citation></ref><ref id="B104-pharmaceutics-15-01700"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kornblatt</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Nicoletti</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Travaglia</surname><given-names>A.</given-names></name></person-group><article-title>The neglected role of copper ions in wound healing</article-title><source>J. Inorg. Biochem.</source><year>2016</year><volume>161</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2016.02.012</pub-id><pub-id pub-id-type="pmid">26920228</pub-id></element-citation></ref><ref id="B105-pharmaceutics-15-01700"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M.X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.W.</given-names></name></person-group><article-title>Metal-Organic Framework (MOF)-Based Drug/Cargo Delivery and Cancer Therapy</article-title><source>Adv. Mater.</source><year>2017</year><volume>29</volume><fpage>1606134</fpage><pub-id pub-id-type="doi">10.1002/adma.201606134</pub-id><pub-id pub-id-type="pmid">28370555</pub-id></element-citation></ref><ref id="B106-pharmaceutics-15-01700"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Biodegradable Core-shell Dual-Metal-Organic-Frameworks Nanotheranostic Agent for Multiple Imaging Guided Combination Cancer Therapy</article-title><source>Theranostics</source><year>2017</year><volume>7</volume><fpage>4605</fpage><lpage>4617</lpage><pub-id pub-id-type="doi">10.7150/thno.20363</pub-id><pub-id pub-id-type="pmid">29158848</pub-id><pub-id pub-id-type="pmcid">PMC5695152</pub-id></element-citation></ref><ref id="B107-pharmaceutics-15-01700"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kamalitdinov</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>J.</given-names></name></person-group><article-title>Bioprinted osteon-like scaffolds enhance in vivo neovascularization</article-title><source>Biofabrication</source><year>2019</year><volume>11</volume><fpage>025013</fpage><pub-id pub-id-type="doi">10.1088/1758-5090/ab078a</pub-id><pub-id pub-id-type="pmid">30769337</pub-id><pub-id pub-id-type="pmcid">PMC7195919</pub-id></element-citation></ref><ref id="B108-pharmaceutics-15-01700"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melero-Martin</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Picard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Paruchuri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bischoff</surname><given-names>J.</given-names></name></person-group><article-title>In vivo vasculogenic potential of human blood-derived endothelial progenitor cells</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>4761</fpage><lpage>4768</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-12-062471</pub-id><pub-id pub-id-type="pmid">17327403</pub-id></element-citation></ref><ref id="B109-pharmaceutics-15-01700"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staton</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>N.J.</given-names></name></person-group><article-title>A critical analysis of current in vitro and in vivo angiogenesis assays</article-title><source>Int. J. Exp. Pathol.</source><year>2009</year><volume>90</volume><fpage>195</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2613.2008.00633.x</pub-id><pub-id pub-id-type="pmid">19563606</pub-id><pub-id pub-id-type="pmcid">PMC2697546</pub-id></element-citation></ref><ref id="B110-pharmaceutics-15-01700"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cidonio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Glinka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Kanczler</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lanham</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ahlfeld</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lode</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Gelinsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oreffo</surname><given-names>R.O.C.</given-names></name></person-group><article-title>Nanoclay-based 3D printed scaffolds promote vascular ingrowth ex vivo and generate bone mineral tissue in vitro and in vivo</article-title><source>Biofabrication</source><year>2020</year><volume>12</volume><fpage>035010</fpage><pub-id pub-id-type="doi">10.1088/1758-5090/ab8753</pub-id><pub-id pub-id-type="pmid">32259804</pub-id></element-citation></ref><ref id="B111-pharmaceutics-15-01700"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farahani</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Dub&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Therriault</surname><given-names>D.</given-names></name></person-group><article-title>Three-Dimensional Printing of Multifunctional Nanocomposites: Manufacturing Techniques and Applications</article-title><source>Adv. Mater.</source><year>2016</year><volume>28</volume><fpage>5794</fpage><lpage>5821</lpage><pub-id pub-id-type="doi">10.1002/adma.201506215</pub-id><pub-id pub-id-type="pmid">27135923</pub-id></element-citation></ref><ref id="B112-pharmaceutics-15-01700"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bates</surname><given-names>D.O.</given-names></name></person-group><article-title>Vascular endothelial growth factors and vascular permeability</article-title><source>Cardiovasc. Res.</source><year>2010</year><volume>87</volume><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvq105</pub-id><pub-id pub-id-type="pmid">20400620</pub-id><pub-id pub-id-type="pmcid">PMC2895541</pub-id></element-citation></ref><ref id="B113-pharmaceutics-15-01700"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S.S.</given-names></name></person-group><article-title>Cell Therapy Applications for Retinal Vascular Diseases: Diabetic Retinopathy and Retinal Vein Occlusion</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2016</year><volume>57</volume><fpage>ORSFj1</fpage><lpage>ORSFj10</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-17594</pub-id><pub-id pub-id-type="pmid">27116667</pub-id></element-citation></ref><ref id="B114-pharmaceutics-15-01700"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pittenger</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>B.J.</given-names></name></person-group><article-title>Mesenchymal stem cells and their potential as cardiac therapeutics</article-title><source>Circ. Res.</source><year>2004</year><volume>95</volume><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000135902.99383.6f</pub-id><pub-id pub-id-type="pmid">15242981</pub-id></element-citation></ref><ref id="B115-pharmaceutics-15-01700"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pittenger</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mosca</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Moorman</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Simonetti</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marshak</surname><given-names>D.R.</given-names></name></person-group><article-title>Multilineage potential of adult human mesenchymal stem cells</article-title><source>Sciences</source><year>1999</year><volume>284</volume><fpage>143</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1126/science.284.5411.143</pub-id><pub-id pub-id-type="pmid">10102814</pub-id></element-citation></ref><ref id="B116-pharmaceutics-15-01700"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheehy</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Mesallati</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vinardell</surname><given-names>T.</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D.J.</given-names></name></person-group><article-title>Tissue Engineering Whole Bones Through Endochondral Ossification: Regenerating the Distal Phalanx</article-title><source>BioRes. Open Access</source><year>2015</year><volume>4</volume><fpage>229</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1089/biores.2015.0014</pub-id><pub-id pub-id-type="pmid">26309799</pub-id><pub-id pub-id-type="pmcid">PMC4540120</pub-id></element-citation></ref><ref id="B117-pharmaceutics-15-01700"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanczler</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Oreffo</surname><given-names>R.O.</given-names></name></person-group><article-title>Osteogenesis and angiogenesis: The potential for engineering bone</article-title><source>Eur. Cells Mater.</source><year>2008</year><volume>15</volume><fpage>100</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.22203/eCM.v015a08</pub-id><pub-id pub-id-type="pmid">18454418</pub-id></element-citation></ref><ref id="B118-pharmaceutics-15-01700"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Pitacco</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nulty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cunniffe</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D.J.</given-names></name></person-group><article-title>3D printed microchannel networks to direct vascularisation during endochondral bone repair</article-title><source>Biomaterials</source><year>2018</year><volume>162</volume><fpage>34</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.01.057</pub-id><pub-id pub-id-type="pmid">29432987</pub-id></element-citation></ref><ref id="B119-pharmaceutics-15-01700"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>K.</given-names></name></person-group><article-title>3D printed scaffolds of calcium silicate-doped &#946;-TCP synergize with co-cultured endothelial and stromal cells to promote vascularization and bone formation</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>5588</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-05196-1</pub-id><pub-id pub-id-type="pmid">28717129</pub-id><pub-id pub-id-type="pmcid">PMC5514115</pub-id></element-citation></ref><ref id="B120-pharmaceutics-15-01700"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Forouzanfar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name></person-group><article-title>A novel method to improve the osteogenesis capacity of hUCMSCs with dual-directional pre-induction under screened co-culture conditions</article-title><source>Cell Prolif.</source><year>2020</year><volume>53</volume><fpage>e12740</fpage><pub-id pub-id-type="doi">10.1111/cpr.12740</pub-id><pub-id pub-id-type="pmid">31820506</pub-id><pub-id pub-id-type="pmcid">PMC7078770</pub-id></element-citation></ref><ref id="B121-pharmaceutics-15-01700"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>She</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C.</given-names></name></person-group><article-title>Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism</article-title><source>Stem Cell Res. Ther.</source><year>2017</year><volume>8</volume><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/s13287-017-0514-5</pub-id><pub-id pub-id-type="pmid">28279229</pub-id><pub-id pub-id-type="pmcid">PMC5345137</pub-id></element-citation></ref><ref id="B122-pharmaceutics-15-01700"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>K.</given-names></name><name name-style="western"><surname>Darzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>McPhee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Del Borgo</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Werkmeister</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gargett</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group><article-title>3D bioprinted endometrial stem cells on melt electrospun poly &#949;-caprolactone mesh for pelvic floor application promote anti-inflammatory responses in mice</article-title><source>Acta Biomater.</source><year>2019</year><volume>97</volume><fpage>162</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2019.08.003</pub-id><pub-id pub-id-type="pmid">31386931</pub-id></element-citation></ref><ref id="B123-pharmaceutics-15-01700"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Bouxsein</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Faugere</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Guldberg</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Gerstenfeld</surname><given-names>L.C.</given-names></name><etal/></person-group><article-title>The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development</article-title><source>J. Clin. Investig.</source><year>2007</year><volume>117</volume><fpage>1616</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1172/JCI31581</pub-id><pub-id pub-id-type="pmid">17549257</pub-id><pub-id pub-id-type="pmcid">PMC1878533</pub-id></element-citation></ref><ref id="B124-pharmaceutics-15-01700"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ramaswamy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Alaql</surname><given-names>Z.S.</given-names></name><name name-style="western"><surname>Eberhardt</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Gerstenfeld</surname><given-names>L.C.</given-names></name><etal/></person-group><article-title>Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>686</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1073/pnas.0708474105</pub-id><pub-id pub-id-type="pmid">18184809</pub-id><pub-id pub-id-type="pmcid">PMC2206597</pub-id></element-citation></ref><ref id="B125-pharmaceutics-15-01700"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kusumbe</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Ramasamy</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>R.H.</given-names></name></person-group><article-title>Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone</article-title><source>Nature</source><year>2014</year><volume>507</volume><fpage>323</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/nature13145</pub-id><pub-id pub-id-type="pmid">24646994</pub-id><pub-id pub-id-type="pmcid">PMC4943525</pub-id></element-citation></ref><ref id="B126-pharmaceutics-15-01700"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ramaswamy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mavalli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duvall</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Guldberg</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Eberhart</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>T.L.</given-names></name><etal/></person-group><article-title>Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice</article-title><source>J. Orthop. Res.</source><year>2009</year><volume>27</volume><fpage>1298</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1002/jor.20886</pub-id><pub-id pub-id-type="pmid">19338032</pub-id><pub-id pub-id-type="pmcid">PMC3767389</pub-id></element-citation></ref><ref id="B127-pharmaceutics-15-01700"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farberg</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Sarhaddi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Donneys</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Buchman</surname><given-names>S.R.</given-names></name></person-group><article-title>Deferoxamine enhances bone regeneration in mandibular distraction osteogenesis</article-title><source>Plast. Reconstr. Surg.</source><year>2014</year><volume>133</volume><fpage>666</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1097/01.prs.0000438050.36881.a9</pub-id><pub-id pub-id-type="pmid">24572857</pub-id><pub-id pub-id-type="pmcid">PMC4484577</pub-id></element-citation></ref><ref id="B128-pharmaceutics-15-01700"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donneys</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Ahsan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tchanque-Fossuo</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Sarhaddi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Buchman</surname><given-names>S.R.</given-names></name></person-group><article-title>Localized deferoxamine injection augments vascularity and improves bony union in pathologic fracture healing after radiotherapy</article-title><source>Bone</source><year>2013</year><volume>52</volume><fpage>318</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2012.10.014</pub-id><pub-id pub-id-type="pmid">23085084</pub-id><pub-id pub-id-type="pmcid">PMC3513581</pub-id></element-citation></ref><ref id="B129-pharmaceutics-15-01700"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sukanya</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Mohanan</surname><given-names>P.V.</given-names></name></person-group><article-title>Degradation of Poly(&#949;-caprolactone) and bio-interactions with mouse bone marrow mesenchymal stem cells</article-title><source>Colloids Surfaces. B Biointerfaces</source><year>2018</year><volume>163</volume><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2017.12.039</pub-id><pub-id pub-id-type="pmid">29287231</pub-id></element-citation></ref><ref id="B130-pharmaceutics-15-01700"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orozco-Castellanos</surname><given-names>L.</given-names></name><name name-style="western"><surname>Marcos-Fern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Richa</surname><given-names>A.</given-names></name></person-group><article-title>Hydrolytic degradation of poly(&#949;-caprolactone) with different end groups and poly(&#949;-caprolactone-co-&#947;-butyrolactone): Characterization and kinetics of hydrocortisone delivery</article-title><source>Polym. Adv. Technol.</source><year>2011</year><volume>22</volume><fpage>430</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1002/pat.1531</pub-id></element-citation></ref><ref id="B131-pharmaceutics-15-01700"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ragu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Faye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iraqui</surname><given-names>I.</given-names></name><name name-style="western"><surname>Masurel-Heneman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolodner</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.E.</given-names></name></person-group><article-title>Oxygen metabolism and reactive oxygen species cause chromosomal rearrangements and cell death</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>9747</fpage><lpage>9752</lpage><pub-id pub-id-type="doi">10.1073/pnas.0703192104</pub-id><pub-id pub-id-type="pmid">17535927</pub-id><pub-id pub-id-type="pmcid">PMC1887571</pub-id></element-citation></ref><ref id="B132-pharmaceutics-15-01700"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poole</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Haws</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Kavanaugh</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Skala</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Duvall</surname><given-names>C.L.</given-names></name></person-group><article-title>ROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease</article-title><source>Biomaterials</source><year>2015</year><volume>41</volume><fpage>166</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.11.016</pub-id><pub-id pub-id-type="pmid">25522975</pub-id><pub-id pub-id-type="pmcid">PMC4274772</pub-id></element-citation></ref><ref id="B133-pharmaceutics-15-01700"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fraisl</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mazzone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Carmeliet</surname><given-names>P.</given-names></name></person-group><article-title>Regulation of angiogenesis by oxygen and metabolism</article-title><source>Dev. Cell</source><year>2009</year><volume>16</volume><fpage>167</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2009.01.003</pub-id><pub-id pub-id-type="pmid">19217420</pub-id></element-citation></ref><ref id="B134-pharmaceutics-15-01700"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pati</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Won Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rhie</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>D.W.</given-names></name></person-group><article-title>Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3935</fpage><pub-id pub-id-type="doi">10.1038/ncomms4935</pub-id><pub-id pub-id-type="pmid">24887553</pub-id><pub-id pub-id-type="pmcid">PMC4059935</pub-id></element-citation></ref><ref id="B135-pharmaceutics-15-01700"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.W.</given-names></name></person-group><article-title>Decellularized extracellular matrix derived from human adipose tissue as a potential scaffold for allograft tissue engineering</article-title><source>J. Biomed. Mater. Res. Part. A</source><year>2011</year><volume>97</volume><fpage>292</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1002/jbm.a.33056</pub-id><pub-id pub-id-type="pmid">21448993</pub-id></element-citation></ref><ref id="B136-pharmaceutics-15-01700"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Marecak</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Amsden</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>L.E.</given-names></name></person-group><article-title>Effect of decellularized adipose tissue particle size and cell density on adipose-derived stem cell proliferation and adipogenic differentiation in composite methacrylated chondroitin sulphate hydrogels</article-title><source>Biomed. Mater.</source><year>2015</year><volume>10</volume><fpage>045010</fpage><pub-id pub-id-type="doi">10.1088/1748-6041/10/4/045010</pub-id><pub-id pub-id-type="pmid">26225549</pub-id></element-citation></ref><ref id="B137-pharmaceutics-15-01700"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Santis</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Alsafadi</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Tas</surname><given-names>S.</given-names></name><name name-style="western"><surname>B&#246;l&#252;kbas</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Prithiviraj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>I.A.N.</given-names></name><name name-style="western"><surname>Mittendorfer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ota</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stegmayr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Daoud</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Extracellular-Matrix-Reinforced Bioinks for 3D Bioprinting Human Tissue</article-title><source>Adv. Mater.</source><year>2021</year><volume>33</volume><fpage>e2005476</fpage><pub-id pub-id-type="doi">10.1002/adma.202005476</pub-id><pub-id pub-id-type="pmid">33300242</pub-id><pub-id pub-id-type="pmcid">PMC11469085</pub-id></element-citation></ref><ref id="B138-pharmaceutics-15-01700"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hamazaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Clapp</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Adin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ellison</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Jorgensen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Batich</surname><given-names>C.D.</given-names></name></person-group><article-title>Embryonic stem cells proliferate and differentiate when seeded into kidney scaffolds</article-title><source>J. Am. Soc. Nephrol. JASN</source><year>2009</year><volume>20</volume><fpage>2338</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1681/ASN.2008111196</pub-id><pub-id pub-id-type="pmid">19729441</pub-id><pub-id pub-id-type="pmcid">PMC2799178</pub-id></element-citation></ref><ref id="B139-pharmaceutics-15-01700"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortiella</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niles</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cantu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brettler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Winston</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>J.E.</given-names></name></person-group><article-title>Influence of acellular natural lung matrix on murine embryonic stem cell differentiation and tissue formation</article-title><source>Tissue Eng. Part A</source><year>2010</year><volume>16</volume><fpage>2565</fpage><lpage>2580</lpage><pub-id pub-id-type="doi">10.1089/ten.tea.2009.0730</pub-id><pub-id pub-id-type="pmid">20408765</pub-id></element-citation></ref><ref id="B140-pharmaceutics-15-01700"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>D.W.</given-names></name></person-group><article-title>Development of Liver Decellularized Extracellular Matrix Bioink for Three-Dimensional Cell Printing-Based Liver Tissue Engineering</article-title><source>Biomacromolecules</source><year>2017</year><volume>18</volume><fpage>1229</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.6b01908</pub-id><pub-id pub-id-type="pmid">28277649</pub-id></element-citation></ref><ref id="B141-pharmaceutics-15-01700"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>D.W.</given-names></name></person-group><article-title>3D Cell Printing of Functional Skeletal Muscle Constructs Using Skeletal Muscle-Derived Bioink</article-title><source>Adv. Healthc. Mater.</source><year>2016</year><volume>5</volume><fpage>2636</fpage><lpage>2645</lpage><pub-id pub-id-type="doi">10.1002/adhm.201600483</pub-id><pub-id pub-id-type="pmid">27529631</pub-id></element-citation></ref><ref id="B142-pharmaceutics-15-01700"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>French</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Boopathy</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>DeQuach</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Chingozha</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Christman</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M.E.</given-names></name></person-group><article-title>A naturally derived cardiac extracellular matrix enhances cardiac progenitor cell behavior in vitro</article-title><source>Acta Biomater.</source><year>2012</year><volume>8</volume><fpage>4357</fpage><lpage>4364</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2012.07.033</pub-id><pub-id pub-id-type="pmid">22842035</pub-id><pub-id pub-id-type="pmcid">PMC3488121</pub-id></element-citation></ref><ref id="B143-pharmaceutics-15-01700"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wickremasinghe</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cornwright</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Azares</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Acevedo-Jake</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Agudo</surname><given-names>N.R.</given-names></name><etal/></person-group><article-title>Treatment of hind limb ischemia using angiogenic peptide nanofibers</article-title><source>Biomaterials</source><year>2016</year><volume>98</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.04.032</pub-id><pub-id pub-id-type="pmid">27182813</pub-id><pub-id pub-id-type="pmcid">PMC4905688</pub-id></element-citation></ref><ref id="B144-pharmaceutics-15-01700"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saleha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Basit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>O.L.</given-names></name></person-group><article-title>Bacterial Contribution in Chronicity of Wounds</article-title><source>Microb. Ecol.</source><year>2017</year><volume>73</volume><fpage>710</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1007/s00248-016-0867-9</pub-id><pub-id pub-id-type="pmid">27742997</pub-id></element-citation></ref><ref id="B145-pharmaceutics-15-01700"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bessa</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Fazii</surname><given-names>P.</given-names></name><name name-style="western"><surname>Di Giulio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cellini</surname><given-names>L.</given-names></name></person-group><article-title>Bacterial isolates from infected wounds and their antibiotic susceptibility pattern: Some remarks about wound infection</article-title><source>Int. Wound J.</source><year>2015</year><volume>12</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1111/iwj.12049</pub-id><pub-id pub-id-type="pmid">23433007</pub-id><pub-id pub-id-type="pmcid">PMC7950398</pub-id></element-citation></ref><ref id="B146-pharmaceutics-15-01700"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>D.</given-names></name></person-group><article-title>Understanding biofilm resistance to antibacterial agents</article-title><source>Nat. Rev. Drug Discov.</source><year>2003</year><volume>2</volume><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1038/nrd1008</pub-id><pub-id pub-id-type="pmid">12563302</pub-id></element-citation></ref><ref id="B147-pharmaceutics-15-01700"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veerachamy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yarlagadda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Manivasagam</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yarlagadda</surname><given-names>P.K.</given-names></name></person-group><article-title>Bacterial adherence and biofilm formation on medical implants: A review</article-title><source>Proc. Inst. Mech. Engineers. Part H J. Eng. Med.</source><year>2014</year><volume>228</volume><fpage>1083</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1177/0954411914556137</pub-id><pub-id pub-id-type="pmid">25406229</pub-id></element-citation></ref><ref id="B148-pharmaceutics-15-01700"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cyphert</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Learn</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>von Recum</surname><given-names>H.A.</given-names></name></person-group><article-title>Recent Advances in the Evaluation of Antimicrobial Materials for Resolution of Orthopedic Implant-Associated Infections In Vivo</article-title><source>ACS Infect. Dis.</source><year>2021</year><volume>7</volume><fpage>3125</fpage><lpage>3160</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00465</pub-id><pub-id pub-id-type="pmid">34761915</pub-id><pub-id pub-id-type="pmcid">PMC9704321</pub-id></element-citation></ref><ref id="B149-pharmaceutics-15-01700"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>VanEpps</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Younger</surname><given-names>J.G.</given-names></name></person-group><article-title>Implantable Device-Related Infection</article-title><source>Shock</source><year>2016</year><volume>46</volume><fpage>597</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000000692</pub-id><pub-id pub-id-type="pmid">27454373</pub-id><pub-id pub-id-type="pmcid">PMC5110396</pub-id></element-citation></ref><ref id="B150-pharmaceutics-15-01700"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schierholz</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Beuth</surname><given-names>J.</given-names></name></person-group><article-title>Implant infections: A haven for opportunistic bacteria</article-title><source>J. Hosp. Infect.</source><year>2001</year><volume>49</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1053/jhin.2001.1052</pub-id><pub-id pub-id-type="pmid">11567552</pub-id></element-citation></ref><ref id="B151-pharmaceutics-15-01700"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kuk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>C.Y.</given-names></name></person-group><article-title>Antimicrobial effects of silver nanoparticles</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2007</year><volume>3</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2006.12.001</pub-id><pub-id pub-id-type="pmid">17379174</pub-id></element-citation></ref><ref id="B152-pharmaceutics-15-01700"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dille</surname><given-names>J.</given-names></name><name name-style="western"><surname>Godet</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis and antibacterial activity of silver nanoparticles against gram-positive and gram-negative bacteria</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2012</year><volume>8</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2011.05.007</pub-id><pub-id pub-id-type="pmid">21703988</pub-id></element-citation></ref><ref id="B153-pharmaceutics-15-01700"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name></person-group><article-title>Potential antibacterial mechanism of silver nanoparticles and the optimization of orthopedic implants by advanced modification technologies</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>3311</fpage><lpage>3327</lpage><pub-id pub-id-type="doi">10.2147/IJN.S165125</pub-id><pub-id pub-id-type="pmid">29892194</pub-id><pub-id pub-id-type="pmcid">PMC5993028</pub-id></element-citation></ref><ref id="B154-pharmaceutics-15-01700"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Astrain</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bur&#243;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palomares</surname><given-names>T.</given-names></name><name name-style="western"><surname>Eceiza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fruk</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corcuera</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gabilondo</surname><given-names>N.</given-names></name></person-group><article-title>Biocompatible hydrogel nanocomposite with covalently embedded silver nanoparticles</article-title><source>Biomacromolecules</source><year>2015</year><volume>16</volume><fpage>1301</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.5b00101</pub-id><pub-id pub-id-type="pmid">25785360</pub-id></element-citation></ref><ref id="B155-pharmaceutics-15-01700"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubey</surname><given-names>P.</given-names></name><name name-style="western"><surname>Matai</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhushan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gopinath</surname><given-names>P.</given-names></name></person-group><article-title>Perturbation of cellular mechanistic system by silver nanoparticle toxicity: Cytotoxic, genotoxic and epigenetic potentials</article-title><source>Adv. Colloid Interface Sci.</source><year>2015</year><volume>221</volume><fpage>4</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.cis.2015.02.007</pub-id><pub-id pub-id-type="pmid">25935324</pub-id></element-citation></ref><ref id="B156-pharmaceutics-15-01700"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kangari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abedini-Talemi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akbarzadeh-Bagheban</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rahmani</surname><given-names>S.</given-names></name></person-group><article-title>Comparison of Two Marketed Hydroxypropyl Methylcellulose Based Artificial Tear Drops in Young Patients with Dry Eye Syndrome</article-title><source>Nov. Biomed.</source><year>2015</year><volume>3</volume><fpage>193</fpage><lpage>199</lpage></element-citation></ref><ref id="B157-pharmaceutics-15-01700"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powers</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>T.J.</given-names></name></person-group><article-title>Dressings for chronic wounds</article-title><source>Dermatol. Ther.</source><year>2013</year><volume>26</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1111/dth.12055</pub-id><pub-id pub-id-type="pmid">23742280</pub-id></element-citation></ref><ref id="B158-pharmaceutics-15-01700"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>K.W.K.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Near-Infrared Light Triggered Phototherapy and Immunotherapy for Elimination of Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Biofilm Infection on Bone Implant</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>8157</fpage><lpage>8170</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c01486</pub-id><pub-id pub-id-type="pmid">32585104</pub-id></element-citation></ref><ref id="B159-pharmaceutics-15-01700"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soleymaniha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shahbazi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rafieerad</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Maleki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Amiri</surname><given-names>A.</given-names></name></person-group><article-title>Promoting Role of MXene Nanosheets in Biomedical Sciences: Therapeutic and Biosensing Innovations</article-title><source>Adv. Healthc. Mater.</source><year>2019</year><volume>8</volume><fpage>e1801137</fpage><pub-id pub-id-type="doi">10.1002/adhm.201801137</pub-id><pub-id pub-id-type="pmid">30362268</pub-id></element-citation></ref><ref id="B160-pharmaceutics-15-01700"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parajuli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Murali</surname><given-names>N.</given-names></name><name name-style="western"><surname>Karki</surname><given-names>B.</given-names></name><name name-style="western"><surname>Samatha</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pant</surname><given-names>B.</given-names></name></person-group><article-title>Advancements in MXene-Polymer Nanocomposites in Energy Storage and Biomedical Applications</article-title><source>Polymers</source><year>2022</year><volume>14</volume><elocation-id>3433</elocation-id><pub-id pub-id-type="doi">10.3390/polym14163433</pub-id><pub-id pub-id-type="pmid">36015690</pub-id><pub-id pub-id-type="pmcid">PMC9415062</pub-id></element-citation></ref><ref id="B161-pharmaceutics-15-01700"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>2D MXene-Integrated 3D-Printing Scaffolds for Augmented Osteosarcoma Phototherapy and Accelerated Tissue Reconstruction</article-title><source>Adv. Sci.</source><year>2020</year><volume>7</volume><fpage>1901511</fpage><pub-id pub-id-type="doi">10.1002/advs.201901511</pub-id><pub-id pub-id-type="pmcid">PMC6974945</pub-id><pub-id pub-id-type="pmid">31993282</pub-id></element-citation></ref><ref id="B162-pharmaceutics-15-01700"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasool</surname><given-names>K.</given-names></name><name name-style="western"><surname>Helal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Gogotsi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>K.A.</given-names></name></person-group><article-title>Antibacterial Activity of Ti&#8323;C&#8322;Tx MXene</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><fpage>3674</fpage><lpage>3684</lpage><pub-id pub-id-type="doi">10.1021/acsnano.6b00181</pub-id><pub-id pub-id-type="pmid">26909865</pub-id></element-citation></ref><ref id="B163-pharmaceutics-15-01700"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>2D Ultrathin MXene-Based Drug-Delivery Nanoplatform for Synergistic Photothermal Ablation and Chemotherapy of Cancer</article-title><source>Adv. Healthc. Mater.</source><year>2018</year><volume>7</volume><fpage>e1701394</fpage><pub-id pub-id-type="doi">10.1002/adhm.201701394</pub-id><pub-id pub-id-type="pmid">29405649</pub-id></element-citation></ref><ref id="B164-pharmaceutics-15-01700"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Niobium Carbide MXene Augmented Medical Implant Elicits Bacterial Infection Elimination and Tissue Regeneration</article-title><source>ACS Nano</source><year>2021</year><volume>15</volume><fpage>1086</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c08045</pub-id><pub-id pub-id-type="pmid">33372766</pub-id></element-citation></ref><ref id="B165-pharmaceutics-15-01700"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><etal/></person-group><article-title>V(2)C Nanosheets as Dual-Functional Antibacterial Agents</article-title><source>ACS Appl. Bio Mater.</source><year>2021</year><volume>4</volume><fpage>4215</fpage><lpage>4223</lpage><pub-id pub-id-type="doi">10.1021/acsabm.1c00008</pub-id><pub-id pub-id-type="pmid">35006834</pub-id></element-citation></ref><ref id="B166-pharmaceutics-15-01700"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lahiri</surname><given-names>J.</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>L.</given-names></name><name name-style="western"><surname>Weis</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Whitesides</surname><given-names>G.M.</given-names></name></person-group><article-title>A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin.biotin</article-title><source>Sciences</source><year>1998</year><volume>280</volume><fpage>708</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1126/science.280.5364.708</pub-id><pub-id pub-id-type="pmid">9563940</pub-id></element-citation></ref><ref id="B167-pharmaceutics-15-01700"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Suo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Reversible dougong structured receptor-ligand recognition for building dynamic extracellular matrix mimics</article-title><source>Proc. Natl. Acad. Sci. USA.</source><year>2022</year><volume>119</volume><fpage>e2117221119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2117221119</pub-id><pub-id pub-id-type="pmid">35181608</pub-id><pub-id pub-id-type="pmcid">PMC8872741</pub-id></element-citation></ref><ref id="B168-pharmaceutics-15-01700"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Valeanu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chirvasuta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stefan</surname><given-names>M.G.</given-names></name></person-group><article-title>New FDA approved antibacterial drugs: 2015&#8211;2017</article-title><source>Discov.</source><year>2018</year><volume>6</volume><fpage>e81</fpage><pub-id pub-id-type="doi">10.15190/d.2018.1</pub-id><pub-id pub-id-type="pmcid">PMC7086068</pub-id><pub-id pub-id-type="pmid">32309599</pub-id></element-citation></ref><ref id="B169-pharmaceutics-15-01700"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cicu&#233;ndez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doadrio</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Hern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Portol&#233;s</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Izquierdo-Barba</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vallet-Reg&#237;</surname><given-names>M.</given-names></name></person-group><article-title>Multifunctional pH sensitive 3D scaffolds for treatment and prevention of bone infection</article-title><source>Acta Biomater.</source><year>2018</year><volume>65</volume><fpage>450</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2017.11.009</pub-id><pub-id pub-id-type="pmid">29127064</pub-id></element-citation></ref><ref id="B170-pharmaceutics-15-01700"><label>170.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Zuza</surname><given-names>E.</given-names></name><name name-style="western"><surname>Meaurio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sarasua</surname><given-names>J.R.</given-names></name></person-group><source>Biodegradable Polylactide-Based Composites</source><publisher-name>IntechOpen</publisher-name><publisher-loc>London, UK</publisher-loc><year>2016</year></element-citation></ref><ref id="B171-pharmaceutics-15-01700"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrido-Mesa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zarzuelo</surname><given-names>A.</given-names></name><name name-style="western"><surname>G&#225;lvez</surname><given-names>J.</given-names></name></person-group><article-title>Minocycline: Far beyond an antibiotic</article-title><source>Br. J. Pharmacol.</source><year>2013</year><volume>169</volume><fpage>337</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1111/bph.12139</pub-id><pub-id pub-id-type="pmid">23441623</pub-id><pub-id pub-id-type="pmcid">PMC3651660</pub-id></element-citation></ref><ref id="B172-pharmaceutics-15-01700"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>T.</given-names></name><name name-style="western"><surname>Grenho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Barros</surname><given-names>J.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cola&#231;o</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Bettencourt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>P.S.</given-names></name></person-group><article-title>A minocycline-releasing PMMA system as a space maintainer for staged bone reconstructions-in vitro antibacterial, cytocompatibility and anti-inflammatory characterization</article-title><source>Biomed. Mater.</source><year>2017</year><volume>12</volume><fpage>035009</fpage><pub-id pub-id-type="doi">10.1088/1748-605X/aa68b8</pub-id><pub-id pub-id-type="pmid">28333042</pub-id></element-citation></ref><ref id="B173-pharmaceutics-15-01700"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rzhepishevska</surname><given-names>O.</given-names></name><name name-style="western"><surname>Grenho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Malheiros</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gon&#231;alves</surname><given-names>L.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Jord&#227;o</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Ramstedt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Levofloxacin-loaded bone cement delivery system: Highly effective against intracellular bacteria and <italic toggle="yes">Staphylococcus aureus</italic> biofilms</article-title><source>Int. J. Pharm.</source><year>2017</year><volume>532</volume><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.08.089</pub-id><pub-id pub-id-type="pmid">28851574</pub-id></element-citation></ref><ref id="B174-pharmaceutics-15-01700"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dou</surname><given-names>X.C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.Q.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.L.</given-names></name></person-group><article-title>Minocycline-released hydroxyapatite-gelatin nanocomposite and its cytocompatibility in vitro</article-title><source>Biomed. Mater.</source><year>2011</year><volume>6</volume><fpage>025002</fpage><pub-id pub-id-type="doi">10.1088/1748-6041/6/2/025002</pub-id><pub-id pub-id-type="pmid">21293054</pub-id></element-citation></ref><ref id="B175-pharmaceutics-15-01700"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.F.</given-names></name></person-group><article-title>Nitric oxide: A newly discovered function on wound healing</article-title><source>Acta Pharmacol. Sin.</source><year>2005</year><volume>26</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1111/j.1745-7254.2005.00058.x</pub-id><pub-id pub-id-type="pmid">15715920</pub-id></element-citation></ref><ref id="B176-pharmaceutics-15-01700"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>F.C.</given-names></name></person-group><article-title>Perspectives series: Host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity</article-title><source>J. Clin. Investig.</source><year>1997</year><volume>99</volume><fpage>2818</fpage><lpage>2825</lpage><pub-id pub-id-type="doi">10.1172/JCI119473</pub-id><pub-id pub-id-type="pmid">9185502</pub-id><pub-id pub-id-type="pmcid">PMC508130</pub-id></element-citation></ref><ref id="B177-pharmaceutics-15-01700"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno-Jim&#233;nez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hulsart-Billstrom</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lanham</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Janeczek</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Kontouli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kanczler</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Oreffo</surname><given-names>R.O.</given-names></name></person-group><article-title>The chorioallantoic membrane (CAM) assay for the study of human bone regeneration: A refinement animal model for tissue engineering</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>32168</fpage><pub-id pub-id-type="doi">10.1038/srep32168</pub-id><pub-id pub-id-type="pmid">27577960</pub-id><pub-id pub-id-type="pmcid">PMC5006015</pub-id></element-citation></ref><ref id="B178-pharmaceutics-15-01700"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharifi-Rad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sharifi-Rad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoseini-Alfatemi</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Iriti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sharifi-Rad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sharifi-Rad</surname><given-names>M.</given-names></name></person-group><article-title>Composition, Cytotoxic and Antimicrobial Activities of Satureja intermedia C.A.Mey Essential Oil</article-title><source>Int. J. Mol. Sci.</source><year>2015</year><volume>16</volume><fpage>17812</fpage><lpage>17825</lpage><pub-id pub-id-type="doi">10.3390/ijms160817812</pub-id><pub-id pub-id-type="pmid">26247936</pub-id><pub-id pub-id-type="pmcid">PMC4581223</pub-id></element-citation></ref><ref id="B179-pharmaceutics-15-01700"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skocibusi&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bezi&#263;</surname><given-names>N.</given-names></name></person-group><article-title>Phytochemical analysis and in vitro antimicrobial activity of two Satureja species essential oils</article-title><source>Phytother. Res. PTR</source><year>2004</year><volume>18</volume><fpage>967</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1002/ptr.1489</pub-id><pub-id pub-id-type="pmid">15742345</pub-id></element-citation></ref><ref id="B180-pharmaceutics-15-01700"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jafari</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ghavidel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zarshenas</surname><given-names>M.M.</given-names></name></person-group><article-title>A Critical Overview on the Pharmacological and Clinical Aspects of Popular Satureja Species</article-title><source>J. Acupunct. Meridian Stud.</source><year>2016</year><volume>9</volume><fpage>118</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.jams.2016.04.003</pub-id><pub-id pub-id-type="pmid">27342885</pub-id></element-citation></ref><ref id="B181-pharmaceutics-15-01700"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sait</surname><given-names>U.</given-names></name><name name-style="western"><surname>Uca</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kartal</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Altun</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Sayar</surname><given-names>E.</given-names></name></person-group><article-title>GC-MS Analysis and Antibacterial Activity of Cultivated <italic toggle="yes">Satureja cuneifolia</italic> Ten</article-title><source>Essential Oil. Turk. J. Chem.</source><year>2014</year><volume>30</volume><fpage>253</fpage><lpage>259</lpage></element-citation></ref><ref id="B182-pharmaceutics-15-01700"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Acgc</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eb</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mk</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lg</surname><given-names>I.J.A.J.o.C.</given-names></name></person-group><article-title>Anti-Alzheimer, antidiabetic and antioxidant potential of <italic toggle="yes">Satureja cuneifolia</italic> and analysis of its phenolic contents by LC-MS/MS</article-title><source>Arab. J. Chem.</source><year>2020</year><volume>13</volume><fpage>4528</fpage><lpage>4537</lpage></element-citation></ref><ref id="B183-pharmaceutics-15-01700"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mochalin</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Shenderova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gogotsi</surname><given-names>Y.</given-names></name></person-group><article-title>The properties and applications of nanodiamonds</article-title><source>Nat. Nanotechnol.</source><year>2011</year><volume>7</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/nnano.2011.209</pub-id><pub-id pub-id-type="pmid">22179567</pub-id></element-citation></ref><ref id="B184-pharmaceutics-15-01700"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amaral</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>M.H.</given-names></name></person-group><article-title>Nanocrystalline diamond: In vitro biocompatibility assessment by MG63 and human bone marrow cells cultures</article-title><source>J. Biomed. Mater. Res. Part A</source><year>2008</year><volume>87</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1002/jbm.a.31742</pub-id><pub-id pub-id-type="pmid">18085649</pub-id></element-citation></ref><ref id="B185-pharmaceutics-15-01700"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wehling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dringen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zare</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Maas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rezwan</surname><given-names>K.</given-names></name></person-group><article-title>Bactericidal activity of partially oxidized nanodiamonds</article-title><source>ACS Nano</source><year>2014</year><volume>8</volume><fpage>6475</fpage><lpage>6483</lpage><pub-id pub-id-type="doi">10.1021/nn502230m</pub-id><pub-id pub-id-type="pmid">24861876</pub-id></element-citation></ref><ref id="B186-pharmaceutics-15-01700"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papo</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Catledge</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Vohra</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>C.</given-names></name></person-group><article-title>Mechanical wear behavior of nanocrystalline and multilayer diamond coatings on temporomandibular joint implants</article-title><source>J. Mater. Sci. Mater. Med.</source><year>2004</year><volume>15</volume><fpage>773</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1023/B:JMSM.0000032817.05997.d2</pub-id><pub-id pub-id-type="pmid">15387413</pub-id></element-citation></ref><ref id="B187-pharmaceutics-15-01700"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catledge</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vohra</surname><given-names>Y.K.</given-names></name></person-group><article-title>Nanostructured diamond coatings for orthopaedic applications</article-title><source>Woodhead Publ. Ser. Biomater.</source><year>2013</year><volume>2013</volume><fpage>105</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1533/9780857093516.2.105</pub-id><pub-id pub-id-type="pmcid">PMC4181380</pub-id><pub-id pub-id-type="pmid">25285213</pub-id></element-citation></ref><ref id="B188-pharmaceutics-15-01700"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujinaga</surname><given-names>T.</given-names></name></person-group><article-title>Topical formulations and wound healing applications of chitosan</article-title><source>Adv. Drug Deliv Rev.</source><year>2001</year><volume>52</volume><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(01)00189-2</pub-id><pub-id pub-id-type="pmid">11718934</pub-id></element-citation></ref><ref id="B189-pharmaceutics-15-01700"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azad</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Sermsintham</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chandrkrachang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>W.F.</given-names></name></person-group><article-title>Chitosan membrane as a wound-healing dressing: Characterization and clinical application</article-title><source>J. Biomed. Mater. Res. Part B Appl. Biomater.</source><year>2004</year><volume>69</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1002/jbm.b.30000</pub-id><pub-id pub-id-type="pmid">15116411</pub-id></element-citation></ref><ref id="B190-pharmaceutics-15-01700"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>S.</given-names></name></person-group><article-title>Chitosan Based Scaffolds and Their Applications in Wound Healing</article-title><source>Achiev. Life Sci.</source><year>2016</year><volume>10</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.als.2016.04.001</pub-id></element-citation></ref><ref id="B191-pharmaceutics-15-01700"><label>191.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kucharska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sikora</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brzoza-Malczewska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Owczarek</surname><given-names>M.</given-names></name></person-group><article-title>Antimicrobial Properties of Chitin and Chitosan</article-title><source>Chitin and Chitosan</source><publisher-name>Wiley</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2019</year><fpage>169</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1002/9781119450467</pub-id></element-citation></ref><ref id="B192-pharmaceutics-15-01700"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thian</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Konishi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawanobe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Choong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aizawa</surname><given-names>M.</given-names></name></person-group><article-title>Zinc-substituted hydroxyapatite: A biomaterial with enhanced bioactivity and antibacterial properties</article-title><source>J. Mater. Sci. Mater. Med.</source><year>2013</year><volume>24</volume><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1007/s10856-012-4817-x</pub-id><pub-id pub-id-type="pmid">23160913</pub-id></element-citation></ref><ref id="B193-pharmaceutics-15-01700"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voicu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ghitulica</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Jinga</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Holban</surname><given-names>A.M.</given-names></name></person-group><article-title>Co doped ZnO thin films deposited by spin coating as antibacterial coating for metallic implants</article-title><source>Ceram. Int.</source><year>2019</year><volume>46</volume><fpage>3904</fpage><lpage>3911</lpage><pub-id pub-id-type="doi">10.1016/j.ceramint.2019.10.118</pub-id></element-citation></ref><ref id="B194-pharmaceutics-15-01700"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mustapha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.</given-names></name></person-group><article-title>Antibacterial activities of zinc oxide nanoparticles against <italic toggle="yes">Escherichia coli</italic> O157:H7</article-title><source>J. Appl. Microbiol.</source><year>2009</year><volume>107</volume><fpage>1193</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2009.04303.x</pub-id><pub-id pub-id-type="pmid">19486396</pub-id></element-citation></ref><ref id="B195-pharmaceutics-15-01700"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chhabra</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kanitkar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kale</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Bellare</surname><given-names>J.R.</given-names></name></person-group><article-title>A nano zinc oxide doped electrospun scaffold improves wound healing in a rodent model</article-title><source>RSC Adv.</source><year>2015</year><volume>6</volume><fpage>1428</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1039/C5RA21821G</pub-id></element-citation></ref><ref id="B196-pharmaceutics-15-01700"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.E.</given-names></name></person-group><article-title>Dual UV irradiation-based metal oxide nanoparticles for enhanced antimicrobial activity in <italic toggle="yes">Escherichia coli</italic> and M13 bacteriophage</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>8057</fpage><lpage>8070</lpage><pub-id pub-id-type="doi">10.2147/IJN.S144236</pub-id><pub-id pub-id-type="pmid">29138562</pub-id><pub-id pub-id-type="pmcid">PMC5677303</pub-id></element-citation></ref><ref id="B197-pharmaceutics-15-01700"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rojas-Andrade</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Chata</surname><given-names>G.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Roseman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Millhauser</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Saltikov</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name></person-group><article-title>Photo-enhanced antibacterial activity of ZnO/graphene quantum dot nanocomposites</article-title><source>Nanoscale</source><year>2017</year><volume>10</volume><fpage>158</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1039/C7NR07367D</pub-id><pub-id pub-id-type="pmid">29143052</pub-id></element-citation></ref><ref id="B198-pharmaceutics-15-01700"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raja</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ashokkumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pavithra Marthandam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jayachandiran</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khatiwada</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Kaviyarasu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ganapathi Raman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Swaminathan</surname><given-names>M.</given-names></name></person-group><article-title>Eco-friendly preparation of zinc oxide nanoparticles using Tabernaemontana divaricata and its photocatalytic and antimicrobial activity</article-title><source>J. Photochem. Photobiol. B Biol.</source><year>2018</year><volume>181</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.jphotobiol.2018.02.011</pub-id><pub-id pub-id-type="pmid">29501725</pub-id></element-citation></ref><ref id="B199-pharmaceutics-15-01700"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhande</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Khobragade</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Mane</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Bhande</surname><given-names>S.</given-names></name></person-group><article-title>Enhanced synergism of antibiotics with zinc oxide nanoparticles against extended spectrum &#946;-lactamase producers implicated in urinary tract infections</article-title><source>J. Nanoparticle Res.</source><year>2013</year><volume>15</volume><fpage>1413</fpage><pub-id pub-id-type="doi">10.1007/s11051-012-1413-4</pub-id></element-citation></ref><ref id="B200-pharmaceutics-15-01700"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name></person-group><article-title>Effects of water chemistry on the dissolution of ZnO nanoparticles and their toxicity to <italic toggle="yes">Escherichia coli</italic></article-title><source>Environ. Pollut.</source><year>2013</year><volume>173</volume><fpage>97</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.envpol.2012.10.026</pub-id><pub-id pub-id-type="pmid">23202638</pub-id></element-citation></ref><ref id="B201-pharmaceutics-15-01700"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Falling Leaves Inspired ZnO Nanorods-Nanoslices Hierarchical Structure for Implant Surface Modification with Two Stage Releasing Features</article-title><source>ACS Appl. Mater. Interfaces</source><year>2017</year><volume>9</volume><fpage>13009</fpage><lpage>13015</lpage><pub-id pub-id-type="doi">10.1021/acsami.7b00666</pub-id><pub-id pub-id-type="pmid">28371577</pub-id></element-citation></ref><ref id="B202-pharmaceutics-15-01700"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutsenko</surname><given-names>S.</given-names></name></person-group><article-title>Human copper homeostasis: A network of interconnected pathways</article-title><source>Curr. Opin. Chem. Biol.</source><year>2010</year><volume>14</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2010.01.003</pub-id><pub-id pub-id-type="pmid">20117961</pub-id><pub-id pub-id-type="pmcid">PMC6365103</pub-id></element-citation></ref><ref id="B203-pharmaceutics-15-01700"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasan</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Lutsenko</surname><given-names>S.</given-names></name></person-group><article-title>Regulation of copper transporters in human cells</article-title><source>Curr. Top. Membr.</source><year>2012</year><volume>69</volume><fpage>137</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/b978-0-12-394390-3.00006-9</pub-id><pub-id pub-id-type="pmid">23046650</pub-id><pub-id pub-id-type="pmcid">PMC6365104</pub-id></element-citation></ref><ref id="B204-pharmaceutics-15-01700"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noyce</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Michels</surname><given-names>H.</given-names></name><name name-style="western"><surname>Keevil</surname><given-names>C.W.</given-names></name></person-group><article-title>Potential use of copper surfaces to reduce survival of epidemic meticillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> in the healthcare environment</article-title><source>J. Hosp. Infect.</source><year>2006</year><volume>63</volume><fpage>289</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2005.12.008</pub-id><pub-id pub-id-type="pmid">16650507</pub-id></element-citation></ref><ref id="B205-pharmaceutics-15-01700"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kadiiska</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>R.P.</given-names></name></person-group><article-title>In vivo copper-mediated free radical production: An ESR spin-trapping study</article-title><source>Spectrochim. Acta. Part A Mol. Biomol. Spectrosc.</source><year>2002</year><volume>58</volume><fpage>1227</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1016/S1386-1425(01)00713-2</pub-id><pub-id pub-id-type="pmid">11993471</pub-id></element-citation></ref><ref id="B206-pharmaceutics-15-01700"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jim&#233;nez Del R&#237;o</surname><given-names>M.</given-names></name><name name-style="western"><surname>V&#233;lez-Pardo</surname><given-names>C.</given-names></name></person-group><article-title>Transition metal-induced apoptosis in lymphocytes via hydroxyl radical generation, mitochondria dysfunction, and caspase-3 activation: An in vitro model for neurodegeneration</article-title><source>Arch. Med. Res.</source><year>2004</year><volume>35</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2004.01.001</pub-id><pub-id pub-id-type="pmid">15163458</pub-id></element-citation></ref><ref id="B207-pharmaceutics-15-01700"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warnes</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Caves</surname><given-names>V.</given-names></name><name name-style="western"><surname>Keevil</surname><given-names>C.W.</given-names></name></person-group><article-title>Mechanism of copper surface toxicity in <italic toggle="yes">Escherichia coli</italic> O157:H7 and Salmonella involves immediate membrane depolarization followed by slower rate of DNA destruction which differs from that observed for Gram-positive bacteria</article-title><source>Environ. Microbiol.</source><year>2012</year><volume>14</volume><fpage>1730</fpage><lpage>1743</lpage><pub-id pub-id-type="doi">10.1111/j.1462-2920.2011.02677.x</pub-id><pub-id pub-id-type="pmid">22176893</pub-id></element-citation></ref><ref id="B208-pharmaceutics-15-01700"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodgkinson</surname><given-names>V.</given-names></name><name name-style="western"><surname>Petris</surname><given-names>M.J.</given-names></name></person-group><article-title>Copper homeostasis at the host-pathogen interface</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>13549</fpage><lpage>13555</lpage><pub-id pub-id-type="doi">10.1074/jbc.R111.316406</pub-id><pub-id pub-id-type="pmid">22389498</pub-id><pub-id pub-id-type="pmcid">PMC3340201</pub-id></element-citation></ref><ref id="B209-pharmaceutics-15-01700"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dilberoglu</surname><given-names>U.M.</given-names></name><name name-style="western"><surname>Gharehpapagh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yaman</surname><given-names>U.</given-names></name><name name-style="western"><surname>Dolen</surname><given-names>M.</given-names></name></person-group><article-title>The Role of Additive Manufacturing in the Era of Industry 4.0</article-title><source>Procedia Manuf.</source><year>2017</year><volume>11</volume><fpage>545</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/j.promfg.2017.07.148</pub-id></element-citation></ref><ref id="B210-pharmaceutics-15-01700"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gisario</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kazarian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martina</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mehrpouya</surname><given-names>M.</given-names></name></person-group><article-title>Metal additive manufacturing in the commercial aviation industry: A review</article-title><source>J. Manuf. Syst.</source><year>2019</year><volume>53</volume><fpage>124</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.jmsy.2019.08.005</pub-id></element-citation></ref><ref id="B211-pharmaceutics-15-01700"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidakis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Petousis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maniadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koudoumas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liebscher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tzounis</surname><given-names>L.</given-names></name></person-group><article-title>Mechanical Properties of 3D-Printed Acrylonitrile-Butadiene-Styrene TiO(<sub>2</sub>) and ATO Nanocomposites</article-title><source>Polymers</source><year>2020</year><volume>12</volume><elocation-id>1589</elocation-id><pub-id pub-id-type="doi">10.3390/polym12071589</pub-id><pub-id pub-id-type="pmid">32708989</pub-id><pub-id pub-id-type="pmcid">PMC7407130</pub-id></element-citation></ref><ref id="B212-pharmaceutics-15-01700"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ford</surname><given-names>S.</given-names></name><name name-style="western"><surname>Despeisse</surname><given-names>M.</given-names></name></person-group><article-title>Additive manufacturing and sustainability: An exploratory study of the advantages and challenges</article-title><source>J. Clean. Prod.</source><year>2016</year><volume>137</volume><fpage>1573</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1016/j.jclepro.2016.04.150</pub-id></element-citation></ref><ref id="B213-pharmaceutics-15-01700"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Wingham</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>J.</given-names></name><name name-style="western"><surname>Majewski</surname><given-names>C.</given-names></name></person-group><article-title>Use of silver-based additives for the development of antibacterial functionality in Laser Sintered polyamide 12 parts</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>892</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-57686-4</pub-id><pub-id pub-id-type="pmid">31964969</pub-id><pub-id pub-id-type="pmcid">PMC6972821</pub-id></element-citation></ref><ref id="B214-pharmaceutics-15-01700"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.F.</given-names></name></person-group><article-title>Application of Natural Flavonoids to Impart Antioxidant and Antibacterial Activities to Polyamide Fiber for Health Care Applications</article-title><source>Antioxidants</source><year>2019</year><volume>8</volume><elocation-id>301</elocation-id><pub-id pub-id-type="doi">10.3390/antiox8080301</pub-id><pub-id pub-id-type="pmid">31408994</pub-id><pub-id pub-id-type="pmcid">PMC6719920</pub-id></element-citation></ref><ref id="B215-pharmaceutics-15-01700"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wencke</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Kutlu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Seefeldt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Esen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ostendorf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Luinstra</surname><given-names>G.A.</given-names></name></person-group><article-title>Additive manufacturing of PA12 carbon nanotube composites with a novel laser polymer deposition process</article-title><source>J. Appl. Polym. Sci.</source><year>2021</year><volume>138</volume><fpage>50395</fpage><pub-id pub-id-type="doi">10.1002/app.50395</pub-id></element-citation></ref><ref id="B216-pharmaceutics-15-01700"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espera</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Valino</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Palaganas</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Advincula</surname><given-names>R.C.</given-names></name></person-group><article-title>3D Printing of a Robust Polyamide-12-Carbon Black Composite via Selective Laser Sintering: Thermal and Electrical Conductivity</article-title><source>Macromol. Mater. Eng.</source><year>2019</year><volume>304</volume><fpage>1800718</fpage><pub-id pub-id-type="doi">10.1002/mame.201800718</pub-id></element-citation></ref><ref id="B217-pharmaceutics-15-01700"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.B.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.M.</given-names></name></person-group><article-title>Macrophage polarization in inflammatory diseases</article-title><source>Int. J. Biol. Sci.</source><year>2014</year><volume>10</volume><fpage>520</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.7150/ijbs.8879</pub-id><pub-id pub-id-type="pmid">24910531</pub-id><pub-id pub-id-type="pmcid">PMC4046879</pub-id></element-citation></ref><ref id="B218-pharmaceutics-15-01700"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sridharan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kearney</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Today</surname><given-names>F.O.B.J.M.</given-names></name></person-group><article-title>Biomaterial based modulation of macrophage polarization: A review and suggested design principles</article-title><source>Mater. Today</source><year>2015</year><volume>18</volume><fpage>313</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.mattod.2015.01.019</pub-id></element-citation></ref><ref id="B219-pharmaceutics-15-01700"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandes</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Gomoll</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Lattermann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Amano</surname><given-names>M.T.</given-names></name></person-group><article-title>Macrophage: A Potential Target on Cartilage Regeneration</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>111</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00111</pub-id><pub-id pub-id-type="pmid">32117263</pub-id><pub-id pub-id-type="pmcid">PMC7026000</pub-id></element-citation></ref><ref id="B220-pharmaceutics-15-01700"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stout</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Suttles</surname><given-names>J.</given-names></name></person-group><article-title>Functional plasticity of macrophages: In situ reprogramming of tumor-associated macrophages</article-title><source>J. Leukoc. Biol.</source><year>2009</year><volume>86</volume><fpage>1105</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1189/jlb.0209073</pub-id><pub-id pub-id-type="pmid">19605698</pub-id><pub-id pub-id-type="pmcid">PMC2774875</pub-id></element-citation></ref><ref id="B221-pharmaceutics-15-01700"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>L.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poron</surname><given-names>F.</given-names></name><name name-style="western"><surname>Baba-Amer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>van Rooijen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Plonquet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gherardi</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Chazaud</surname><given-names>B.</given-names></name></person-group><article-title>Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis</article-title><source>J. Exp. Med.</source><year>2007</year><volume>204</volume><fpage>1057</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1084/jem.20070075</pub-id><pub-id pub-id-type="pmid">17485518</pub-id><pub-id pub-id-type="pmcid">PMC2118577</pub-id></element-citation></ref><ref id="B222-pharmaceutics-15-01700"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sica</surname><given-names>A.</given-names></name><name name-style="western"><surname>Allavena</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garlanda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Locati</surname><given-names>M.</given-names></name></person-group><article-title>Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation</article-title><source>Hum. Immunol.</source><year>2009</year><volume>70</volume><fpage>325</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2009.02.008</pub-id><pub-id pub-id-type="pmid">19236898</pub-id></element-citation></ref><ref id="B223-pharmaceutics-15-01700"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troidl</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#246;llmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nef</surname><given-names>H.</given-names></name><name name-style="western"><surname>Masseli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Szardien</surname><given-names>S.</given-names></name><name name-style="western"><surname>Willmer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rolf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rixe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Troidl</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction</article-title><source>J. Cells Mol. Med.</source><year>2009</year><volume>13</volume><fpage>3485</fpage><lpage>3496</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00707.x</pub-id><pub-id pub-id-type="pmcid">PMC4516503</pub-id><pub-id pub-id-type="pmid">19228260</pub-id></element-citation></ref><ref id="B224-pharmaceutics-15-01700"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yunna</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mengru</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Weidong</surname><given-names>C.</given-names></name></person-group><article-title>Macrophage M1/M2 polarization</article-title><source>Eur. J. Pharmacol.</source><year>2020</year><volume>877</volume><fpage>173090</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173090</pub-id><pub-id pub-id-type="pmid">32234529</pub-id></element-citation></ref><ref id="B225-pharmaceutics-15-01700"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Munari</surname><given-names>F.</given-names></name><name name-style="western"><surname>S&#225;nchez-Rodr&#237;guez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scolaro</surname><given-names>T.</given-names></name><name name-style="western"><surname>Castegna</surname><given-names>A.</given-names></name></person-group><article-title>The Metabolic Signature of Macrophage Responses</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1462</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01462</pub-id><pub-id pub-id-type="pmid">31333642</pub-id><pub-id pub-id-type="pmcid">PMC6618143</pub-id></element-citation></ref><ref id="B226-pharmaceutics-15-01700"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saklatvala</surname><given-names>J.</given-names></name></person-group><article-title>Glucocorticoids: Do we know how they work?</article-title><source>Arthritis Res.</source><year>2002</year><volume>4</volume><fpage>146</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1186/ar398</pub-id><pub-id pub-id-type="pmid">12010562</pub-id><pub-id pub-id-type="pmcid">PMC128923</pub-id></element-citation></ref><ref id="B227-pharmaceutics-15-01700"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brook</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saklatvala</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>A.R.</given-names></name></person-group><article-title>Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38</article-title><source>Mol. Cells Biol.</source><year>2001</year><volume>21</volume><fpage>771</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.3.771-780.2001</pub-id><pub-id pub-id-type="pmcid">PMC86669</pub-id><pub-id pub-id-type="pmid">11154265</pub-id></element-citation></ref><ref id="B228-pharmaceutics-15-01700"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abu Samra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ebrahimiadib</surname><given-names>N.</given-names></name><name name-style="western"><surname>Meese</surname><given-names>H.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>C.S.</given-names></name></person-group><article-title>Long-term side effects of glucocorticoids</article-title><source>Expert Opin. Drug Saf.</source><year>2016</year><volume>15</volume><fpage>457</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1517/14740338.2016.1140743</pub-id><pub-id pub-id-type="pmid">26789102</pub-id></element-citation></ref><ref id="B229-pharmaceutics-15-01700"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D.C.</given-names></name></person-group><article-title>Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery</article-title><source>Biomaterials</source><year>2006</year><volume>27</volume><fpage>3031</fpage><lpage>3037</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2005.12.021</pub-id><pub-id pub-id-type="pmid">16443270</pub-id></element-citation></ref><ref id="B230-pharmaceutics-15-01700"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Dellagnelo</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Benetti</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M.A.S.</given-names></name></person-group><article-title>Pharmacodynamic and Pharmacokinetic Studies of &#946;-Cyclodextrin:Dexamethasone Acetate Complexes in Mice</article-title><source>Braz. Arch. Biol. Technol.</source><year>2014</year><volume>57</volume><fpage>887</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1590/S1516-8913201400874</pub-id></element-citation></ref><ref id="B231-pharmaceutics-15-01700"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loftsson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stef&#225;nsson</surname><given-names>E.</given-names></name></person-group><article-title>Cyclodextrins in ocular drug delivery: Theoretical basis with dexamethasone as a sample drug</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2007</year><volume>17</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S1773-2247(07)50001-8</pub-id></element-citation></ref><ref id="B232-pharmaceutics-15-01700"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Collett</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>M.V.</given-names></name></person-group><article-title>Influence of cyclodextrin complexation on the in vitro permeation and skin metabolism of dexamethasone</article-title><source>Int. J. Pharm.</source><year>2000</year><volume>200</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(00)00365-3</pub-id><pub-id pub-id-type="pmid">10845694</pub-id></element-citation></ref><ref id="B233-pharmaceutics-15-01700"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loftsson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fririksd&#243;ttir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Th&#243;risd&#243;ttir</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stef&#225;nsson</surname><given-names>E.</given-names></name></person-group><article-title>The effect of hydroxypropyl methylcellulose on the release of dexamethasone from aqueous 2-hydroxypropyl-&#946;-cyclodextrin formulations</article-title><source>Int. J. Pharm.</source><year>1994</year><volume>104</volume><fpage>181</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/0378-5173(94)90194-5</pub-id></element-citation></ref><ref id="B234-pharmaceutics-15-01700"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doile</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Fortunato</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Schm&#252;cker</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>Schucko</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>P.O.</given-names></name></person-group><article-title>Physicochemical properties and dissolution studies of dexamethasone acetate-beta-cyclodextrin inclusion complexes produced by different methods</article-title><source>AAPS PharmSciTech</source><year>2008</year><volume>9</volume><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1208/s12249-008-9042-z</pub-id><pub-id pub-id-type="pmid">18446497</pub-id><pub-id pub-id-type="pmcid">PMC2976901</pub-id></element-citation></ref><ref id="B235-pharmaceutics-15-01700"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Du</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name></person-group><article-title>Mussel-inspired one-pot synthesis of a fluorescent and water-soluble polydopamine-polyethyleneimine copolymer</article-title><source>Macromol. Rapid Commun.</source><year>2015</year><volume>36</volume><fpage>909</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1002/marc.201500021</pub-id><pub-id pub-id-type="pmid">25790157</pub-id></element-citation></ref><ref id="B236-pharmaceutics-15-01700"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sang</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Su</surname><given-names>A.P.</given-names></name></person-group><article-title>Heparin coating on 3D printed poly (l-lactic acid) biodegradable cardiovascular stent via mild surface modification approach for coronary artery implantation</article-title><source>Chem. Eng. J.</source><year>2019</year><volume>378</volume><fpage>122116</fpage></element-citation></ref><ref id="B237-pharmaceutics-15-01700"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bost</surname><given-names>M.</given-names></name><name name-style="western"><surname>Houdart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oberli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kalonji</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huneau</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Margaritis</surname><given-names>I.</given-names></name></person-group><article-title>Dietary copper and human health: Current evidence and unresolved issues</article-title><source>J. Trace Elem. Med. Biol. Organ Soc. Miner. Trace Elem. GMS</source><year>2016</year><volume>35</volume><fpage>107</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.jtemb.2016.02.006</pub-id><pub-id pub-id-type="pmid">27049134</pub-id></element-citation></ref><ref id="B238-pharmaceutics-15-01700"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medeiros</surname><given-names>D.M.</given-names></name></person-group><article-title>Copper, iron, and selenium dietary deficiencies negatively impact skeletal integrity: A review</article-title><source>Exp. Biol. Med.</source><year>2016</year><volume>241</volume><fpage>1316</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1177/1535370216648805</pub-id><pub-id pub-id-type="pmcid">PMC4950270</pub-id><pub-id pub-id-type="pmid">27190269</pub-id></element-citation></ref><ref id="B239-pharmaceutics-15-01700"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goggs</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vaughan-Thomas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clegg</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Innes</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Mobasheri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shakibaei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bondy</surname><given-names>C.A.</given-names></name></person-group><article-title>Nutraceutical therapies for degenerative joint diseases: A critical review</article-title><source>Crit. Rev. Food Sci. Nutr.</source><year>2005</year><volume>45</volume><fpage>145</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1080/10408690590956341</pub-id><pub-id pub-id-type="pmid">16048146</pub-id></element-citation></ref><ref id="B240-pharmaceutics-15-01700"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solier</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ca&#241;eque</surname><given-names>T.</given-names></name><name name-style="western"><surname>Versini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mansart</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sindikubwabo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>L.</given-names></name><name name-style="western"><surname>Emam</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gestraud</surname><given-names>P.</given-names></name><name name-style="western"><surname>Panto&#537;</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>A druggable copper-signalling pathway that drives inflammation</article-title><source>Nature</source><year>2023</year><volume>617</volume><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06017-4</pub-id><pub-id pub-id-type="pmid">37100912</pub-id><pub-id pub-id-type="pmcid">PMC10131557</pub-id></element-citation></ref><ref id="B241-pharmaceutics-15-01700"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>P.T.</given-names></name></person-group><article-title>Hypomagnesemia: A clinical perspective</article-title><source>Int. J. Nephrol. Renov. Dis.</source><year>2014</year><volume>7</volume><fpage>219</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.2147/IJNRD.S42054</pub-id><pub-id pub-id-type="pmcid">PMC4062555</pub-id><pub-id pub-id-type="pmid">24966690</pub-id></element-citation></ref><ref id="B242-pharmaceutics-15-01700"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLean</surname><given-names>R.M.</given-names></name></person-group><article-title>Magnesium and its therapeutic uses: A review</article-title><source>Am. J. Med.</source><year>1994</year><volume>96</volume><fpage>63</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(94)90117-1</pub-id><pub-id pub-id-type="pmid">8304365</pub-id></element-citation></ref><ref id="B243-pharmaceutics-15-01700"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rice</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>M.K.</given-names></name></person-group><article-title>In vivo control of NF-kappa B activation by I kappa B alpha</article-title><source>EMBO J.</source><year>1993</year><volume>12</volume><fpage>4685</fpage><lpage>4695</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1993.tb06157.x</pub-id><pub-id pub-id-type="pmid">8223478</pub-id><pub-id pub-id-type="pmcid">PMC413911</pub-id></element-citation></ref><ref id="B244-pharmaceutics-15-01700"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rechsteiner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>S.W.</given-names></name></person-group><article-title>PEST sequences and regulation by proteolysis</article-title><source>Trends Biochem. Sci.</source><year>1996</year><volume>21</volume><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(96)10031-1</pub-id><pub-id pub-id-type="pmid">8755249</pub-id></element-citation></ref><ref id="B245-pharmaceutics-15-01700"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didonato</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Mercurio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Karin</surname><given-names>M.</given-names></name></person-group><article-title>Phosphorylation of I&#954;B &#945; precedes but is not sufficient for its dissociation from NF-&#954;B</article-title><source>Mol. Cells Biol.</source><year>1995</year><volume>15</volume><fpage>1302</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1128/MCB.15.3.1302</pub-id><pub-id pub-id-type="pmcid">PMC230353</pub-id><pub-id pub-id-type="pmid">7862124</pub-id></element-citation></ref><ref id="B246-pharmaceutics-15-01700"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Katsuki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Decano</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Halu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Pestana</surname><given-names>D.V.S.</given-names></name><name name-style="western"><surname>Kum</surname><given-names>A.S.T.</given-names></name><name name-style="western"><surname>Kuromoto</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>W.S.</given-names></name><etal/></person-group><article-title>Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OATP2B1 and Dll4-Notch Signaling</article-title><source>Circulation</source><year>2019</year><volume>139</volume><fpage>78</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.034588</pub-id><pub-id pub-id-type="pmid">30586693</pub-id><pub-id pub-id-type="pmcid">PMC6311723</pub-id></element-citation></ref><ref id="B247-pharmaceutics-15-01700"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Back</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Bahn</surname><given-names>G.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy</article-title><source>J. Control. Release Off.</source><year>2015</year><volume>216</volume><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.08.025</pub-id><pub-id pub-id-type="pmid">26282098</pub-id></element-citation></ref><ref id="B248-pharmaceutics-15-01700"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C.Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.C.</given-names></name></person-group><article-title>Icariin attenuates LPS-induced acute inflammatory responses: Involvement of PI3K/Akt and NF-kappaB signaling pathway</article-title><source>Eur. J. Pharmacol.</source><year>2010</year><volume>642</volume><fpage>146</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2010.05.012</pub-id><pub-id pub-id-type="pmid">20519138</pub-id></element-citation></ref><ref id="B249-pharmaceutics-15-01700"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name></person-group><article-title>Icariin inhibits LPS-induced cell inflammatory response by promoting GR&#945; nuclear translocation and upregulating GR&#945; expression</article-title><source>Life Sci.</source><year>2018</year><volume>195</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2018.01.006</pub-id><pub-id pub-id-type="pmid">29317219</pub-id></element-citation></ref><ref id="B250-pharmaceutics-15-01700"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horcajada</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gref</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baati</surname><given-names>T.</given-names></name><name name-style="western"><surname>Allan</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Maurin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Couvreur</surname><given-names>P.</given-names></name><name name-style="western"><surname>F&#233;rey</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Serre</surname><given-names>C.</given-names></name></person-group><article-title>Metal-organic frameworks in biomedicine</article-title><source>Chem. Rev.</source><year>2012</year><volume>112</volume><fpage>1232</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1021/cr200256v</pub-id><pub-id pub-id-type="pmid">22168547</pub-id></element-citation></ref><ref id="B251-pharmaceutics-15-01700"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>A low cytotoxic cationic metal-organic framework carrier for controllable drug release</article-title><source>J. Med. Chem.</source><year>2014</year><volume>57</volume><fpage>5679</fpage><lpage>5685</lpage><pub-id pub-id-type="doi">10.1021/jm5004107</pub-id><pub-id pub-id-type="pmid">24922463</pub-id></element-citation></ref><ref id="B252-pharmaceutics-15-01700"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frazer</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gifford</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Garofalo</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Mohandas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Palazzolo</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>E.M.</given-names></name></person-group><article-title>Computational and biological analysis of 680 kb of DNA sequence from the human 5q31 cytokine gene cluster region</article-title><source>Genome Res.</source><year>1997</year><volume>7</volume><fpage>495</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1101/gr.7.5.495</pub-id><pub-id pub-id-type="pmid">9149945</pub-id></element-citation></ref><ref id="B253-pharmaceutics-15-01700"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reinhardt</surname><given-names>R.L.</given-names></name></person-group><article-title>The differential expression of IL-4 and IL-13 and its impact on type-2 immunity</article-title><source>Cytokine</source><year>2015</year><volume>75</volume><fpage>25</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2015.05.008</pub-id><pub-id pub-id-type="pmid">26073683</pub-id><pub-id pub-id-type="pmcid">PMC5118948</pub-id></element-citation></ref><ref id="B254-pharmaceutics-15-01700"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hershey</surname><given-names>G.K.</given-names></name></person-group><article-title>IL-13 receptors and signaling pathways: An evolving web</article-title><source>J. Allergy Clin. Immunol.</source><year>2003</year><volume>111</volume><fpage>677</fpage><lpage>690; quiz 691</lpage><pub-id pub-id-type="doi">10.1067/mai.2003.1333</pub-id><pub-id pub-id-type="pmid">12704343</pub-id></element-citation></ref><ref id="B255-pharmaceutics-15-01700"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brombacher</surname><given-names>F.</given-names></name></person-group><article-title>The role of interleukin-13 in infectious diseases and allergy</article-title><source>BioEssays News Rev. Mol. Cells Dev. Biol.</source><year>2000</year><volume>22</volume><fpage>646</fpage><lpage>656</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1521-1878(200007)22:7&amp;#x0003c;646::AID-BIES7&amp;#x0003e;3.0.CO;2-9</pub-id><pub-id pub-id-type="pmid">10878577</pub-id></element-citation></ref><ref id="B256-pharmaceutics-15-01700"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nauta</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Fibbe</surname><given-names>W.E.</given-names></name></person-group><article-title>Immunomodulatory properties of mesenchymal stromal cells</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>3499</fpage><lpage>3506</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-02-069716</pub-id><pub-id pub-id-type="pmid">17664353</pub-id></element-citation></ref><ref id="B257-pharmaceutics-15-01700"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo Sicco</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reverberi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Balbi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ulivi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Principi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pascucci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Becherini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bosco</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Varesio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Franzin</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Mesenchymal Stem Cell-Derived Extracellular Vesicles as Mediators of Anti-Inflammatory Effects: Endorsement of Macrophage Polarization</article-title><source>Stem Cells Transl. Med.</source><year>2017</year><volume>6</volume><fpage>1018</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1002/sctm.16-0363</pub-id><pub-id pub-id-type="pmid">28186708</pub-id><pub-id pub-id-type="pmcid">PMC5442783</pub-id></element-citation></ref><ref id="B258-pharmaceutics-15-01700"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimarino</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Caplan</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Bonfield</surname><given-names>T.L.</given-names></name></person-group><article-title>Mesenchymal stem cells in tissue repair</article-title><source>Front. Immunol.</source><year>2013</year><volume>4</volume><fpage>201</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00201</pub-id><pub-id pub-id-type="pmid">24027567</pub-id><pub-id pub-id-type="pmcid">PMC3761350</pub-id></element-citation></ref><ref id="B259-pharmaceutics-15-01700"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name></person-group><article-title>Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization</article-title><source>Cardiovasc. Res.</source><year>2019</year><volume>115</volume><fpage>1205</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvz040</pub-id><pub-id pub-id-type="pmid">30753344</pub-id><pub-id pub-id-type="pmcid">PMC6529919</pub-id></element-citation></ref><ref id="B260-pharmaceutics-15-01700"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>N.</given-names></name><name name-style="western"><surname>Scholtemeijer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>K.</given-names></name></person-group><article-title>Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential</article-title><source>Trends Pharmacol. Sci.</source><year>2020</year><volume>41</volume><fpage>653</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2020.06.009</pub-id><pub-id pub-id-type="pmid">32709406</pub-id><pub-id pub-id-type="pmcid">PMC7751844</pub-id></element-citation></ref><ref id="B261-pharmaceutics-15-01700"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reischl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Miltschitzky</surname><given-names>J.R.E.</given-names></name><name name-style="western"><surname>Vieregge</surname><given-names>V.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Twardy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kasajima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Friess</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kamaly</surname><given-names>N.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>P.A.</given-names></name></person-group><article-title>Ac2-26-Nanoparticles Induce Resolution of Intestinal Inflammation and Anastomotic Healing via Inhibition of NF-&#954;B Signaling in a Model of Perioperative Colitis</article-title><source>Inflamm. Bowel Dis.</source><year>2021</year><volume>27</volume><fpage>1379</fpage><lpage>1393</lpage><pub-id pub-id-type="doi">10.1093/ibd/izab008</pub-id><pub-id pub-id-type="pmid">33512505</pub-id></element-citation></ref><ref id="B262-pharmaceutics-15-01700"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pupjalis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Goetsch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kottas</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Gerke</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK/STAT/SOCS signalling</article-title><source>EMBO Mol. Med.</source><year>2011</year><volume>3</volume><fpage>102</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1002/emmm.201000113</pub-id><pub-id pub-id-type="pmid">21254404</pub-id><pub-id pub-id-type="pmcid">PMC3377061</pub-id></element-citation></ref><ref id="B263-pharmaceutics-15-01700"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K.Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.Y.</given-names></name></person-group><article-title>Annexin A1-derived peptide Ac2-26 facilitates wound healing in diabetic mice</article-title><source>Wound Repair Regen.</source><year>2020</year><volume>28</volume><fpage>772</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1111/wrr.12860</pub-id><pub-id pub-id-type="pmid">32856346</pub-id></element-citation></ref><ref id="B264-pharmaceutics-15-01700"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsekova</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Spasova</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Manolova</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Markova</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Rashkov</surname><given-names>I.B.</given-names></name></person-group><article-title>Electrospun curcumin-loaded cellulose acetate/polyvinylpyrrolidone fibrous materials with complex architecture and antibacterial activity</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2017</year><volume>73</volume><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2016.12.086</pub-id><pub-id pub-id-type="pmid">28183599</pub-id></element-citation></ref><ref id="B265-pharmaceutics-15-01700"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahsan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Parveen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>N.U.</given-names></name><name name-style="western"><surname>Hadi</surname><given-names>S.M.</given-names></name></person-group><article-title>Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin</article-title><source>Chem. Biol. Interact.</source><year>1999</year><volume>121</volume><fpage>161</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/S0009-2797(99)00096-4</pub-id><pub-id pub-id-type="pmid">10418962</pub-id></element-citation></ref><ref id="B266-pharmaceutics-15-01700"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulido-Moran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moreno-Fernandez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ramirez-Tortosa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ramirez-Tortosa</surname><given-names>M.</given-names></name></person-group><article-title>Curcumin and Health</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>264</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21030264</pub-id><pub-id pub-id-type="pmid">26927041</pub-id><pub-id pub-id-type="pmcid">PMC6273481</pub-id></element-citation></ref><ref id="B267-pharmaceutics-15-01700"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karuppagounder</surname><given-names>V.</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thandavarayan</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Sreedhar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Giridharan</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Afrin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Harima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miyashita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Curcumin alleviates renal dysfunction and suppresses inflammation by shifting from M1 to M2 macrophage polarization in daunorubicin induced nephrotoxicity in rats</article-title><source>Cytokine</source><year>2016</year><volume>84</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2016.05.001</pub-id><pub-id pub-id-type="pmid">27203664</pub-id></element-citation></ref><ref id="B268-pharmaceutics-15-01700"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.J.</given-names></name></person-group><article-title>Curcumin suppresses the production of interleukin-6 in Prevotella intermedia lipopolysaccharide-activated RAW 264.7 cells</article-title><source>J. Periodontal Implant Sci.</source><year>2011</year><volume>41</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.5051/jpis.2011.41.3.157</pub-id><pub-id pub-id-type="pmid">21811692</pub-id><pub-id pub-id-type="pmcid">PMC3139050</pub-id></element-citation></ref><ref id="B269-pharmaceutics-15-01700"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Sharmili</surname><given-names>V.</given-names></name><name name-style="western"><surname>Abas</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alitheen</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Shaari</surname><given-names>K.</given-names></name><name name-style="western"><surname>Israf</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Lajis</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Syahida</surname><given-names>A.</given-names></name></person-group><article-title>BDMC33, A curcumin derivative suppresses inflammatory responses in macrophage-like cellular system: Role of inhibition in NF-&#954;B and MAPK signaling pathways</article-title><source>Int. J. Mol. Sci.</source><year>2012</year><volume>13</volume><fpage>2985</fpage><lpage>3008</lpage><pub-id pub-id-type="doi">10.3390/ijms13032985</pub-id><pub-id pub-id-type="pmid">22489138</pub-id><pub-id pub-id-type="pmcid">PMC3317699</pub-id></element-citation></ref><ref id="B270-pharmaceutics-15-01700"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Shie</surname><given-names>M.Y.</given-names></name></person-group><article-title>Mesoporous Calcium Silicate Nanoparticles with Drug Delivery and Odontogenesis Properties</article-title><source>J. Endod.</source><year>2017</year><volume>43</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.joen.2016.09.012</pub-id><pub-id pub-id-type="pmid">27939733</pub-id></element-citation></ref><ref id="B271-pharmaceutics-15-01700"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moustapha</surname><given-names>A.</given-names></name><name name-style="western"><surname>P&#233;r&#233;tout</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Rainey</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Sureau</surname><given-names>F.</given-names></name><name name-style="western"><surname>Geze</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petit</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Dewailly</surname><given-names>E.</given-names></name><name name-style="western"><surname>Slomianny</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petit</surname><given-names>P.X.</given-names></name></person-group><article-title>Curcumin induces crosstalk between autophagy and apoptosis mediated by calcium release from the endoplasmic reticulum, lysosomal destabilization and mitochondrial events</article-title><source>Cell Death Discov.</source><year>2015</year><volume>1</volume><fpage>15017</fpage><pub-id pub-id-type="doi">10.1038/cddiscovery.2015.17</pub-id><pub-id pub-id-type="pmid">27551451</pub-id><pub-id pub-id-type="pmcid">PMC4979459</pub-id></element-citation></ref><ref id="B272-pharmaceutics-15-01700"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemos</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Babaeijandaghi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Low</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Fiore</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nedospasov</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>F.M.</given-names></name></person-group><article-title>Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors</article-title><source>Nat. Med.</source><year>2015</year><volume>21</volume><fpage>786</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1038/nm.3869</pub-id><pub-id pub-id-type="pmid">26053624</pub-id></element-citation></ref><ref id="B273-pharmaceutics-15-01700"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>J.S.</given-names></name></person-group><article-title>Anticoagulant activities of curcumin and its derivative</article-title><source>BMB Rep.</source><year>2012</year><volume>45</volume><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.5483/BMBRep.2012.45.4.221</pub-id><pub-id pub-id-type="pmid">22531131</pub-id></element-citation></ref><ref id="B274-pharmaceutics-15-01700"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.L.</given-names></name></person-group><article-title>Curcumin and diabetes: A systematic review</article-title><source>Evid. Based Complement. Altern. Med. Ecam</source><year>2013</year><volume>2013</volume><fpage>636053</fpage><pub-id pub-id-type="doi">10.1155/2013/636053</pub-id><pub-id pub-id-type="pmid">24348712</pub-id><pub-id pub-id-type="pmcid">PMC3857752</pub-id></element-citation></ref><ref id="B275-pharmaceutics-15-01700"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Setchell</surname><given-names>K.D.</given-names></name></person-group><article-title>Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones</article-title><source>Am. J. Clin. Nutr.</source><year>1998</year><volume>68</volume><fpage>1333s</fpage><lpage>1346s</lpage><pub-id pub-id-type="doi">10.1093/ajcn/68.6.1333S</pub-id><pub-id pub-id-type="pmid">9848496</pub-id></element-citation></ref><ref id="B276-pharmaceutics-15-01700"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>F.H.</given-names></name></person-group><article-title>Multi-targeted therapy of cancer by genistein</article-title><source>Cancer Lett.</source><year>2008</year><volume>269</volume><fpage>226</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.03.052</pub-id><pub-id pub-id-type="pmid">18492603</pub-id><pub-id pub-id-type="pmcid">PMC2575691</pub-id></element-citation></ref><ref id="B277-pharmaceutics-15-01700"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.Q.</given-names></name></person-group><article-title>Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production</article-title><source>Biochem. Pharmacol.</source><year>2003</year><volume>65</volume><fpage>709</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(02)01585-X</pub-id><pub-id pub-id-type="pmid">12628484</pub-id></element-citation></ref><ref id="B278-pharmaceutics-15-01700"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Batnasan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Ba</surname><given-names>X.Q.</given-names></name></person-group><article-title>Daidzein suppresses pro-inflammatory chemokine Cxcl2 transcription in TNF-&#945;-stimulated murine lung epithelial cells via depressing PARP-1 activity</article-title><source>Acta Pharmacol. Sin.</source><year>2014</year><volume>35</volume><fpage>496</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1038/aps.2013.191</pub-id><pub-id pub-id-type="pmid">24632845</pub-id><pub-id pub-id-type="pmcid">PMC4813725</pub-id></element-citation></ref><ref id="B279-pharmaceutics-15-01700"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Dilger</surname><given-names>R.N.</given-names></name></person-group><article-title>Immunomodulatory potential of dietary soybean-derived isoflavones and saponins in pigs</article-title><source>J. Anim. Sci.</source><year>2018</year><volume>96</volume><fpage>1288</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1093/jas/sky036</pub-id><pub-id pub-id-type="pmid">29471443</pub-id><pub-id pub-id-type="pmcid">PMC6140853</pub-id></element-citation></ref><ref id="B280-pharmaceutics-15-01700"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>G.C.</given-names></name></person-group><article-title>Inhibitory effect of isoflavones on peroxynitrite-mediated low-density lipoprotein oxidation</article-title><source>Biosci. Biotechnol. Biochem.</source><year>2002</year><volume>66</volume><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1271/bbb.66.22</pub-id><pub-id pub-id-type="pmid">11866114</pub-id></element-citation></ref><ref id="B281-pharmaceutics-15-01700"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Lafuente</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guillam&#243;n</surname><given-names>E.</given-names></name><name name-style="western"><surname>Villares</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rostagno</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>J.A.</given-names></name></person-group><article-title>Flavonoids as anti-inflammatory agents: Implications in cancer and cardiovascular disease</article-title><source>Inflamm. Res.</source><year>2009</year><volume>58</volume><fpage>537</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1007/s00011-009-0037-3</pub-id><pub-id pub-id-type="pmid">19381780</pub-id></element-citation></ref><ref id="B282-pharmaceutics-15-01700"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ann</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Y.</given-names></name></person-group><article-title>Dietary Supplementation of Genistein Attenuates Inflammatory Responses and Oxidative Stress during Cutaneous Wound Healing in Diabetic Mice</article-title><source>J. Agric. Sci.</source><year>2015</year><volume>7</volume><fpage>80</fpage><pub-id pub-id-type="doi">10.5539/jas.v7n2p80</pub-id></element-citation></ref><ref id="B283-pharmaceutics-15-01700"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Karin</surname><given-names>M.</given-names></name></person-group><article-title>Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases</article-title><source>N. Engl. J. Med.</source><year>1997</year><volume>336</volume><fpage>1066</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1056/NEJM199704103361506</pub-id><pub-id pub-id-type="pmid">9091804</pub-id></element-citation></ref><ref id="B284-pharmaceutics-15-01700"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spagnuolo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tedesco</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bilotto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>G.L.</given-names></name></person-group><article-title>The flavonoid quercetin in disease prevention and therapy: Facts and fancies</article-title><source>Biochem. Pharmacol.</source><year>2012</year><volume>83</volume><fpage>6</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2011.08.010</pub-id><pub-id pub-id-type="pmid">21856292</pub-id></element-citation></ref><ref id="B285-pharmaceutics-15-01700"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Takemra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>The effect of quercetin delivery system on osteogenesis and angiogenesis under osteoporotic conditions</article-title><source>J. Mater. Chemistry. B</source><year>2017</year><volume>5</volume><fpage>612</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1039/C6TB02312F</pub-id><pub-id pub-id-type="pmid">32263677</pub-id></element-citation></ref><ref id="B286-pharmaceutics-15-01700"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Quercetin-Loaded Ceria Nanocomposite Potentiate Dual-Directional Immunoregulation via Macrophage Polarization against Periodontal Inflammation</article-title><source>Small</source><year>2021</year><volume>17</volume><fpage>e2101505</fpage><pub-id pub-id-type="doi">10.1002/smll.202101505</pub-id><pub-id pub-id-type="pmid">34499411</pub-id></element-citation></ref><ref id="B287-pharmaceutics-15-01700"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Quercetin alleviates rat osteoarthritis by inhibiting inflammation and apoptosis of chondrocytes, modulating synovial macrophages polarization to M2 macrophages</article-title><source>Free Radic. Biol. Med.</source><year>2019</year><volume>145</volume><fpage>146</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.09.024</pub-id><pub-id pub-id-type="pmid">31550528</pub-id></element-citation></ref><ref id="B288-pharmaceutics-15-01700"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>R.Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Quercetin protects against cisplatin-induced acute kidney injury by inhibiting Mincle/Syk/NF-&#954;B signaling maintained macrophage inflammation</article-title><source>Phytother. Res. PTR</source><year>2020</year><volume>34</volume><fpage>139</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1002/ptr.6507</pub-id><pub-id pub-id-type="pmid">31497913</pub-id></element-citation></ref><ref id="B289-pharmaceutics-15-01700"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>C.</given-names></name></person-group><article-title>Research on the chelation between quercetin and Cr(III) ion by Density Functional Theory (DFT) method</article-title><source>J. Mol. Struct. THEOCHEM</source><year>2008</year><volume>860</volume><fpage>40</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.theochem.2008.03.020</pub-id></element-citation></ref><ref id="B290-pharmaceutics-15-01700"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricard-Blum</surname><given-names>S.</given-names></name></person-group><article-title>The collagen family</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2011</year><volume>3</volume><fpage>a004978</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a004978</pub-id><pub-id pub-id-type="pmid">21421911</pub-id><pub-id pub-id-type="pmcid">PMC3003457</pub-id></element-citation></ref><ref id="B291-pharmaceutics-15-01700"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theocharis</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Skandalis</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Gialeli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Karamanos</surname><given-names>N.K.</given-names></name></person-group><article-title>Extracellular matrix structure</article-title><source>Adv. Drug Deliv Rev.</source><year>2016</year><volume>97</volume><fpage>4</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.11.001</pub-id><pub-id pub-id-type="pmid">26562801</pub-id></element-citation></ref><ref id="B292-pharmaceutics-15-01700"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>S.L.</given-names></name></person-group><article-title>Evolving challenges in hepatic fibrosis</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2010</year><volume>7</volume><fpage>425</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2010.97</pub-id><pub-id pub-id-type="pmid">20585339</pub-id></element-citation></ref><ref id="B293-pharmaceutics-15-01700"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coelho</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>McCulloch</surname><given-names>C.A.</given-names></name></person-group><article-title>Contribution of collagen adhesion receptors to tissue fibrosis</article-title><source>Cell Tissue Res.</source><year>2016</year><volume>365</volume><fpage>521</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1007/s00441-016-2440-8</pub-id><pub-id pub-id-type="pmid">27351420</pub-id></element-citation></ref><ref id="B294-pharmaceutics-15-01700"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>siRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats</article-title><source>Acta Pharmacol. Sin.</source><year>2012</year><volume>33</volume><fpage>897</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1038/aps.2012.39</pub-id><pub-id pub-id-type="pmid">22659625</pub-id><pub-id pub-id-type="pmcid">PMC4011146</pub-id></element-citation></ref><ref id="B295-pharmaceutics-15-01700"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sefat</surname><given-names>F.</given-names></name><name name-style="western"><surname>Denyer</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Youseffi</surname><given-names>M.</given-names></name></person-group><article-title>Effects of different transforming growth factor beta (TGF-&#946;) isomers on wound closure of bone cell monolayers</article-title><source>Cytokine</source><year>2014</year><volume>69</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2014.05.010</pub-id><pub-id pub-id-type="pmid">25022965</pub-id></element-citation></ref><ref id="B296-pharmaceutics-15-01700"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>J.</given-names></name><name name-style="western"><surname>Onar-Thomas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wiencke</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Cowdrey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Prados</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>W.A.</given-names></name><etal/></person-group><article-title>PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome</article-title><source>Neuro-Oncology</source><year>2012</year><volume>14</volume><fpage>1146</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nos140</pub-id><pub-id pub-id-type="pmid">22753230</pub-id><pub-id pub-id-type="pmcid">PMC3424210</pub-id></element-citation></ref><ref id="B297-pharmaceutics-15-01700"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Florek</surname><given-names>C.</given-names></name><name name-style="western"><surname>Michniak-Kohn</surname><given-names>B.B.</given-names></name></person-group><article-title>Constructing Human Skin Equivalents on Porcine Acellular Peritoneum Extracellular Matrix for In Vitro Irritation Testing</article-title><source>Tissue Eng. Part A</source><year>2016</year><volume>22</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1089/ten.tea.2015.0209</pub-id><pub-id pub-id-type="pmid">26415037</pub-id></element-citation></ref><ref id="B298-pharmaceutics-15-01700"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stark</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Boehnke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mirancea</surname><given-names>N.</given-names></name><name name-style="western"><surname>Willhauck</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Pavesio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fusenig</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Boukamp</surname><given-names>P.</given-names></name></person-group><article-title>Epidermal homeostasis in long-term scaffold-enforced skin equivalents</article-title><source>J. Investig. Dermatol. Symp. Proc.</source><year>2006</year><volume>11</volume><fpage>93</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/sj.jidsymp.5650015</pub-id><pub-id pub-id-type="pmid">17069016</pub-id></element-citation></ref><ref id="B299-pharmaceutics-15-01700"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karsdal</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Detlefsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Krag</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schuppan</surname><given-names>D.</given-names></name></person-group><article-title>Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis?</article-title><source>Hepatology</source><year>2020</year><volume>71</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1002/hep.30969</pub-id><pub-id pub-id-type="pmid">31553813</pub-id></element-citation></ref><ref id="B300-pharmaceutics-15-01700"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.J.</given-names></name></person-group><article-title>Copper regulation of hypoxia-inducible factor-1 activity</article-title><source>Mol. Pharmacol.</source><year>2009</year><volume>75</volume><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1124/mol.108.051516</pub-id><pub-id pub-id-type="pmid">18842833</pub-id><pub-id pub-id-type="pmcid">PMC2685058</pub-id></element-citation></ref><ref id="B301-pharmaceutics-15-01700"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duval</surname><given-names>E.</given-names></name><name name-style="western"><surname>Leclercq</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elissalde</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Demoor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gal&#233;ra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boum&#233;diene</surname><given-names>K.</given-names></name></person-group><article-title>Hypoxia-inducible factor 1alpha inhibits the fibroblast-like markers type I and type III collagen during hypoxia-induced chondrocyte redifferentiation: Hypoxia not only induces type II collagen and aggrecan, but it also inhibits type I and type III collagen in the hypoxia-inducible factor 1alpha-dependent redifferentiation of chondrocytes</article-title><source>Arthritis Rheum.</source><year>2009</year><volume>60</volume><fpage>3038</fpage><lpage>3048</lpage><pub-id pub-id-type="doi">10.1002/art.24851</pub-id><pub-id pub-id-type="pmid">19790048</pub-id></element-citation></ref><ref id="B302-pharmaceutics-15-01700"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brownley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cholok</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mangiavini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Breuler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ranganathan</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Inhibition of Hif1&#945; prevents both trauma-induced and genetic heterotopic ossification</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E338</fpage><lpage>E347</lpage><pub-id pub-id-type="doi">10.1073/pnas.1515397113</pub-id><pub-id pub-id-type="pmid">26721400</pub-id><pub-id pub-id-type="pmcid">PMC4725488</pub-id></element-citation></ref><ref id="B303-pharmaceutics-15-01700"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wynn</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Ramalingam</surname><given-names>T.R.</given-names></name></person-group><article-title>Mechanisms of fibrosis: Therapeutic translation for fibrotic disease</article-title><source>Nat. Med.</source><year>2012</year><volume>18</volume><fpage>1028</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1038/nm.2807</pub-id><pub-id pub-id-type="pmid">22772564</pub-id><pub-id pub-id-type="pmcid">PMC3405917</pub-id></element-citation></ref><ref id="B304-pharmaceutics-15-01700"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uccelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moretta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pistoia</surname><given-names>V.</given-names></name></person-group><article-title>Mesenchymal stem cells in health and disease</article-title><source>Nat. Reviews. Immunol.</source><year>2008</year><volume>8</volume><fpage>726</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1038/nri2395</pub-id><pub-id pub-id-type="pmid">19172693</pub-id></element-citation></ref><ref id="B305-pharmaceutics-15-01700"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Z.</given-names></name></person-group><article-title>JAM-A promotes wound healing by enhancing both homing and secretory activities of mesenchymal stem cells</article-title><source>Clin. Sci.</source><year>2015</year><volume>129</volume><fpage>575</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1042/CS20140735</pub-id><pub-id pub-id-type="pmid">25994236</pub-id></element-citation></ref><ref id="B306-pharmaceutics-15-01700"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis</article-title><source>J. Transl. Med.</source><year>2015</year><volume>13</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s12967-015-0417-0</pub-id><pub-id pub-id-type="pmid">25638205</pub-id><pub-id pub-id-type="pmcid">PMC4371881</pub-id></element-citation></ref><ref id="B307-pharmaceutics-15-01700"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>Human adipose-derived stem cells inhibit bioactivity of keloid fibroblasts</article-title><source>Stem Cell Res. Ther.</source><year>2018</year><volume>9</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s13287-018-0786-4</pub-id><pub-id pub-id-type="pmid">29467010</pub-id><pub-id pub-id-type="pmcid">PMC5822616</pub-id></element-citation></ref><ref id="B308-pharmaceutics-15-01700"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aoki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dohi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akaishi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hyakusoku</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>T.</given-names></name></person-group><article-title>siRNA knockdown of tissue inhibitor of metalloproteinase-1 in keloid fibroblasts leads to degradation of collagen type I</article-title><source>J. Investig. Dermatol.</source><year>2014</year><volume>134</volume><fpage>818</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1038/jid.2013.396</pub-id><pub-id pub-id-type="pmid">24042342</pub-id></element-citation></ref><ref id="B309-pharmaceutics-15-01700"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>H.</given-names></name><etal/></person-group><article-title>HucMSC-Exosome Mediated-Wnt4 Signaling Is Required for Cutaneous Wound Healing</article-title><source>Stem Cells</source><year>2015</year><volume>33</volume><fpage>2158</fpage><lpage>2168</lpage><pub-id pub-id-type="doi">10.1002/stem.1771</pub-id><pub-id pub-id-type="pmid">24964196</pub-id></element-citation></ref><ref id="B310-pharmaceutics-15-01700"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Nakata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kasugai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>S.</given-names></name></person-group><article-title>Comparison of gingiva-derived and bone marrow mesenchymal stem cells for osteogenesis</article-title><source>J. Cells Mol. Med.</source><year>2019</year><volume>23</volume><fpage>7592</fpage><lpage>7601</lpage><pub-id pub-id-type="doi">10.1111/jcmm.14632</pub-id><pub-id pub-id-type="pmcid">PMC6815943</pub-id><pub-id pub-id-type="pmid">31657140</pub-id></element-citation></ref><ref id="B311-pharmaceutics-15-01700"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moshaverinia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zadeh</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Snead</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name></person-group><article-title>Application of stem cells derived from the periodontal ligament or gingival tissue sources for tendon tissue regeneration</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>2642</fpage><lpage>2650</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.12.053</pub-id><pub-id pub-id-type="pmid">24397989</pub-id><pub-id pub-id-type="pmcid">PMC3929697</pub-id></element-citation></ref><ref id="B312-pharmaceutics-15-01700"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaussain Miller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Septier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bonnefoix</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lecolle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lebreton-Decoster</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coulomb</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pellat</surname><given-names>B.</given-names></name><name name-style="western"><surname>Godeau</surname><given-names>G.</given-names></name></person-group><article-title>Human dermal and gingival fibroblasts in a three-dimensional culture: A comparative study on matrix remodeling</article-title><source>Clin. Oral Investig.</source><year>2002</year><volume>6</volume><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s00784-001-0143-2</pub-id><pub-id pub-id-type="pmid">11996162</pub-id></element-citation></ref><ref id="B313-pharmaceutics-15-01700"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafiee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cavalcanti</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Saidy</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Schneidereit</surname><given-names>D.</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ravichandran</surname><given-names>A.</given-names></name><name name-style="western"><surname>De-Juan-Pardo</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Hutmacher</surname><given-names>D.W.</given-names></name></person-group><article-title>Convergence of 3D printed biomimetic wound dressings and adult stem cell therapy</article-title><source>Biomaterials</source><year>2021</year><volume>268</volume><fpage>120558</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120558</pub-id><pub-id pub-id-type="pmid">33307369</pub-id></element-citation></ref><ref id="B314-pharmaceutics-15-01700"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavalcante</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Costa Fda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Araujo J&#250;nior</surname><given-names>E.</given-names></name></person-group><article-title>Granulocyte colony-stimulating factor and reproductive medicine: A review</article-title><source>Iran. J. Reprod. Med.</source><year>2015</year><volume>13</volume><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">26131007</pub-id><pub-id pub-id-type="pmcid">PMC4475767</pub-id></element-citation></ref><ref id="B315-pharmaceutics-15-01700"><label>315.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malashchenko</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Meniailo</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Shmarov</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Gazatova</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Melashchenko</surname><given-names>O.B.</given-names></name><name name-style="western"><surname>Goncharov</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Seledtsova</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Seledtsov</surname><given-names>V.I.</given-names></name></person-group><article-title>Direct anti-inflammatory effects of granulocyte colony-stimulating factor (G-CSF) on activation and functional properties of human T cell subpopulations in vitro</article-title><source>Cells Immunol.</source><year>2018</year><volume>325</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2018.01.007</pub-id><pub-id pub-id-type="pmid">29357983</pub-id></element-citation></ref><ref id="B316-pharmaceutics-15-01700"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Endometrial stem cell-derived granulocyte-colony stimulating factor attenuates endometrial fibrosis via sonic hedgehog transcriptional activator Gli2</article-title><source>Biol. Reprod.</source><year>2018</year><volume>98</volume><fpage>480</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1093/biolre/ioy005</pub-id><pub-id pub-id-type="pmid">29329377</pub-id></element-citation></ref><ref id="B317-pharmaceutics-15-01700"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name></person-group><article-title>Extending the serum half-life of G-CSF via fusion with the domain III of human serum albumin</article-title><source>BioMed Res. Int.</source><year>2013</year><volume>2013</volume><fpage>107238</fpage><pub-id pub-id-type="doi">10.1155/2013/107238</pub-id><pub-id pub-id-type="pmid">24151579</pub-id><pub-id pub-id-type="pmcid">PMC3787585</pub-id></element-citation></ref><ref id="B318-pharmaceutics-15-01700"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>T.G.</given-names></name></person-group><article-title>G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method</article-title><source>Int. J. Pharm.</source><year>2006</year><volume>311</volume><fpage>223</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2005.12.023</pub-id><pub-id pub-id-type="pmid">16423477</pub-id></element-citation></ref><ref id="B319-pharmaceutics-15-01700"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Song</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walczysko</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN</article-title><source>Nature</source><year>2006</year><volume>442</volume><fpage>457</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/nature04925</pub-id><pub-id pub-id-type="pmid">16871217</pub-id></element-citation></ref><ref id="B320-pharmaceutics-15-01700"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tilkorn</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hager</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mirastschijski</surname><given-names>U.</given-names></name></person-group><article-title>Skin Wound Healing: An Update on the Current Knowledge and Concepts</article-title><source>Eur. Surg. Res. Eur. Chir. Forschung. Rech. Chir. Eur.</source><year>2017</year><volume>58</volume><fpage>81</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1159/000454919</pub-id><pub-id pub-id-type="pmid">27974711</pub-id></element-citation></ref><ref id="B321-pharmaceutics-15-01700"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhett</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ghatnekar</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Palatinus</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>O&#8217;Quinn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yost</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Gourdie</surname><given-names>R.G.</given-names></name></person-group><article-title>Novel therapies for scar reduction and regenerative healing of skin wounds</article-title><source>Trends Biotechnol.</source><year>2008</year><volume>26</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2007.12.007</pub-id><pub-id pub-id-type="pmid">18295916</pub-id></element-citation></ref><ref id="B322-pharmaceutics-15-01700"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>G.-d.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.-m.</given-names></name></person-group><article-title>Application and modification of poly(vinylidene fluoride) (PVDF) membranes&#8212;A review</article-title><source>J. Membr. Sci.</source><year>2014</year><volume>463</volume><fpage>145</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.memsci.2014.03.055</pub-id></element-citation></ref><ref id="B323-pharmaceutics-15-01700"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Efome</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>D.</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>C.Q.</given-names></name></person-group><article-title>Enhanced performance of PVDF nanocomposite membrane by nanofiber coating: A membrane for sustainable desalination through MD</article-title><source>Water Res.</source><year>2016</year><volume>89</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.watres.2015.11.040</pub-id><pub-id pub-id-type="pmid">26630042</pub-id></element-citation></ref><ref id="B324-pharmaceutics-15-01700"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devi</surname><given-names>P.I.</given-names></name><name name-style="western"><surname>Ramachandran</surname><given-names>K.</given-names></name></person-group><article-title>Dielectric studies on hybridised PVDF&#8211;ZnO nanocomposites</article-title><source>J. Exp. Nanosci.</source><year>2011</year><volume>6</volume><fpage>281</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1080/17458080.2010.497947</pub-id></element-citation></ref><ref id="B325-pharmaceutics-15-01700"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Greiser</surname><given-names>U.</given-names></name><name name-style="western"><surname>Creagh-Flynn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cutlar</surname><given-names>L.</given-names></name></person-group><article-title>Injectable hyperbranched poly(&#946;-amino ester) hydrogels with on-demand degradation profiles to match wound healing processes</article-title><source>Chem. Sci.</source><year>2018</year><volume>9</volume><fpage>2179</fpage><lpage>2187</lpage><pub-id pub-id-type="doi">10.1039/C7SC03913A</pub-id><pub-id pub-id-type="pmid">29719691</pub-id><pub-id pub-id-type="pmcid">PMC5903369</pub-id></element-citation></ref><ref id="B326-pharmaceutics-15-01700"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>T.-S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Jun</surname><given-names>M.B.-G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Aranas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Topography-Supported Nanoarchitectonics of Hybrid Scaffold for Systematically Modulated Bone Regeneration and Remodeling</article-title><source>Adv. Funct. Mater.</source><year>2022</year><volume>32</volume><fpage>2206863</fpage><pub-id pub-id-type="doi">10.1002/adfm.202206863</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-15-01700-f001" orientation="portrait"><label>Figure 1</label><caption><p>Schematic of the preparation of the B + V scaffold [<xref rid="B16-pharmaceutics-15-01700" ref-type="bibr">16</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g001.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f002" orientation="portrait"><label>Figure 2</label><caption><p>(<bold>A</bold>&#8211;<bold>C</bold>): Digital camera photographs of PMMA-embedded blocks from longitudinal sections and 3D reconstructed &#956;CT images of blood vessels from (<bold>D</bold>&#8211;<bold>F</bold>) side view and (<bold>G</bold>&#8211;<bold>I</bold>) top view of CPC, MS/CPC, and MS/CPC/rhBMP-2 scaffolds after 4 weeks of implantation. White arrow: newly formed blood vessels [<xref rid="B77-pharmaceutics-15-01700" ref-type="bibr">77</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g002.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f003" orientation="portrait"><label>Figure 3</label><caption><p>Schematic elucidation of the fabrication of functional 3D scaffold and 3D culture for in vitro and in vivo analysis [<xref rid="B22-pharmaceutics-15-01700" ref-type="bibr">22</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g003.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f004" orientation="portrait"><label>Figure 4</label><caption><p>Different additives incorporated in the hydrogel according to the different antimicrobial mechanisms.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g004.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f005" orientation="portrait"><label>Figure 5</label><caption><p>Preparation of the AgNP-Cross-Linked Superporous Hydrogel Dressing [<xref rid="B85-pharmaceutics-15-01700" ref-type="bibr">85</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g005.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f006" orientation="portrait"><label>Figure 6</label><caption><p>Schematic of 3D printer, fabrication of 3D-printed scaffold, and application to wound dressing [<xref rid="B30-pharmaceutics-15-01700" ref-type="bibr">30</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g006.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f007" orientation="portrait"><label>Figure 7</label><caption><p>(<bold>A</bold>) Typical morphology of gram-negative <italic toggle="yes">E. coli</italic> captures of the tested samples for <italic toggle="yes">E. coli</italic> in the petri dishes after 24 h cultivation. (<bold>B</bold>) PA12/Cu<sub>2</sub>O 0.5 wt.%, (<bold>C</bold>) PA12/Cu<sub>2</sub>O 1.0 wt.%, (<bold>D</bold>) PA12/Cu<sub>2</sub>O 2.0 wt.%, (<bold>E</bold>) PA12/Cu<sub>2</sub>O 4.0 wt.%, (<bold>F</bold>) PA12/Cu<sub>2</sub>O 6.0 wt.% [<xref rid="B83-pharmaceutics-15-01700" ref-type="bibr">83</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g007.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f008" orientation="portrait"><label>Figure 8</label><caption><p>(<bold>A</bold>) Typical morphology of Gram-positive <italic toggle="yes">S. aureus</italic> captures of tested samples for Gram-positive <italic toggle="yes">S. aureus</italic> in Petri dishes after 24 h cultivation. (<bold>B</bold>) PA12/Cu<sub>2</sub>O 0.5 wt.%, (<bold>C</bold>) PA12/Cu<sub>2</sub>O 1.0 wt.%, (<bold>D</bold>) PA12/Cu<sub>2</sub>O 2.0 wt.%, (<bold>E</bold>) PA12/Cu<sub>2</sub>O 4.0 wt.%, and (<bold>F</bold>) PA12/Cu<sub>2</sub>O 6.0 wt.% [<xref rid="B83-pharmaceutics-15-01700" ref-type="bibr">83</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g008.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f009" orientation="portrait"><label>Figure 9</label><caption><p>Anti-inflammatory response of various surface-modified membranes based on PCL fibrous membrane. The concentration of TNF-&#945; (<bold>a</bold>) and IL-6 (<bold>b</bold>), secreted from the RAW 264.7 cells with and without LPS treatment for 24 h, was quantified by ELISA (** <italic toggle="yes">p</italic> &lt; 0.01 and *** <italic toggle="yes">p</italic> &lt; 0.001) [<xref rid="B33-pharmaceutics-15-01700" ref-type="bibr">33</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g009.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f010" orientation="portrait"><label>Figure 10</label><caption><p>(<bold>a</bold>) Immunofluorescent staining of Raw264.7 cells after cultured for 4 days. (<bold>b</bold>,<bold>c</bold>) Quantitative analysis of iNOS and Arg-1. (<bold>d</bold>) The expression of Notch1 was detected by Western blotting. (<bold>e</bold>) Immunofluorescent staining of Notch1. (n&#8201;=&#8201;3; # represent <italic toggle="yes">p</italic> &lt; 0.05 when compared with Ti/SF, Ti/SF/MOF and Ti/SF/I, respectively; **, ## and ++ represent <italic toggle="yes">p</italic> &lt; 0.01) [<xref rid="B80-pharmaceutics-15-01700" ref-type="bibr">80</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g010.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f011" orientation="portrait"><label>Figure 11</label><caption><p>In vivo collagen deposition within the mesh after 1 week. Collagen deposition (black arrow) viewed by Picro Sirius red staining within mesh area in (<bold>A</bold>) MES, (<bold>B</bold>) MES-Hydrogel and (<bold>C</bold>) MES-Hy-eMSCs and (<bold>D</bold>&#8211;<bold>F</bold>) corresponding magnified view in dashed area [<xref rid="B122-pharmaceutics-15-01700" ref-type="bibr">122</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g011.jpg"/></fig><fig position="float" id="pharmaceutics-15-01700-f012" orientation="portrait"><label>Figure 12</label><caption><p>Fate of meshes after 1 week of in vivo implantation. SEM images show cross-sections of (<bold>A</bold>&#8211;<bold>C</bold>) MES (<bold>D</bold>&#8211;<bold>F</bold>) MES_Hydrogel and (<bold>G</bold>&#8211;<bold>I</bold>) MES_Hydrogel_eMSC constructs (within the red dashed area) 1 week after implantation in NSG mice; lower panels (<bold>C</bold>,<bold>F</bold>,<bold>I</bold>) show the morphology of reticular fibers (m), their interaction with the host tissue integration (white*) and the formation of new ECM [<xref rid="B122-pharmaceutics-15-01700" ref-type="bibr">122</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01700-g012.jpg"/></fig><table-wrap position="float" id="pharmaceutics-15-01700-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01700-t001_Table 1</object-id><label>Table 1</label><caption><p>Different additives in hydrogels with different mechanism to methodology.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Function</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Additive</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Methodology</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="10" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vascularization</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Growth factors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEGF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>VEGF can induce endothelial cell proliferation, promotes cell migration, and inhibits apoptosis.</p></list-item><list-item><p>VEGF-induced angiogenesis with increased vascular permeability plays a critical regulatory role in the generation of blood vessels.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wang et al. made BMP-2 and VEGF adsorbed onto silk fiber (SF) microspheres (diameter of 1.5 &#177; 0.3 &#956;m) that were prepared using a co-flow capillary device. These microspheres were subsequently doped into the SF/nHAp scaffolds to provide regulated and controlled release.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B16-pharmaceutics-15-01700" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FGF-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FGF-2 can stimulate VEGF expression, granulation tissue formation, and vascular maturation.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xiong et al. used 3D printing to fabricate a gelatin-sulfonated silk composite scaffold (3DG-SF-SO<sub>3</sub>-FGF). The basic FGF-2 was incorporated in this scaffold by binding with a sulfonic acid group (SO<sub>3</sub>).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B17-pharmaceutics-15-01700" ref-type="bibr">17</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PDGF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PDGF can recruit SMC/pericytes to immature vessels to stabilize and remodel them.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Heparin and its derivatives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heparin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heparin can accelerate neovascularization by binding angiogenic factors, such as VEGF, and improve their stability.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An et al. coated poly-L-lysine (PLL) and heparin on the surface of 3D printed hydrogel scaffolds, which were made from cross-linking of GelMA and HAMA via electrostatic interactions between PLL and heparin.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B18-pharmaceutics-15-01700" ref-type="bibr">18</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heparan sulfate</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heparan sulfate can not only protect growth factors from degradation by proteases, but it also promote the binding of growth factors to their receptors, thus promoting growth factor activity.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jiang et al. fabricated a scaffold with collagen and heparan sulfate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-pharmaceutics-15-01700" ref-type="bibr">19</xref>]</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Other materials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiogenic peptides</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiogenic peptides are functionally equivalent to VEGF and can bind to the same receptors to initiate angiogenesis.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wang et al. made a dual-delivery bone tissue engineering scaffold by low-temperature 3D printing of &#946;-tricalcium phosphate and&#8212;osteogenic peptide (OP) containing water/PLGA/DCM emulsion&#8212;and coating AP on the scaffold surface.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-pharmaceutics-15-01700" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desferrioxamine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Desferrioxamine can promote HIF1-&#945; synthesis by simulating hypoxia, which was demonstrated to be essential for the regulation of genes related to angiogenesis.</p></list-item><list-item><p>Desferrioxamine can lead to the activation of a cascade of pro-angiogenic genes, such as VEGF when it was activated.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yan et al. designed a bionic degradable polycaprolactone (PCL) scaffold using 3D printing technology. It can control the release of DFO by surface degradation and layer-by-layer assembly techniques.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-pharmaceutics-15-01700" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Catalase</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Catalase can break down hydrogen peroxide and produce oxygen, which not only reduces the damage caused by H<sub>2</sub>O<sub>2</sub>, but the oxygen that it produces also helps to induce angiogenesis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rija et al. intercalated catalase in hydrogels to form functional decellularized adipose tissue-alginate (DAT-A) hydrogels using 3D printing technology.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B22-pharmaceutics-15-01700" ref-type="bibr">22</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Decellularized extracellular matrix</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>The dECM plays a huge role in pro-vascularization with the removal of immunogenicity while retaining a large amount of nutrients such as large amounts of growth factors.</p></list-item><list-item><p>It can facilitate the induced differentiation of pluripotent stem cells on dECM scaffolds into tissue-specific cell types</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kim et al. used S-dECM bioink to print and fabricate 3D pre-vascularized skin patches for wound healing with infusion of adipose-derived stem cells (ASCs) and endothelial progenitor cells (EPCs).</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B23-pharmaceutics-15-01700" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-15-01700" ref-type="bibr">24</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bejleri et al. fabricated a 3D bioprinted patch containing cECM for the delivery of pediatric cardiac progenitor cells hCPCs which is printed with bioinks consisting of cECM, hCPCs, and GelMA.</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Antibacterial</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Photothermal materials</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MXenes can kill microorganisms such as Gram-positive and negative bacteria by disrupting bacterial membranes directly through physical contact, especially when supplemented with NIR irradiation for higher antimicrobial efficiency</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nie et al. fabricated a personalized MXene composite hydrogel scaffold GelMA/&#946;-TCP/sodium alginate (Sr2+)/MXene (Ti3C2) (GTAM) with both photothermal antibacterial and osteogenic capabilities using 3D printing technology.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-pharmaceutics-15-01700" ref-type="bibr">25</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Antibiotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vancomycin + Ceftazidime</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vancomycin can exert a strong bactericidal ability by inhibiting cell wall biosynthesis through specific binding to the dipeptide d-Ala-d-Ala (AA) at the end of bacterial cell wall precursors.<break/>Ceftazidime can inhibit bacterial peptidoglycan synthesis by inhibiting penicillin-binding proteins, leading to cell wall instability and inhibition of synthesis and cell death.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yu et al. fabricated a mesh-like PCL scaffold by using 3D printing technology and poly(lactic-co-glycolic-acid) (PLGA) nanofibers with a hybrid sheath core structure by using co-axial electrospinning technique. Subsequently, they fabricated this nanofiber membrane in two layers (electrospun PLGA/vancomycin/ceftazidime layer and a coaxially spun PLGA/BMP-2 layer).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-pharmaceutics-15-01700" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Levofloxacin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Levofloxacin can inhibit bacterial helicase activity, which leads to the inability of DNA to replicate and synthesize properly, ultimately causing bacterial death.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sadaba et al. produced poly (lactic acid) (PLA) scaffolds with 3D printing technology and subsequently added polydopamine-coated BaSO<sub>4</sub> particles within the scaffolds and adsorbed levofloxacin in it.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-pharmaceutics-15-01700" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minocycline</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minocycline can inhibit protein synthesis in bacteria.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Martin et al. utilized 3D printing technology to prepare a PLA scaffold and combined the scaffold with collagen, minocycline and bio-inspired citrate hydroxyapatite nanoparticles (cHA).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-15-01700" ref-type="bibr">28</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">NO</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO can play a bactericidal role by damaging DNA, proteins and lipids of microorganisms.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kabirian et al. designed a 3D printed small-diameter vascular graft (SDVG) which was printed from polylactic acid and coated with blending of 10 wt% S-nitroso-N-acetyl-D-penicillamine mixed in a polymer matrix consisting of poly (ethylene glycol) and polycaprolactone to achieve controlled release of NO.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-15-01700" ref-type="bibr">29</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<italic toggle="yes">Satureja cuneifolia</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Satureja cuneifolia</italic> (SC) is a natural aromatic plant which is rich in phenolic compounds with antimicrobial activity, which are strongly oxidizing and can cause protein coagulation and destroy bacterial proteins thus exerting antimicrobial effects.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ilhan et al. used 3D printing technique to make SA/PEG composite scaffold and loaded methanol extract of SC into it.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmaceutics-15-01700" ref-type="bibr">30</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nanodiamonds</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The active oxygen-containing groups on the surface of NDS promote their interaction with cellular components to quickly kill Gram-positive and negative bacteria and prevent bacterial adhesion.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifai et al. fabricated selective laser melting titanium (SLM-Ti) scaffolds by using 3D printing and selective laser melting (SLM), and applied nanodiamond (ND) coating on the scaffolds for functionalization modification.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-pharmaceutics-15-01700" ref-type="bibr">31</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Chitosan</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Its antimicrobial activity results from the interaction of the positive charge it carries with ions on the surface of negatively charged cells. Such activity disrupts bacterial cell membranes, prevents the transport of cellular material, increase the internal osmotic pressure, and cause the rupture of microbial cells, among other things.</p></list-item><list-item><p>Chitosan can interact with bacterial DNA and prevents DNA transcription, thus inhibiting microbial ribonucleic acid (RNA) synthesis.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intini et al. used 3D printing technology to manufacture porous chitosan scaffolds with 200&#8201;&#956;m&#8201;inter-filament opening.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmaceutics-15-01700" ref-type="bibr">32</xref>]</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Immunomodulation</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Adrenocorticos-teroids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dexamethasone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>It can reduce the expression of cyclooxygenase 2 (COX-2).</p></list-item><list-item><p>It inhibits prostaglandin production, inflammatory signaling, and neutrophil and macrophage exudation and aggregation to the site of inflammation.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lee et al. designed a robust and biodegradable 3D tubular scaffold by the combination of electrostatic spinning technique (ELSP) and 3D printing technique, and subsequently loaded DEX onto this scaffold using a mild surface modification reaction of PDA, polyethyleneimine (PEI), and carboxymethyl &#946;-cyclodextrin (&#946;CD).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-pharmaceutics-15-01700" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prednisolone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>It can inhibit the accumulation of inflammatory cells (including macrophages and leukocytes) at sites of inflammation, and their phagocytosis.</p></list-item><list-item><p>It can prevent the release of lysosomal enzymes, and the synthesis and release of chemical mediators of inflammation.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Farto-Vaamonde et al. utilized two different ways to load prednisolone or dexamethasone into a 3D printed PLA scaffold. The first one is immersing the pre-printed 3D PLA scaffold in a prednisolone solution, which covers its surface with prednisolone and allows for rapid release to exert its antimicrobial properties. The second one is immersing the polylactic acid filament in dexamethasone solution to make the polylactic acid swells reversibly.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-pharmaceutics-15-01700" ref-type="bibr">34</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Animal sources</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interleukin-4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>IL-4 can activate the production of Th2 cytokine and thus promotes the polarization of M2-type macrophages.</p></list-item><list-item><p>IL-4 has the ability to antagonize the Th1-driven pro-inflammatory immune response, as evidenced by the downregulation of the synthesis of pro-inflammatory cytokines such as IL-10 and TNF-&#945; and the inhibition of pro-inflammatory chemokines.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wang et al. used GelMA-Dextran (PGelDex) as bioink and incorporated both IL-4 loaded silver-coated gold nanorods (AgGNRs) and hMSCs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-pharmaceutics-15-01700" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ac2-26 peptide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It can inhibit tumor necrosis factor-&#945; (TNF-&#945;) production in monocytes, inhibit NF-&#954;B signaling of the proinflammatory pathway, and promote phagocytosis of neutrophils.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xu et al. fabricated a polylactic acid/4-arm polyethylene glycol hydrogel (PCL@tetra-PEG) composite scaffold with the encapsulation of Ac2-26 peptide.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-pharmaceutics-15-01700" ref-type="bibr">36</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Plant sources</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Its inhibitory effect on cytokine production and expression.</p></list-item><list-item><p>Curcumin can exert anti-inflammatory activity in LPS/interferon-&#947; (IFN-&#947;) treated macrophages through several mechanisms, for example, by blocking nuclear factor-&#954;B (NF-&#954;B) and signal transducer and activator of transcription 1 (STAT1) signaling pathways, thereby inhibiting LPS-induced IL-6 expression in RAW264.7 cells.</p></list-item><list-item><p>Flavin derivatives can also inhibit NO, TNF-&#945; and IL-1&#946; expression by suppressing the mitogen-activated protein kinase (MAPK)/NF-&#954;B pathway in IFN-&#947;/LPS-stimulated macrophages.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chen et al. made mesoporous CS (MesoCS/curcumin) scaffolds with curcumin. MesoCS nanoparticles were first prepared using a template followed by dissolving turmeric as a stock solution in 0.5 M NaOH to various concentration and finally mixing the scaffolds at the same 0.4 mL/g liquid/powder ratio to make the scaffolds.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmaceutics-15-01700" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isoflavones</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>It can eliminate free radicals produced by macrophages during inflammation, thereby reducing the release of various inflammatory mediators induced by ROS.</p></list-item><list-item><p>It have ability to inhibit the phosphorylation of I&#954;B, an inhibitor of NF-&#954;B, thereby reducing the degradation of I&#954;B, inhibiting NF-&#954;B activation, and subsequently reducing the pro-inflammatory cytokine production among others.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarkar et al. loaded three soy isoflavones (Genistein, Daidzein, and Glycitein) in a 5:4:1 ratio mimicking their original ratios in soy on 3D printed TCP scaffolds with pores.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmaceutics-15-01700" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>It can induce phosphorylation of protein kinase B and promote signal transduction and nuclear translocation of transcriptional activator protein 6 (STAT6), it can increase the expression of the M2 phenotype upon binding to anti-inflammatory cytokine-related genes.</p></list-item><list-item><p>Quercetin can block the NF-&#954;B signaling pathway, thus promoting M2 polarization for anti-inflammatory repair effects.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wang et al. fabricated layered micro/nano surfaces on the surface of Ti<sub>6</sub>Al<sub>4</sub>V implants using 3D printing technique, alkali heat treatment and hydrothermal treatment after deposition of titanium dioxide (TiO<sub>2</sub>) on this surface. Because of the excellent ability to chelate metal cations of quercetin, it can be adsorbed as a monomer on TiO<sub>2</sub>, effectively creating a quercetin coating on the surface of the 3D printed Ti<sub>6</sub>Al<sub>4</sub>V implant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-pharmaceutics-15-01700" ref-type="bibr">39</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Regulation of collagen deposition</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Collagen</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Different types and ratios of collagen deposition play different roles in different periods of wound repair.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Martin et al. utilized 3D printing technology to prepare a PLA scaffold and combined the scaffold with collagen, minocycline and bio-inspired citrate hydroxyapatite nanoparticles (cHA).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-15-01700" ref-type="bibr">28</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Extracellular Matrix</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Extracellular matrix is mainly composed of various components such as collagen, non-collagen, and elastin, and collagen as the main component can not only give the extracellular matrix the function of directly regulating collagen deposition, but also avoid the degradation and shrinkage process caused by a single collagen. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kim et al. used S-dECM bioink to print and fabricate 3D pre-vascularized skin patches for wound healing with infusion of ASCs and EPCs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-pharmaceutics-15-01700" ref-type="bibr">23</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Silk fiber</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">As one of the filamentous proteins, <italic toggle="yes">Antheraea assama</italic> SF can improve cell fate and promote ECM secretion owing to its Arg-Gly-Asp (RGD) content.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bandyopadhyay et al. mixed a blend of SF from mulberry (<italic toggle="yes">Bombyx mori</italic>) and non-mulberry (<italic toggle="yes">Antheraea assama</italic>) silk with gelatin as inks for 3D bioprinting to simulate the extracellular microenvironment of the meniscus. Subsequently, EDC and NHS were chemically cross-linked to enhance their stability and mechanical strength. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-pharmaceutics-15-01700" ref-type="bibr">40</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Curcumin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin has the function of inhibiting the NF-&#954;&#946; signaling pathway, thus promoting osteoblast differentiation and the secretion of ECM.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bose et al. fabricated a PCL-PEG+curcumin-coated TCP scaffold using 3D printing technology. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-pharmaceutics-15-01700" ref-type="bibr">41</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Granulocyte colony-stimulating factor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">As an anti-inflammatory protein, endometrial stem cell-derived G-CSF can reduce scar formation by reducing Gli2 protein expression levels to regulate collagen deposition and reduce endometrial fibrosis.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wen et al. made G-CSF-loaded slow-release microsphere (G-CSF-SRM) hydrogel scaffolds with 3D printing technology.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-pharmaceutics-15-01700" ref-type="bibr">42</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Polyvinylidene fluoride</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyvinylidene fluoride (PVDF) has excellent piezoelectric properties, biocompatibility, thermal stability and resistance to chemical irritation. Electricity generated by piezoelectric materials can reverse the effects of the gradual weakening of bioelectric stimulation with wound healing which may cause disruption of gene regulation, leading to downregulation of the wound healing cascade and eventually disorganized deposition of collagen fibers and abnormal remodeling of the ECM.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liang et al. fabricated a novel ZnO nanoparticle-modified PVDF/SA piezoelectric hydrogel 3D scaffold (ZPFSA). The incorporation of SA precisely reduces the hydrophobicity of PVDF and creates the possibility of preparing hydrogels from its 3D printing.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-pharmaceutics-15-01700" ref-type="bibr">43</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-15-01700-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01700-t002_Table 2</object-id><label>Table 2</label><caption><p>Different functions of various ions in hydrogels.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Function</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Methodology</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silicon ion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vascularization</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Promote the expression of angiogenesis-related factors in vascular endothelial cells.</p></list-item><list-item><p>Stimulate in vitro migration, differentiation and tubule-like formation of vascular endothelial cells.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Use a novel calcium phosphate cement (CPC) as the basis for a scaffold that combined mesoporous silica (MS) with recombinant human bone morphogenetic protein-2 (rhBMP-2).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-pharmaceutics-15-01700" ref-type="bibr">77</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Magnesium ion</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vascularization</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Stimulate the proliferation of HUVEC.</p></list-item><list-item><p>Increase its response to some motogenic factors.</p></list-item><list-item><p>Upregulate integrin function and thus promote endothelial cell migration.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fabricated Mg-doped &#946;-TCP (Mg-TCP) scaffolds by 3D printing and sintering, in which MgO was mixed in different ratios.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B78-pharmaceutics-15-01700" ref-type="bibr">78</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Make Ta-PDA-Mg scaffolds by doping Mg<sup>2+</sup> on the surface of 3D printed tantalum scaffolds by using the surface adhesion ability of polydopamine.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-pharmaceutics-15-01700" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunomodulation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Increase I&#954;B&#945; levels, and lead to reduced NF-&#954;B activation and secretion of proinflammatory cytokines.</p></list-item><list-item><p>Inhibit Notch1 protein expression to exert anti-inflammatory effects.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Load magnesium ions in the form of Mg-MOF-74 into 3D bioprinted scaffolds to exert anti-inflammatory effects in combination with icariin.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-pharmaceutics-15-01700" ref-type="bibr">80</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zinc ions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibacterial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>The negative charge of the bacterial film, an electrostatic reaction between the film and the oppositely charged ZnO nanoparticles leads to the rupture of the film eventually triggering bacterial death.</p></list-item><list-item><p>ZnO nanoparticles can release free Zn ions to disrupt the internal ionic homeostasis of the bacterium and subsequently lead to the death of the bacterium.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Made yttrium oxide-stabilized zirconium oxide (3Y-ZrO<sub>2</sub>) nanopowder into 3Y-ZrO<sub>2</sub> ceramic by 3D printing, mold plasticity, and sintering. Then the ISO resin was uniformly coated onto the ceramic. Subsequently, ZnO nanosolution was dropped on this ceramic to finally produce ZnO-ISO bilayer modified ceramics.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-pharmaceutics-15-01700" ref-type="bibr">81</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Copper ion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vascularization</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Stimulate endothelial cell proliferation and differentiation.</p></list-item><list-item><p>Stimulates angiogenesis by mimicking hypoxia, stabilizing the expression of hypoxia-inducible factor (HIF-1a) and promoting the expression of VEGF.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prepared a novel metal-organic framework, a &#946;-tricalcium phosphate (Cu-TCPP-TCP) scaffold containing a copper coordinated tetrakis (4-carboxyphenyl) porphyrin (Cu-TCPP) nanosheet interfacial structure, by using 3D printing technology.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-pharmaceutics-15-01700" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibacterial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Highly toxic hydroxyl radicals produced by copper can oxidize with most bacterial macromolecules to exert antibacterial effects.</p></list-item><list-item><p>Associate with affecting the bacterial outer membrane potential, leading to the rupture of the bacterial membrane, and eventually to bacterial death.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Used 3D printing technology to prepare nanocomposites of medical grade polyamide 12 (PA12) with copper oxide (cuprous oxide) in different ratios.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-pharmaceutics-15-01700" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunomodulation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit the activation of macrophages and suppress the synthesis and release of inflammatory factors.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Made Cu-BGC scaffolds by incorporating different concentrations of copper (0.781&#8211;25 mg/mL) into bioactive microcrystalline glass using 3D printing technology.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B84-pharmaceutics-15-01700" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Regulation of collagen deposition</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upregulate hypoxia-inducible factor-1 (HIF-1) expression and stimulates the expression of SOX-9, which leads to increased levels of COL II and ACAN expression.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fabricated Cu-BGC scaffolds by doping different concentrations of copper (0.781&#8211;25 mg/mL) into bioactive microcrystalline glass with 3D printing technology.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silver ion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibacterial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Anchoring of AgNps on bacterial membranes leading to rupture of bacterial membranes and leakage of bacterial contents, resulting in bacterial cell death.</p></list-item><list-item><p>Nanoparticles can penetrate into bacterial membranes and interact with biomolecules, resulting in bacterial dysfunction.</p></list-item><list-item><p>AgNps may catalyze the reduction in O<sub>2</sub> to reactive oxygen species (ROS), leading to downregulation of antioxidant enzyme expression, DNA damage and apoptosis.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silver is mainly used in the form of metallic silver nanoparticles (AgNPs).<break/>Designed a superporous polyacrylamide (PAM)/Hydroxypropyl Methyl Cellulose (HPMC) hydrogel with antibacterial ability by using silver-ethylene interactions and 3D printing technology.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-pharmaceutics-15-01700" ref-type="bibr">85</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-15-01700-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01700-t003_Table 3</object-id><label>Table 3</label><caption><p>Different cells in hydrogel.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cells</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Functions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Methodology</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Merits</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HUVECs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vascularization</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevent the need for pre-formed channels or growth factor-induced angiogenesis.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HUVECs was seeded in the Laponite (LAP) nanoclay with VEGF.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low cost, ease of isolation, and strong angiogenic potential</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-pharmaceutics-15-01700" ref-type="bibr">110</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MSCs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vascularization</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increase the expression of vascular growth factors.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A 3D-printed GelMA hydrogel scaffold with a controlled internal structure which was filled with MSCs.</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Immunomodulatory and tissue repair promoting effects</p></list-item><list-item><p>Potential for multi-directional tissue differentiation</p></list-item><list-item><p>The ability to secrete a variety of cytokines</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-pharmaceutics-15-01700" ref-type="bibr">118</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunomodulation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Promote paracrine activity during inflammation and induce a shift from an M1-type phenotype to an M2-type phenotype in macrophages.</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">A scaffold which was composed by the aloe vera&#8211;sodium alginate (AV-ALG) hydrogel-coated endometrial mesenchymal stem cells (eMSCs) and 3D melt electrospun wire nets.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B122-pharmaceutics-15-01700" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Regulation of collagen deposition</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Inhibition of inflammation in scar tissue.</p></list-item><list-item><p>Affect fibroblast activity in scar formation, and reduce scar formation by inhibiting the gene expression of TGF-&#946;1 and decreasing type I collagen production.</p></list-item><list-item><p>Play a positive role in collagen remodeling in scar tissue.</p></list-item></list>
</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>